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Abstract 
This thesis presents work to examine the genetic basis of CCL rupture in dogs.  It 
describes research to identify causative mutations that will help to develop a genetic 
screening test to identify dogs that have a high risk of developing CCL rupture.  
 
Cranial Cruciate Ligament (CCL) rupture is the most common cause of hind limb 
lameness in dogs and is especially common in large and giant breeds such as 
Newfoundlands, Rottweilers and Staffordshire Bull Terriers.  
 
CCL rupture cases and from two continents (Europe n = 48 and North America n = 48) 
were examined using genome wide association studies (GWAS). A candidate gene study 
was performed using Sequenom iPlex genotyping, on cases and controls from 
Newfoundlands (99 cases, 172 controls) and three other susceptible breeds: Labradors 
(124 cases, 165 controls), Rottweilers (57 cases, 81 controls) and Staffordshire Bull 
Terriers (13 cases, 38 controls). One hundred and eighty-six SNPs across 26 candidate 
genes were investigated for association with CCL rupture. To investigate downstream 
events, gene expression was compared between healthy and CCL rupture tissue. An in-
vitro laboratory model of CCL rupture was investigated by examining ligamentocytes 
induced with and without TNFα. To investigate whether there was an auto-immune 
component to CCL rupture, the two main loci of the dog leucocyte antigen (DLA) 
system were assessed for disease association. 
 
Principle component analysis of the GWAS data revealed population stratification 
within the Newfoundland breed, indicative of the continent of origin (Europe or North 
America). GWAS identified three main regions associated with CCL rupture (on 
chromosomes 1, 3 and 33). Significantly associated genes SORCS2 and SEMA5B 
function in neurological pathways; this may indicate that mechanotransduction, 
neurological and neuromuscular pathways play an important role in the pathogenesis 
and susceptibility to CCL rupture. Candidate gene analysis identified associations with 
two collagen genes (collagen type-V and collagen type-I) and three extracellular matrix 
proteins; Aggrecan (ACAN), Opticin (OPTC) and Latent transforming growth factor beta 
2 (LTBP2). Gene expression analysis revealed significant differential expressions in 
COL1A1 and COL1A2. These results indicate that the strength and stability of the 
ligament is probably important in susceptibility to CCL rupture. Gene expression results 
also revealed that genes involved in degradation (TRAP and DIRC2) are upregulated, 
indicating that the cells are trying to repair themselves whilst a simultaneous 
degradative process is still on going. The TNFα model may be used as an in-vitro model 
to study CCL rupture, but may be more useful as a model for examining changes that 
occur after CCL rupture rather than the early stages of the disease. We showed no 
association with the DLA region and CCL rupture. 
 
The identified associated regions should be further investigated and refined using next 
generation, targeted re-sequencing and transcriptomic approaches. This could identify 
the specific causative mutations involved in CCL rupture susceptibility. This study 
confirms that there are complex multigenetic and environmental factors involved in 
CCL rupture susceptibility. The work has contributed to the understanding of causative 
factors involved in CCL rupture susceptibility and may be an important step in the 
development of a screening test(s) to reduce the incidence of CCL rupture in dogs and 
thus improve their health and welfare.  
 
  
- 9 - 
 
List of abbreviations 
The following lists the commonly used abbreviations in this thesis: 
ACL  Anterior Cruciate ligament (human analogue of the CCL)  
BONF   Bonferroni multiple correction 
BONF p   Bonferroni multiple correction p-value 
CCL  Cranial Cruciate Ligament 
cDNA Complementary DNA 
Chr  Chromosome 
CMH Cochran-Mantel-Haenszel test for association 
CT  Threshold cycle 
DLA  Dog Leukocyte Antigen 
DMEM Dulbecco's modiﬁed Eagle's medium 
DNA  Deoxyribonucleic acid 
ECM  Extracellular matrix 
EDTA Ethylene-diamine-tetra-acetic acid 
EMMAX  Efficient Mixed-Model Association eXpedited analysis 
EU  European 
GWAS  Genome Wide Association Study 
HWE  Hardy Weinberg equilibrium 
INDEL Insertion or Deletion of a base pair in the DNA sequence 
Kb  Kilobase 
LD  Linkage disequilibrium 
MAF  Minor allele frequency 
Mb  Megabase 
MHC  Major Histocompatibility Complex 
NA  North American 
OR   Odds ratio 
p p-value 
PCA  Principle component analysis 
PCR  Polymerase chain reaction 
Pos  Position 
QA  Quality Assurance 
Q-PCR  Quantitative real time PCR 
QQ Plot  Quantile-Quantile plot 
RNA Ribonucleic acid 
SAP  Shrimp alkaline phosphatase 
SEM Standard error of the mean 
SNP  Single Nucleotide Polymorphism 
TNFα  Tumour necrosis factor alpha 
VLA Veterinary Laboratory Agency 
 
  
- 10 - 
 
 
 
 
 
  
Chapter 1.  
Introduction 
 
  
- 11 - 
 
Cruciate ligaments – anatomy and function 
Cranial cruciate ligament (CCL) rupture is the most common musculoskeletal 
condition that requires orthopaedic surgery in dogs (Canis familiaris). Complete 
rupture or partial tearing of the CCL is the most common cause of pelvic limb (hind 
leg) lameness [1-6].  
 
 
Figure 1.1. Cranial view of the left stifle joint of the dog. The patella has been 
removed. Adapted from Textbook of Veterinary Anatomy, 4th Edition [7] 
 
The main ligaments that stabilise the stifle (knee) joint are the medial and lateral 
collateral ligaments - located on the outside of the joint [8] and the cranial and 
caudal cruciate ligaments which are located in an intracapsular but extrasynovial 
location [9]. It is the CCL that is the primary stabiliser of the stifle joint and is the 
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ligament most commonly ruptured in both dogs and in humans (along with the 
medial collateral ligament [10]). The CCL attaches to the fossa on the caudal aspect 
of the medial side of the lateral femoral condyle [11]. The CCL passes cranially, 
medially and distally across the intercondylar fossa and attaches to the cranial 
intercondyloid area of the tibia [11]. The ligament acts to resist hyperextension of 
the stifle and limits internal rotation of the tibia with respect to the femur [12, 13]. 
The CCL has two distinct functional bands – the craniomedial and the caudolateral 
bands [11]. The craniomedial band is taut during flexion and extension of the stifle 
joint, whereas the caudolateral band is only taut when the stifle is in extension [11]. 
Both bands are taut during extension of the stifle, so they act to stabilise the joint 
and prevent over-extension. If the CCL becomes torn, instability results and this can 
be associated with lameness, chronic pain and stiffness. In dogs, osteoarthritis will 
develop and is unpreventable [14]. The CCL is analogous to the anterior cruciate 
ligament (ACL) in humans. They are often inappropriately used interchangeably; in 
this project CCL refers to the canine cruciate ligament and the ACL refers to the 
human ligament.  
 
Veterinary diagnosis and treatment of CCL rupture 
One of the key diagnostic tests for CCL rupture is  the “draw sign” [15]. This is 
where the clinician holds the femur and then manipulates the tibia. If the tibia 
displaces cranially relative to the femur, it indicates loss of integrity of the CCL. 
Radiographs may also be taken to investigate changes that might typically occur, 
such as joint effusion and osteophytosis. However, these are not able to detail soft 
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tissue (such as ligaments). Arthroscopy, ultrasound, magnetic resonance imaging 
(MRI) or exploratory arthrotomy may also be used to confirm the diagnosis [16, 17]. 
 
For treatment, a conservative approach, such as rest and analgesia (e.g. non-
steroidal anti-inflammatory drugs) may initially be used, especially if the ligament is 
only stretched or partially torn, or when the patient is a small breed of dog. 
However, in most dogs, especially the large or giant breeds, surgical reconstruction 
options are the recommended approach to management and are the only way to 
stabilise the ruptured ligament. 
 
There are many different surgical techniques that can be performed to stabilise the 
joint and manage CCL rupture [18]. The most common forms available currently, 
are tibial plateau levelling osteotomy (TPLO) [19], tibial tuberosity advancement 
(TTA) [20], lateral suture stabilisation (LSS) [21] and “over the top” (OTT) fascial 
grafting [22]. They all endeavour to stabilise the joint and prevent abnormal 
movement or further pain within the joint. Veterinary fees for such surgical 
procedures can place a heavy financial burden on dog owners or their pet health 
insurers. In the United States, it was estimated that the annual cost for treating CCL 
rupture (for surgery and follow up care) was $1.32 billion in 2003 [1]. These costs 
are increasing year on year, as the surgical techniques become more advanced 
requiring more specialist equipment and as dogs are becoming increasingly popular 
as pets. In the UK, the number of dogs in 2012 was estimated to be around 8 million 
[23], with the UK Kennel club currently recognising 210 different dog breeds and 
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registering over 200,000 pure bred dogs a year [24]. Within the UK, if a dog has had 
surgery to stabilise the stifle, it cannot be shown in championship shows without 
specific permission from the Kennel Club [24]. Following surgery, the dog may never 
recover 100% normal function [2, 14, 25] due to the knee failing to gain complete 
stability. Any underlying causes of CCL rupture or inflammation within the joint or 
synovium may still have an active effect whilst progressive osteoarthritis occurs 
simultaneously within the joint [26]. These add to the pain and inflammation in the 
joint. 
 
Pathology of CCL rupture 
Susceptibility 
The effects of age, bodyweight, the size of dog, bone conformation, hormonal, 
autoimmune components and genetic factors are all key contributory factors to CCL 
rupture [4, 5, 14-16, 27-36], as is the underlying ligament structure/strength. There 
may be many other pathways involved in CCL rupture susceptibility, such as 
sensorimotor systems, neurological or neurovascular pathways [37-39], but the 
relative impacts of these have not been described in detail. These pathways may 
act to initiate CCL rupture and/or repair, or they may be secondary to rupture. 
Substance P (and other neurological pathways) have previously been associated 
with rheumatoid- and osteo-arthritis [40, 41] and so it is feasible that they too may 
be involved in CCL rupture. 
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Ligament structure 
Ligaments are strong connective tissue structures that connect bone to bone across 
a joint. Ligaments have a complex hierarchical structure similar to that of tendons 
[42-44], with many different collagen fibres of different sizes arranged 
longitudinally along the length [43, 45, 46]. For illustrative purposes the structure of 
the tendon is shown in Figure 1.2 (adapted from Kastelic et al. [47]). 
 
Figure 1.2. The microscopic structure of a tendon (adapted from Kastelic et al.) 
[47]. This is shown to illustrate the longitudinal arrangement of collagen fibrils, 
which is similar to that which occurs in ligaments. 
 
Although tendons have many fibril unit classifications (as shown above), Clark et al. 
[42] found only two distinct classifications within the CCL – collagen fibre bundles 
and fascicles. The collagen fibre bundle is the basic unit of the ligament structure. 
Cells (from which the ECM proteins are released) are present between the collagen 
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fibres, arranged in a longitudinal direction [43, 46]. The cell population is mainly 
composed of fibroblasts, but chondrocyte-like cells may also be present [48, 49]. 
 
Ligaments are two thirds water and the main structural component in the dry 
weight of a ligament is collagen [37, 50]. Collagens are essential to the integrity, 
structure and strength of the ligament. Collagen is arranged in fibres made from 
many fibrils. The conversion of the fibrils to fibres involves the enzyme lysyl-oxidase 
(LOX) [51] which promotes cross-linking between each fibre. This gives the ligament 
its core structure and increased strength and stability. The fibrils, instead of being 
completely straight are crimped and it is thought that the crimp is important in 
allowing the ligament to absorb a degree of tensile load bearing without the 
ligament being damaged [43]. The greater the force applied to the ligament, the 
straighter the collagen fibres become.  
 
Collagen comprises 75% of the dry weight of the CCL. There are several types of 
collagen in ligaments; the primary form (85% of total collagen present) being 
collagen type I (COL1A1, COL1A2) [43], the remaining collagens are type III, type V, 
type VI, type XI and type XIV [43]. Collagen type I has a triple helical structure [52] 
formed by two different alpha chains A1 and A2, whose genes reside on different 
chromosomes (Chromosome 9 and 14 in the dog). They are normally present in the 
ratio of 2:1 - COL1A1:COLA2 [53]. The remaining matrix components of ligaments 
are proteoglycans, actin, laminin, integrins and some uncharacterised proteins [43, 
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47, 54]. As these are all structural components of ligament, important in tensile 
strength, they can be considered as possible candidate elements for CCL rupture. 
 
Collagen is released from cells as procollagen, which is then cleaved into 
tropocollagen [55-57]. This tropocollagen is converted to collagen fibrils with the 
aid of the enzyme lysyl-oxidase (LOX) [58]. LOX acts on lysine and hydroxylysine 
residues deaminating them to aldehyde groups. This allows covalent bonding to 
form between the different tropocollagen molecules producing collagen fibrils [51]. 
This post-translational modification of the procollagen chains is crucial for the 
formation of mature collagen molecules [59]. Collagens are renowned for their 
triple helix structure which is formed as a result of a repetitive motif, typically (Gly-
X-Y)n where X is normally proline and Y hydroxyproline [52]. This repetitive 
backbone forms a very stable, tightly coiled alpha helical structure – hence the high 
tensile strength of collagen fibres under normal conditions. 
 
Levels of cross-linking along with the high collagen turnover rate in the ligament 
may also play an important role in determining whether or not the CCL is likely to 
rupture [50, 60]. Furthermore, Comerford et al. [50] found that ruptured CCLs had 
significantly higher concentrations of immature collagen cross-links present in them 
compared to intact control CCLs. High levels of immature collagen cross-links in the 
CCL may indicate that the ligament cannot withstand day-to-day stresses making it 
more likely to rupture. The time at which the ligament had ruptured was unknown, 
so the higher levels of immature collagen may be due to the ligament trying to 
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repair itself (remodelling) after an initial injury or it could be an underlying cause of 
the injury. The various histological changes over time may reflect weakening of the 
ligament which then fails when loaded [50, 60, 61]. One of the key problems in 
investigations into CCL rupture is that it is impossible to stage the injury (start of 
rupture, partial rupture or complete rupture), so it is difficult to equate the changes 
seen with certainty, to before, during or after the rupture.  
 
Collagen is not the only component of interest in ligaments – proteoglycans (PGs) 
and glycosaminoglycans (GAGs) also play an important role in integrity of ligaments 
[43, 62, 63]. Examples of such PGs include aggrecan, biglycan, decorin, fibromodulin 
and lumican [64-68]. Cells secrete the PGs directly into the extracellular 
environment, where they are important in the strength, structure and assembly of 
the extracellular matrix. Due to the electrostatic attraction between the PGs and 
water [63], they are important in the osmotic potential of the ligament and the 
ability to withstand stress and compression. An increase in water content changes 
the viscoelastic properties of the ligament and may lead to an increase in CCL 
rupture [46, 50, 69, 70]. PGs are important in collagen formation, assembly and 
organisation of the fibrils [66, 71, 72]. They are also to be considered ideal 
candidates to study for association with CCL rupture susceptibility [68, 73]. 
 
Bone conformation 
A steep tibial plateau angle (TPA) has also been proposed as a possible aetiological 
factor for CCL rupture in dogs [74-78]. The tibial plateau angle (TPA) can be 
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demonstrated on the radiograph (Figure 1.3) and is the angle at the top of the tibia 
bone (between the tibial plateau and the long axis of the tibia). It is thought to be 
important in CCL rupture as the gradient of the tibia determines the strain placed 
on the CCL. Static loading models have indicated that the gradient of the tibial 
plateau correlates with the strain placed on the CCL [79, 80]. However, such models 
do not involve dynamic stabilisation from major muscle groups acting across the 
stifle joint, so this remains a controversial area. Some researchers have found a 
significantly greater TPA in dogs with CCL rupture compared to dogs without CCL 
ruptures [81], whereas  other research shows no statistical evidence for tibial 
plateau gradients and CCL rupture [82, 83].  
 
 
Figure 1.3. Radiograph of the stifle joint showing the tibial plateau (kindly 
provided by Professor John Innes, University of Liverpool). 
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Narrow intercondylar notch width has also been implicated in the 
aetiopathogenesis of CCL rupture [76, 84-86]. The intercondylar notch is the site of 
the origin of the CCL and the ligament passes cranially, medially and distally 
through the notch [11]. If the notch is stenosed, there is likely to be impingement 
on the CCL such that the CCL may be more likely to be mechanically damaged. An 
illustrative diagram depicting the anatomical location of the intercondylar notch is 
shown in Figure 1.4. 
  
 
  
- 21 - 
 
 
Figure 1.4. Cranial aspect of the left stifle joint of a dog depicting the 
intercondylar notch. The patella has been displaced and retracted distally. The 
joint is in extreme flexion and the joint capsule opened to reveal the intracapsular 
structures. Adapted from Colour Atlas of Clinical Anatomy of the Dog and Cat 2nd 
Edition [87].  
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Degeneration of the ligament structure 
Although CCL rupture often presents as acute onset lameness, it is generally 
thought to occur after progressive degeneration and subsequent weakening of the 
ligament [4]. As such, it is typically a non-contact injury in dogs. This degeneration 
has been associated with changes in the extracellular matrix (ECM) [4, 50], with a 
reduction in the structural and functional properties of the CCL. This weakening 
may then enable the ligament to stretch or partially tear under what might be 
considered physiological loads, before a complete rupture presents itself [88]. The 
degeneration and weakening of the ligament may also be explained by higher than 
normal levels of collagenase being present in transected ligaments compared to 
normal, healthy ligaments. Amiel et al. [89] documented this finding when 
examining normal and transected CCLs of rabbits. Degeneration of the ligament 
may also be consistent with normal age related changes that occur over time. Over 
time, gradual functional and structural deterioration of the ligament structure 
occurs, with loss of ligamentocytes, metaplasia of the ligamentocytes to other cells 
(such as chondrocytes) and loss of collagen fibril organisation and strength [4, 90, 
91]. Age related degenerative changes are consistent with reports that CCL rupture 
has an increased incidence in older dogs [27]. 
 
Size and obesity of dogs 
Large breeds of dogs are more susceptible to CCL rupture than smaller breeds [92]. 
This can be attributed to more stresses on the joint in the larger breeds of dog. 
Duval et al. [27] and Whitehair et al. [93] have both documented that dogs 
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weighing >22kg had a higher prevalence of CCL rupture, at a younger age, than 
smaller dogs under 22kg. Obesity has also been documented to increase the risk of 
CCL rupture in Cocker Spaniels [94]. This study showed that Cocker Spaniels with 
CCL had a greater body weight than Cocker Spaniels without CCL rupture. Another 
experiment in Labrador Retrievers showed that those on a limited food intake 
regime had a significantly lower incidence and severity of osteoarthritis compared 
to those dogs with no food restrictions [95]. 
 
Hormonal influences 
Another factor that also might play a part in CCL rupture is hormonal influences on 
tissue metabolism. In humans, ACL rupture was reported to be more common in 
females compared to males [96-99]. Female dogs have a higher incidence of CCL 
rupture than male dogs [93] and CCL rupture was found to be more common in 
dogs neutered early (before 8 months) compared to dogs neutered after puberty 
[100, 101]. Differences in oestrogen, progesterone, testosterone and relaxin 
between male and female athletes, as well as the continual monthly variations of 
hormones in females, have all been hypothesised to play a role in the increased risk 
of rupture of the ACL in women [30, 96, 99, 102, 103]. Research has shown a 
statistically increased risk of ACL damage for female athletes during the ovulatory 
phase of the menstrual cycle [104].  
 
 
  
- 24 - 
 
Auto-immune components 
Auto-immune reactions have been hypothesised as influencing factors for CCL 
rupture [3, 31, 105, 106] because synovial inflammation (synovitis) is commonly 
found in the joint during repair of the ligament. Whether this is a consequence of 
the CCL rupture or a damage initiating factor is still under debate. However, 
synovitis has been found to increase the risk of contralateral CCL rupture [31, 107]. 
In rabbits, persistent synovitis has been found to cause disorganisation of the 
ligament framework, causing marked changes in the morphological characteristics 
of the CCL. This resulted in a significant decrease in tensile strength of the ligament 
[108]. 
 
Inflammatory cells, such as B and T lymphocytes, TRAP positive macrophages and 
CD1+ cells have all been found to be increased in the synovium of CCL ruptured 
dogs [109, 110] and also in the synovium of dogs with stifle arthritis [111]. 
Normally, the synovium that surrounds the stifle joint acts as a protective barrier to 
the cruciate ligaments which are enveloped between synovial membranes. The CCL 
is shielded from the immune system by a thin synovial lining. This means that any 
locally produced antigens will form immune complexes that will remain within the 
synovial space and have an unhindered local affect [105]. Due to the CCL being 
primarily composed of collagen type I fibres, any anti-collagen type I antibodies 
formed would bind to the CCL making it more susceptible to degradation and 
rupture [105]. If the CCL is damaged, neo-epitopes and other damage-associated 
molecular patterns (DAMPs) may be released from the ligament tissue and act as 
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antigens, causing innate and adaptive immune response to local tissues [112, 113]. 
This process may not act alone in causing CCL rupture, but it may well act as a 
promoter for further rupture. Persistence of the antigen presence and subsequent 
immune response, along with the prolonged inflammation, is thought to play an 
exacerbatory role in CCL rupture and the associated pain and inflammation within 
the joint.  
 
Whether the inflammatory and auto-immune components cause CCL rupture or if 
they occur secondary to the rupture of the CCL is still under debate [114-116]. 
Exposed antigens may also play a role in initiating osteoarthritis (OA), as OA has 
been proposed to be, at least partially, caused by an auto-immune response with 
collagen as the direct initiator [112, 117]. It is unclear whether the degradation of 
the CCL and subsequent release of collagen antigens is a significant cause of the OA 
or whether the direct and prolonged inflammation within the synovial joint leads to 
OA [26, 117]. Whichever the case, OA occurs simultaneously with the CCL injury and 
is unavoidable and untreatable.  
 
Major Histocompatibility Complex and CCL rupture 
Cell mediated immunity is regulated by the major histocompatibility complex 
(MHC) which can have an important role in disease susceptibility and resistance 
[118]. MHC has been implicated in many autoimmune diseases such as diabetes 
[119], hypothyroid disease [120], Addison’s disease [121], systemic lupus 
erythematosus (SLE) [122], anal furunculosis (AF) [123] and rheumatoid arthritis 
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(RA) [124]. In dogs the MHC region is found on chromosome 12 and the genes are 
called the “dog leucocyte antigen” (DLA) system.  
 
MHC molecules are transmembrane glycoproteins, which capture and present 
epitopes of antigens to T-cell receptors and initiate immune response cascades. The 
MHC region is highly polymorphic, with many alleles existing for each gene. 
Expression of the genes is codominant, with most individuals being heterozygous. 
This allows a wide range of antigen presentation to be available and maximises the 
immune response to foreign antigens. Loss of heterogeneity (diversity of MHC) due 
to inbreeding can result in an increased susceptibility to autoimmune diseases 
[125]. 
 
Genetics 
It should be considered that a genetic element could be a significant predisposing 
factor of pathological CCL changes and the subsequent degeneration. From 
epidemiological studies, it is apparent that CCL rupture is not a classical genetic 
disease, as characterised by simple Mendelian genetics [126]. It is instead thought 
to be a polygenic, multifactorial, complex genetic trait [36]. As it is obviously not a 
monogenic condition, it will not be possible to find a single, simple, genetic basis 
explaining the rupture susceptibility. It will however, hopefully become possible to 
determine which dogs are more at risk of developing a ruptured CCL. Those with 
predisposing alleles may be detected by a genetic screening test. This information 
could then be used to inform breeding strategies, whereby dogs could be screened 
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for the “risk” alleles before breeding. In order to achieve this, it would be necessary 
to identify a set of susceptibility markers.  
 
It has been widely reported that several dog breeds are more or less susceptible to 
CCL rupture than others. Breeds such as the Greyhound, Dachshund, Basset Hound 
and Doberman Pinchers are less likely to rupture their CCL [27, 93] than dogs in the 
high risk category such as Newfoundlands, Labrador Retrievers, Rottweilers and 
Saint Bernards [2, 6, 13, 27, 60]. Dogs in the high risk category often rupture their 
ligament without any apparent traumatic circumstances and as a result, young dogs 
rupture their CCL suddenly when only performing simple day-to-day activities, such 
as during play, walking or running [6, 14].  
 
Rupture of one CCL puts a dog at higher risk of rupturing (or otherwise damaging) 
the contralateral CCL - studies have indicated this to be around 54% risk in 
Labradors [107]. This value can vary between 22-54% depending on which breed is 
being studied [33, 107, 127, 128].  
 
The genetic mode of inheritance of CCL rupture is postulated by some researchers 
to be autosomal recessive with around a 51% penetrance [6]. This means that for 
every dog that has the “risk” allele, just over half of the dogs will actually rupture 
their cruciate ligament. With a heritability of only 27% [6], this clearly implies that 
other factors, both intrinsic and extrinsic such as those listed above contribute to 
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development of CCL rupture. Nonetheless, the inherited genetic component, 
although relatively small is still likely to play an important role in CCL susceptibility. 
As one cannot tell whether or not a dog will be affected, there is a need to identify 
the specific genes and/or genomic regions that might be involved in the CCL rupture 
susceptibility, initiation or progression.  
 
Newfoundland dogs and CCL rupture 
Newfoundlands are a large breed of dog commonly used for draught and water 
rescue work. They are known for their gentle docile nature as well as their strength 
and endurance [129].  
 
Figure 1.5. Structure and form of a Newfoundland dog1 
 
                                                     
1 Reproduced with permission: ©David Cant 2013 
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The origins of the Newfoundland dog as a breed are vague, but the breed is thought 
to have arisen when a “large Mastiff-type dog” was brought back to England from 
Canada by European fisherman and explorers. The modern breed as known today, 
developed from there around the 1800s. Many, if not all American Newfoundlands 
have an ancestry traceable back to one imported European dog (Siki) around the 
end of World War 1 and whose son (Ch. Harlingen Neptune of Waseek) started the 
first large kennel in the United States [130].  
 
Strict breed standards dictate which dogs can be registered within a breed in the 
dog clubs. In the UK the standard colours for registration are solid black, brown or 
grey, black with white markings, brown with white markings and Landseer (white 
with black markings). American standard colours are the same with the solid colour 
markings, but registration restrictions mean white markings on the coat are only 
allowed on the chin, chest, toes and tip of tail. In Canada brown and grey colours 
are not recognised within the breed/kennel clubs and in some European countries 
such as France and Germany (including the Fédération Cynologique Internationale), 
the Landseer is considered to be a separate breed, although in the UK and 
USA/Canada the breed is considered to be the same [129, 131, 132]. 
 
CCL rupture is a major clinical problem within the Newfoundland breed along with 
other genetic conditions including hip and elbow dysplasia [133-135], cystinuria 
[136], dilated cardiomyopathy (DCM) [137] and sub-aortic stenosis (SAS) [138].  
Estimates from other studies in the USA, suggest that CCL rupture has a 22% 
 
  
- 30 - 
 
prevalence in Newfoundland dogs, a heritability of 27% [6] with a postulated 
recessive mode of inheritance, strongly indicating that that there is a genetic 
component to the CCL rupture [6]. Heritability may be under-represented however, 
because a dog may have the risk alleles and not rupture its CCL; hence it is likely the 
true value could be much higher. In the past 10 years (from 2002-2011) the mean 
number of Newfoundlands registered each year with the UK Kennel Club was 976 
(range 838 - 1,145). Considering the estimated impact of 22% prevalence of CCL 
rupture in Newfoundland dogs, this would estimate to be around 215 incidences of 
CCL rupture a year (excluding any contralateral ligament rupture). Radiograph 
scoring schemes for hip and elbow dysplasia [139, 140] and DNA screening tests for 
DCM and SAS [141] are already in place to try and reduce the incidence of these 
conditions in the breed. It is hoped that a DNA screening test for CCL rupture will be 
added to the list at some stage in the future, to help further improve the health and 
welfare of the breed.  
 
Canine genetic studies 
The dog has 78 chromosomes which are arranged in pairs; in each pair, one 
chromosome is inherited from each parent. The canine genome was published in 
2004 by the BROAD institute at MIT/Harvard using sequences from a female boxer 
dog and a poodle [142]. Since the publication of the canine genome, huge advances 
have been made in investigating conditions with genetic components in the dog. A 
new annotation of the canine genome (CanFam3) was released in May 2012. In this 
thesis, unless otherwise stated all analyses and descriptions relate to the CanFam3 
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genome annotation, although many SNPs and genes investigated had sequences 
initially chosen from CanFam2. 
 
Pedigree dogs are seen as a suitable species to study as models for many complex 
human genetic diseases. Studies of many naturally occurring diseases in dogs such 
as CCL rupture, arthritis, epilepsy, deafness and cataracts have identified similar 
aetiologies and/or pathogeneses to human versions of these diseases [142-145]. 
Comparative genetics is much easier to translate between dogs and humans than 
mice and humans because dogs are genetically more similar to the human than the 
mouse [146]. Many genes in dogs have orthologues in humans with the same 
function. Therefore, not only can the research from this study be used for studies of 
CCL rupture in Newfoundlands and other dog breeds, but it could also have 
implications in human research. Causal genetic variants for diseases such as 
Duchenne muscular dystrophy [147], narcolepsy [148] and osteogenesis imperfecta 
[149] were first identified in the canine version of the disease and then were 
subsequently systematically applied to these Mendelian disorders in Man. 
 
The canine genome shares substantial homology with the human genome and dogs 
offer great advantages over humans for studying certain diseases. Dogs have a 
significantly shorter lifespan than humans, so longitudinal studies are much easier 
to conduct in dogs than in humans and reduce the need for specialised housing for 
studies in mice/rats. Dogs also share the same environment with man [144] so the 
impact of environmental factors (housing, weather, cigarette smoke etc.) can be 
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taken into account. The dog has a highly conserved breed structure and 
comprehensive pedigree data is readily available from many generations [144]. 
Pure breed pedigree dogs in particular, show very high linkage disequilibrium (LD) 
[150]. This means that smaller numbers of a breed can be used in a genetic study to 
achieve the same statistical power needed for a similar study conducted on human 
subjects. It also means that fewer genetic variations need be studied within a breed 
as the SNPs are often in LD with each other.  
 
The dog has a unique population structure with minimal variation due to the small 
amount of founders in each breed and “closed” breeding populations [151]. There 
are two distinct “bottlenecks” in the history of dog evolution [142, 151, 152]. The 
first bottleneck occurred when dogs became domesticated from their close 
ancestor the wolf. The second when humans started selectively breeding the dogs 
for desirable, breed-specific characteristics i.e. to hunt, to retrieve, to point, for 
long snouts, short legs etc. [143]. This has resulted in large phenotypic diversity 
between breeds. As a result of the breeding patterns that have developed to enable 
a breeder to produce the ideal pedigree dog, for example, the use of popular sires 
as studs, genetic diversity is reduced within each breed [151]. One example of such 
restrictive breeding practises is that for a dog to be registered as a “pure-breed” in 
accordance with the kennel club guidelines, both of its parents must have been 
registered under the same breed classification.  
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Genetic variations 
The release of the human genome in 2001 enabled great advances in investigations 
into diseases and population genetics [153]. As a result the natural variations in 
DNA can be assessed and can provide estimation for risk of an individual to specific 
disease susceptibility or resistance. The most common variations in DNA are called 
single nucleotide polymorphisms or SNPs [154]. These are variations in the DNA 
sequence and involve substitution of one of the bases (A, T, C or G) in the DNA 
sequence with another. Other common DNA variations that have been identified in 
DNA include; INDELs (Insertion/deletion) [155] where a base or number of bases 
is/are inserted or deleted in the sequence, microsatellite markers (MSAT) [156] 
where 2-4 bases are repeated within the DNA sequence and the number of repeats 
can vary between individuals and copy number variations (CNV) [157] where a 
section of the DNA is replicated. MSATs have traditionally been used as the 
molecular markers of choice to determine genetic associations with disease [158]. 
More recently however, SNP chip arrays have superseded MSAT analysis due to the 
high frequency of SNPs within the genome [159]. 
 
SNPs within a gene may be intronic (within an intron), exonic (within an exon), 
synonymous (the amino acid is not changed as a result of the SNP), non-
synonymous/missense (the amino acid is changed by the SNP and the protein 
coding sequence is altered). SNPs that cause a frameshift in the DNA sequence (by 
addition or deletion of a base) often lead to truncated proteins by generation of 
premature stop codons within the DNA reading frame [160]. The non-functional 
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protein generated as a result can have severe consequences in health and disease 
[161, 162]. SNPs can also be found in parts of the genome that are devoid of 
protein coding genes, i.e. intergenic regions, where the SNP may be involved in the 
regulation of gene expression (in promoter or enhancer regions) or non-coding 
regulatory RNA molecules. Intergenic SNPs that show association with disease may 
be in LD with SNPs that are up or downstream of an actual gene, or in LD with a SNP 
that is within a functional gene. The exact function of variants in non-coding regions 
of the genome still often remains unclear. 
 
 
Intronic and synonymous SNPs are most likely to be non-functional mutations as 
they do not have a direct effect on the protein coding regions. This is because the 
mutation is spliced out before the translation of RNA to protein (an intronic SNP), 
or the amino acid in the sequence is not changed (a synonymous SNP). However, 
they may be functional if they affect splice sites or regulatory regions that affect 
downstream processing, protein folding or function and/or the stability of 
microRNA [163]. These SNPs, although sometimes significantly associated with a 
disease are unlikely to be the actual causative mutation but are likely to be in LD 
with the causative mutation which may be exonic or a non-synonymous mutation 
that causes a change in the amino acid. As a result of the amino acid change, the 
protein folding will be altered as the secondary, tertiary and quaternary protein 
structures may be changed (as established by Anfinsens dogma [164] – the protein 
folding is determined by the amino-acid sequence). The frequency of these types of 
mutations in a population is higher relative to mutations that have a direct effect on 
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protein coding, structure and formation such as non-synonymous (missense) SNPs 
and frameshift mutations (INDELs) [165]. 
 
In order to study genetic variation within a species, it is important to understand 
how the variations are linked within a species. The developments of genetic maps 
and advances in analysing linkage disequilibrium (LD) have made this possible. LD is 
the non-random association of alleles at two loci during recombination [166]. When 
a particular allele at one locus is found together with a specific allele at a second 
locus, more often than expected if the loci were segregating independently, then 
they are said to be in linkage disequilibrium with each other. LD is also a measure of 
population size and genetic structure [167]. In large, out-bred populations (such as 
humans), genetic diversity is huge as there have been many recombination events 
throughout evolution i.e. LD is low. However, large populations themselves do not 
necessarily correspond with low LD if there are only a small number of founders in 
the population (i.e isolated populations).  
 
The dog has high LD when compared to the “out-bred” human population, due to a 
small number of founders and limited outbreeding [150, 168]. Genetic variants 
differ between dog breeds and although LD is relatively short between breeds, it is 
greatly extended within a breed and is much greater than that seen in human 
populations [150]. Of the dog breeds that have been studied to date, Labrador 
Retrievers show the shortest LD because the heterogeneity within the breed is high, 
especially when compared to breeds such as the Japanese Akita and the Pekinese 
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[150]. This is due to the Labradors popularity as a breed (it is the UK’s most popular 
breed of dog [23]) in comparison to the Akita and Pekinese which are much less 
popular. There were severe reductions in the Akita breed numbers during World 
War 2 [150] which significantly reduced the number of founder dogs for the 
modern breed and consequently reduced LD. 
 
Maintaining genetic diversity is of great importance when considering inherited 
diseases. Genetic diversity in dogs is reduced due to selection pressures (popular 
sires and dams), bottlenecks in breed creation and closed breeding populations 
[169]. This has led to a considerable number of inherited genetic diseases and 
defects that are overly prevalent in certain breeds. The inbreeding coefficient can 
be used to determine the level of genetic diversity within a breed [170]. The higher 
the inbreeding coefficient, the more common ancestors are present in a pedigree. 
The UK Kennel Club will no longer register mother/son, father/daughter or 
brother/sister matings, a plan that has been put into place to reduce the level of 
inbreeding. They have also introduced a MateSelect™ program that allows the 
breeder to determine the inbreeding coefficient of each mating.  
The Kennel Club describes the inbreeding coefficient as: 
“The probability that two copies of the same gene have been inherited from a 
common founder - that is an ancestor shared by both parents. The lower the inbreeding 
coefficient, the lower the probability (risk) that this will happen.” [171] 
The Newfoundland breed as a whole has an inbreeding coefficient of 4.8%, which 
translates to approximately a 1 in 21 chance that the dog will inherit the same gene 
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from a common ancestor that appears in both the sire’s and dam’s pedigree. For a 
pure-bred dog this is relatively low compared to some breeds such as the King 
Charles Spaniel which has an inbreeding coefficient of 11.8% and suffers severe 
hereditary health problems. The other breeds investigated in this project have 
inbreeding coefficient values of 6.4% (Labrador Retrievers), 6.8% (Rottweilers) and 
6.7% (Staffordshire Bull Terriers). 
 
Quantitative trait mapping for complex polygenic disorders (such as CCL rupture) 
remains difficult relative to monogenic trait/disease mapping [172]. This 
emphasises the need for accurate and clear phenotyping so that any background 
“noise” – such as breed, geographical location, coat colour etc. can be reduced. 
Since the release of the dog genome in 2004, many advances in understanding the 
genetic basis of canine (and human) diseases have been made in a relatively short 
time frame. With the release of the newest canine genome assembly (CanFam3 in 
2012), in addition to the advent of newer next-generation sequencing platforms, it 
should become easier to identify causative mutations that are involved in complex 
diseases. Large regions of association within chromosomes can be narrowed down 
to specific mutations, which will hopefully then be used to develop screening tests. 
 
Aims of the Project 
It is hypothesised that there is a genetic basis to CCL rupture which can be 
identified at a molecular level. To investigate this, the project aims were to use 
molecular genetic techniques (GWAS, Sequenom, Q-PCR and tissue culture) to; 
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1. Identify genetic mutations and putative genes which are associated with 
resistance or susceptibility to CCL rupture in Newfoundland dogs. 
2.  Determine whether there are any genetic differences between 
Newfoundland dogs from two different populations (Europe and North 
America).  
3. Determine whether the genetic mutations identified within the 
Newfoundland breed are specific only to the Newfoundlands or can also be 
found in other CCL rupture susceptible dog breeds (Labrador Retrievers, 
Rottweilers and Staffordshire Bull Terriers). 
4. To determine the expression levels of select candidate genes between 
ruptured and healthy CCL tissue. 
5. To determine if there is an autoimmune component to CCL rupture by 
studying the DLA region for association. 
6. To determine if TNFα stimulation of ligamentocytes in vitro can be used as a 
laboratory model of the pathological changes seen in CCL rupture. 
 
Once the associated SNPs have been identified they could be used to develop 
genetic screening tests to identify susceptible/resistant dogs. This data can then be 
used to initiate breeding strategies to try and reduce the incidence of CCL rupture 
in dogs. This will be of great economic and emotional benefit to dogs, dog breeders, 
owners and all! 
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Chapter 2.        
General Materials 
& Methods 
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The laboratory techniques presented in this chapter are generic to all subsequent 
experiments described herein. Deviations from the general protocol for individual 
experiments are detailed in the relevant chapters of the thesis. 
 
Clinical diagnosis and phenotypic status 
The phenotypic description of the dogs was determined according to the 
inclusion/exclusion criteria of the study.  
 Inclusion criteria (cases): Dogs with CCL rupture of any age. CCL rupture 
must have been confirmed during surgery. 
 Exclusion criteria (controls): Healthy control dogs, with no symptoms of CCL 
damage, were over five years of age and showed no obvious signs of CCL 
rupture (hind limb lameness or pain).  
 
Ideally, the control dogs should have been examined by a veterinary surgeon with a 
minimum qualification of a CertSAS to ensure no clinical features of CCL rupture 
(such as medial buttress formation, stifle joint effusion, positive tibial thrust or 
positive cranial draw) were present. This clinical assessment was not available for 
all control samples submitted and is a recognised limitation of the project; only 35% 
of control samples were subjected to this assessment. 
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Dogs included in the study 
Samples from Newfoundland dogs that had ruptured their CCL (cases) and those 
that had no clinical evidence of CCL rupture (controls) had DNA extracted from 
either EDTA blood (excess from other veterinary tests already being carried out), or 
salivary swabs – see Sample collection method, page 44, for more detail.  
 
The majority of the Newfoundland CCL rupture cases and controls were collected 
by attending dog shows, mailing sample collection kits to the owners and breeders 
or by obtaining samples sent from veterinary surgeons. The remaining CCL rupture 
cases and controls, as well as the cases/controls for other breeds used in the study 
(see below) were taken from the UK DNA archive for companion animals 
(http://www.liv.ac.uk/dna_archive_for_companion_animals/) and had already 
been collected for previous research studies [173]. Full informed, written owner 
consent had been given to use these samples in research studies.  
 
Other breeds that have a high risk of developing CCL rupture were also included in 
this project to enable comparisons of the genetic predisposition between the 
breeds. These breeds were Labrador Retrievers, Rottweilers and Staffordshire Bull 
Terriers. The decision to use the other breeds (especially the Staffordshire Bull 
Terriers) was taken retrospectively after the main sample collection process had 
been carried out. This meant that specific collection of the samples needed (both 
cases and controls) could not be carried out as for the Newfoundlands. Therefore, 
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the majority of samples from these breeds were obtained from those already 
integrated into archive databases – which were limited in number. 
 
The CCL rupture case samples for the other breeds were taken from the UK DNA 
archive for companion animals at Liverpool. The phenotype of the dog (breed, age, 
sex, CCL rupture) was known. The control samples for the Labrador Retrievers, 
Rottweilers, Staffordshire Bull Terriers and some Newfoundland samples were 
taken from the Veterinary Laboratory agency (VLA) archive (a subset of samples 
within the UK DNA archive for companion animals). The VLA samples represented a 
random population of UK dogs with no disease information and were therefore 
assumed to be controls with no cruciate ligament rupture – this is a recognised 
limitation in the project as no clear diagnostic information is available.  
 
Specific information on breed, sex, age and numbers of cases and controls used are 
given in the Appendix (Appendix 1). 
 
Each sample submitted to the study was accompanied by a consent form (shown in 
Appendix 2) in which the owner gave their full informed written consent. The 
owner supplied information about the dog, including age at sample collection, sex, 
whether the dog was neutered/spayed. Information about the injury (if applicable) 
was also provided, such as age at diagnosis/injury, how the injury was caused (slip, 
fall, accident or during normal activity) and surgical information was provided when 
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available. The owner also consented to allow the sample to be stored and 
integrated in the UK DNA archive for companion animals and used as appropriate in 
this study and other scientific research. 
 
Samples were initially collected from dogs within the UK only, but sample 
submission rate was very low, despite multiple approaches and addresses to UK 
Newfoundland breeders and owners at their club meetings and dog shows for 
samples. On the basis that at the current rate of sample collection, progress would 
not be enough to enable the project to proceed within a suitable timeframe, the 
sample collection area was extended to include North America and mainland 
Europe.  
 
Linblad Toh et al. (2005) [142] suggested that for a multigenic trait, at least 100 
cases and 100 controls were needed to detect disease alleles. Factors including 
allele frequency, the interaction of the allele with other variants and the risk that 
having the allele confers to the dog, also determines the number of cases and 
controls needed to produce a significant study. They found that an allele that gives 
a 5-fold increase in disease risk will be detected with 97% power and an allele that 
increases risk 2 fold will be detected with 50% power using 100 cases/100 controls. 
These numbers (as well as some studies using smaller cohorts of dogs) have been 
successfully used to map traits and diseases such as epilepsy, diabetes and atopic 
and digital dermatitis [174-177]. In our study, the numbers of dogs (for the majority 
of breeds) are close to Linblad Toh’s estimates; 99 cases and 172 controls for the 
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Newfoundlands, 124 cases and 165 controls for the Labrador Retrievers, 57 cases 
and 81 controls for the Rottweilers with the Staffordshire Bull Terriers falling short 
at 13 cases and 38 controls. As the dogs are pure-breeds the relationship status 
between each dog is such that the linkage is high enough to detect mutations in a 
much smaller number of dogs than would be required if the study was being 
conducted on a human population.  
 
Sample Collection for DNA extraction 
In order to perform the experiments in this project it was necessary to collect 
biological samples to obtain DNA from dogs with and without CCL rupture. Blood or 
saliva samples were collected from Newfoundlands and other selected dog breeds 
(Labrador Retrievers, Rottweilers and Staffordshire Bull Terriers) and were 
integrated within the UK DNA archive for companion animals at Liverpool 
(www.liv.ac.uk/dna_archive_for_companion_animals). The research in this project 
was approved by the University's Research Ethics Sub-Committee. 
 
Collection of veterinary blood samples solely for research purposes in the UK 
without a home office licence is prohibited; however, residual blood remaining 
after a diagnostic sampling may be used for research and does not require a 
licence. Collecting saliva with swabs is considered a non-invasive procedure and 
does not require a licence. 
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Sample submission was either an EDTA tube of blood (residual blood remaining 
from routine veterinary diagnostic tests carried out on the dog), or, if blood was not 
available then salivary swabs were taken using the Oragene™ saliva collection kits 
(Oragene™, DNA Genotek, Ontario, Canada). Samples were only included in the 
project if the owners gave their full written consent to the blood/samples being 
stored and used in scientific research.  
 
Oragene™ sampling kits were mailed to owners, who collected the sample 
themselves. The Oragene™ kit consisted of sponges and a collection tube 
containing the Oragene™ buffer solution. The owner simply had to place the 
sponges in the dogs’ mouth (at the cheek pouch) and saturate the sponges with 
saliva. The sponges were then removed from the mouth, placed directly into the 
collection tube, shaken and then mailed back to us by standard post. The benefits 
of using the Oragene™ sample collection process is that the sample is stable after 
collection for up 6 months at room temperature and is easily mailed to and from 
the owners for ease of collection. At the start of the sample collection process the 
only kits available were the human collection kits (OG-510). Soon after beginning 
the project, Oragene™ released the animal collection kits (OA-400) which was 
subsequently used as the standard collection method. The difference between the 
two kits was a change in design (tubes rather than pots) and a slight (unidentifiable) 
change in buffer solution that required an extra processing stage in the DNA 
extraction method – detailed further on in the chapter in the DNA extraction 
section. 
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DNA extraction 
Blood 
DNA was extracted and prepared from EDTA blood using the Qiagen DNA Blood 
midi kit (Crawley, UK) following the manufacturer’s instructions and as previously 
described [178]. The DNA was then quantified using a nanodrop 
spectrophotometer (Thermo scientific, Massachusetts, USA, www.nanodrop.com). 
 
Saliva 
DNA from Oragene™ saliva kits was extracted following the manufacturer’s 
protocol (DNA genotek, Canada) [179], but modified such that the whole sample 
could be processed instead of 500µl aliquot. Briefly, samples were mixed and 
placed in a water bath at 50˚C for one hour. Excess liquid was squeezed from the 
sponges into the collection tube. Oragene™ DNA purifier was added to the tube 
(1/25th volume) and vortexed to mix. Samples were cooled on ice for 10 minutes 
and then centrifuged at 4000g for 17.5 minutes. The supernatant was transferred to 
a new labelled tube. For animal kits, 5M NaCl (60µl/ml) and an equal volume of 
100% ethanol was added and then mixed by inverting 10 times before leaving at 
room temperature 10 minutes. The NaCl addition was omitted for the human kits. 
Samples were centrifuged at 4000g for 17.5 minutes. The supernatant was removed 
and 1ml of 70% ethanol was added and left for 1 minute. The ethanol was removed 
and the pellet dried for 15 minutes. The pellet was resuspended in 300μl buffer AE, 
vortexed for 30 seconds and placed in a 50˚C water bath one hour. The DNA was 
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transferred into a pre-labelled tube and was quantified using a nanodrop 
spectrophotometer (Thermo scientific, Massachusetts, USA, www.nanodrop.com). 
 
Salivary DNA extraction often generates lower quality DNA than that of blood, due 
to potential carryover from contaminants like residual food, hair, ingested dirt etc. 
within the sample. Furthermore, the collection of samples from salivary collection 
kits may introduce additional variation as they are collected in an uncontrolled 
manner by the owners. Owners may not have followed the instructions adequately, 
for example the owner may have sampled the dog immediately after food or drink 
or dropped the swab on floor. Variation in the amount of saliva collected on the 
swabs may also have affected the amount of DNA available. Some dogs may have 
been sampled with a dry mouth resulting in fewer cells from which DNA can be 
extracted resulting in a lower yield of DNA. Pooling a large quantity of saliva into 
the collection kit (for example collecting “drool”) effectively overloads the 
extraction process and can also reduce the yield of the DNA. The quality and 
quantity of DNA from salivary swabs, although lower than whole blood extracted 
DNA, is adequate for downstream applications such as genetic studies [180, 181]. 
 
Clean-up of DNA 
DNA purity was assessed using the 260:280 and 260:230 ratios obtained from the 
nanodrop spectrophotometer readouts. Pure DNA fluoresces at 260nm, pure 
uncontaminated DNA will have a 260:280 ratio between 1.8-1.9. DNA absorbs 
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ultraviolet (UV) light at 260nm, protein and phenol absorb UV at 280nm and 
carbohydrates at 230nm. Any substantial decrease in the values will indicate 
contamination with protein/phenol/carbohydrate. In some instances it was 
necessary to “clean up” the DNA to remove contaminants, as there were notably 
lower 260:280 and 260:230 ratios and a greatly increased peak at 230nm caused by 
organic carryover from the extraction process. Several methods were evaluated 
before deciding which method was the best to use on the samples in question. 
 
Ethanol purification of DNA 
Briefly, 1/10th volume of 3M sodium acetate and 2½ times volume of 100% ethanol 
were added to the “dirty” DNA. Samples were vortexed and cooled on ice for 15 
minutes before centrifugation at 10000g for 15 minutes. The supernatant was 
removed and 500µl of 70% ethanol was added to wash the pellet. The pellet was air 
dried for 15 minutes and then resuspended in 300µl buffer TE. DNA concentration 
and purity were quantified using a nanodrop spectrophotometer.  
 
Chloroform Clean-up of DNA 
The DNA was transferred to an eppendorf tube, 1/20th volume of chloroform was 
added, and the sample vortexed vigorously for 10 seconds. The sample was 
centrifuged at maximum speed for 10 minutes. The upper aqueous layer was 
transferred to a new pre-labelled tube and DNA was quantified using a nanodrop 
spectrophotometer.  
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Qiagen Column clean-up of DNA 
Ethanol (200µl of 100%) was added to 200µl of DNA and vortexed briefly. The 
sample was transferred into a Qiagen spin column (Qiagen, Crawley, UK) and 
centrifuged at 6000g for 1 minute. The filtrate was discarded and 50µl of buffer 
AW1 (Qiagen, Crawley, UK) was added and the sample centrifuged again at 6000g 
for 1 minute. The filtrate was discarded and 500µl of buffer AW2 (Qiagen, Crawley, 
UK) was added and the sample centrifuged at 20000g for 3 minutes. The filtrate was 
discarded and the samples centrifuged again at 20000g for 1 minute. The spin 
column was transferred to a new collection tube, 200µl of buffer AE (Qiagen, 
Crawley, UK) was added and the sample kept at room temperature for 1 minute 
before centrifuging at 6000g for 1 minute. The eluate was added back to the 
column and re-centrifuged at 6000g for 1 minute. The DNA was then transferred 
into a pre-labelled tube and was quantified using a nanodrop spectrophotometer. 
 
Of the above methods the chloroform clean-up method produced the best results; 
on average the chloroform lowered carbohydrate contamination by 26.6% 
compared to 23.4% by ethanol purification (as assessed by absorbance at 230nm on 
the nanodrop spectrophotometer) the column clean-up diminished yield such that 
it was not a viable method to use – data not shown. It was not possible to remove 
all of the carbohydrate contamination from the sample as saliva contains large 
amounts of carbohydrate from the heavily-glycosylated protein mucin [182]. As a 
result the 260/230 absorbance ratio alone was not considered a useful method of 
assessing the purity of DNA extractions from saliva samples, although it is adequate 
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for DNA prepared from blood. The chloroform clean-up method was used to “clean-
up” the contaminated DNA in this project. 
 
Quantification, normalisation and storage of DNA 
DNA was quantified using a nanodrop spectrophotometer (Thermo Scientific, 
Massachusetts, US) and was normalised (standardised) using molecular grade water 
either by hand or by using the Hamilton Microlab® Star robot (Bonaduz, 
Switzerland).  Samples were normalised to 100ng/μl for Illumina HD genotyping and 
20ng/μl for Sequenom genotyping. DNA was stored at -20˚C or-80˚C until it was 
required in experiments. All DNA for long term storage was integrated in the UK 
DNA Archive for Companion Animals at -80˚C. An XL20 robot (BioMarkerLab, 
California, US) was used to cherry pick samples that were already in the archive that 
were required for the study using the unique 2D barcodes allocated to each sample 
tube. 
 
Tissue collection and culture of ligament cells 
In order to examine changes in gene expression in CCL ruptured tissue it was 
necessary to collect both ruptured and healthy/control CCL tissues. Ruptured CCL 
tissue was collected at the time of reconstructive CCL surgery and was immediately 
placed into RNAlater (Invitrogen, California, US). The control tissue was sourced 
from cadavers of dogs that had been euthanased for reasons other than 
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degenerative joint disease and which had been donated to the University for 
teaching. 
 
CCL tissue was harvested from the stifle of the cadavers by sharp dissection, using 
an aseptic technique. Additionally, separate scalpels were used for incision of skin 
and the remaining dissection and the scalpel was rinsed in 100% ethanol between 
the cut into joint capsule and the extraction of the CCL. 
 
Ligamentocyte cell identification 
The primary cell type within the CCL is the ligament fibrocyte, otherwise known as a 
ligamentocyte [46, 183, 184]. These ligamentocytes are responsible for the creation 
and the maintenance of the extracellular matrix (ECM). The predominant ECM 
protein in the CCL is collagen type I, which is essential for the integrity and support 
of the ligament structure. The cells show typical fibroblast-like morphology.  
 
Monolayer cultures 
Ligament tissues were harvested from the cadavers by sharp dissection of the stifle 
joint, using an aseptic technique as described above. The tissue was immediately 
washed with Hanks Balanced Salt Solution (HBSS), before being digested overnight 
with 0.1%w/v bacterial collagenase in Dulbecco's modiﬁed Eagle's medium 
(DMEM/F12) with 5% fetal bovine serum (FBS) and 1% penicillin/1% 
streptomycin/1% amphotericin, at 37˚C on an orbital shaker. Following overnight 
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digestion, the released cells were recovered by sieving through a 40µm sieve to 
remove debris. Cells were pelleted by centrifugation at 1000g for 10 minutes and 
the pellet washed by resuspension of cell pellet in 5ml media (DMEM/F12 
glutamax). The cells were centrifuged at 1000g for a further 10 minutes to wash 
cells and remove all traces of collagenase. 
 
The cell pellet was resuspended in 1ml of tissue culture medium (DMEM/F12 
glutamax, 10% FBS, 1% penicillin, 1% streptomycin, 1% amphotericin) and the cells 
counted before seeding plates/flasks at appropriate density to allow cell 
proliferation and establishment of monolayer cultures. When cells reached 80% 
confluence, usually after 4-5 days at 37˚C, they were released with Trypsin/EDTA 
(1x). The media was replenished every 3 days. For subsequent experiments the cells 
were plated into six-well plates in triplicate and when confluent were either 
induced with TNFα (see Chapter 8) in media for 24 hours, or left in normal media as 
a control. 
 
After all experiments the cells were either cryopreserved for long term storage or 
lysed with Trizol for the first stage of RNA extraction. 
 
Lysis of monolayer cells using Trizol 
At the end of each culture period, the media was removed from the monolayer 
cultures and the cells washed with HBSS. Trizol was added at a ratio of 1ml/10cm3 
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(250µl for 24 well plate, 500µl for 12 well plate and 1ml for 6 well plate, 2.5ml for 
T25 flask). The cells were lysed by pipetting up and down several times and then 
left for 5 minutes at room temperature. The lysed cells were then transferred to 
RNAase-free eppendorf tubes and stored at -80˚C until RNA was extracted. 
 
Cryopreservation and resuscitation of cryopreserved cells 
Cryopreservation was used for long term storage of cells [185]. After trypsinisation 
the ligamentocytes were pelleted by centrifugation at 1000g for 5 minutes. 1x106 
cells were placed in each cryotube. The majority of media was removed leaving the 
cell pellet in approximately 300µl of media to which 1ml of cryofluid (92% FBS, 8% 
DMSO) was added. The cell pellet was resuspended. The cells were transferred to a 
cryotube which was subsequently wrapped in cotton wool and placed in a padded 
envelope at -80˚C overnight before being transferred to liquid nitrogen for long 
term storage [method from Professor SD Carter: personal communication].  
 
To re-inoculate cells in culture, frozen vials were removed from liquid nitrogen and 
immediately placed into a 37˚C water bath for 1 minute. The sides of the tube were 
wiped in ethanol before opening; 5ml of pre-warmed media was added dropwise to 
the cells. This was mixed gently and centrifuged at 1000g for 5 minutes. The 
supernatant was discarded and 1ml of media was added to the pellet. The cells 
were then counted and seeded at appropriate densities (1x106/ml). 
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RNA extraction 
Samples were lysed using Trizol (Invitrogen, California, US). For tissue samples, the 
tissue was wrapped in foil and placed into liquid nitrogen to deep freeze the 
samples. The tissue was then homogenised using a dismembrator (Mikro-
Dismembrator, Sartorius Stedim Biotech, France) and the powder was placed in Trizol 
(1ml of Trizol for 100mg tissue). For monolayer cells, the cells were lysed directly on 
the plate by adding 1ml of Trizol per 10cm3 as detailed above.  
 
RNA was extracted using PureLink RNA mini kits (Ambion, UK) using the normal 
phase separation, binding, washing and elution stages as detailed in the 
manufacturer’s protocol [186]. An added step of on-column DNase treatment 
(PureLink DNAase kit, Ambion, UK) [187] was carried out on the sample to remove 
genomic DNA contamination. RNA was eluted with 100µl RNAase free water. 
 
Assessment of quality and quantity of RNA 
Traditionally, RNA was assessed for purity using agarose gel electrophoresis and by 
measuring the bands of the 28S and 18S ribosomal RNA, but this was a subjective 
approach and required large amounts of RNA [188]. A newer method, now 
determined to be the gold standard for RNA quality assessment, requires only low 
volumes of RNA (1µl) and uses an automated comparison of the 28S and 18S RNA 
peaks [189]. The purified RNA was assessed for quality using the Agilent 2100 
Bioanalyser and a RNA Nano 6000 Chip Kit (Agilent, California, US). The integrity of 
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the RNA was assessed using the RNA Integrity number (RIN) value [189]. The RIN is 
calculated from the electrophoretic trace and is a measure of the integrity of the 
RNA, it ranges from 10 (intact RNA) to 1 (completely degraded RNA). The 
bioanalyser also gives the quantity of RNA present in the sample, as well as the 
28s:18s ratio, which for pure RNA has a 2:1 ratio.  
 
For this project, samples that had a 28s:18s ratio of ≥1.6 and a RIN value of ≥8 were 
selected. If necessary, the RNA was normalised to 0.1μg/μl using RNAase free 
molecular grade water before conversion to cDNA. 
 
cDNA synthesis 
cDNA is more stable than single stranded RNA, therefore the mRNA samples were 
transcribed immediately into cDNA to avoid any degradation and deterioration of 
the sample. There are three commonly used methods of producing cDNA from 
single stranded RNA, oligo dT’s, specific primers or random hexamers, as shown in 
Figure 2.1.  
. 
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Figure 2.1. The three methods commonly used to reverse transcribe RNA into 
cDNA – Baird 2013. 
 
OligoDt was chosen in this project as it only hybridises to polyadenylated mRNA at 
the 3’ end polyA tail and therefore minimises genomic DNA contamination. This 
method is highly specific in only transcribing polyA mRNA, but it can be limited in 
the fact that transcription may only proceed as far as 1.5KB, such that very long 
mRNA may not be transcribed completely to the 5’ end. Any primers designed for 
the cDNA should be designed as close to the 3’ end of the RNA as possible to ensure 
efficient conversion. 
 
Reverse transcription was performed using oligoDt primers and Superscript II 
reverse transcriptase (Invitrogen, California, US) according to the manufacturer’s 
instructions. Briefly, 10μl RNA (0.1μg/μl) was mixed with 1µl oligo-DT (0.5µg/μl 
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Invitrogen, California, US) and 1µl of 10nM dNTP mix (Invitrogen, California, US). The 
RNA was heated at 65˚C for 5 minutes, before being quickly chilled on ice. The tube was 
centrifuged to sediment the contents before 4µl of 5x first strand buffer (Invitrogen, 
California, US), 2µl of 0.1M DTT (Invitrogen, California, US) and 1µl of RNAsin (40U/μl, 
Promega, Wisconsin, US) was added. The tube was gently mixed and then heated at 
42˚C for 2 minutes. Superscript II reverse transcriptase (1µl, 200U/μl, Invitrogen, 
California, US) was added and the sample heated at 42˚C for 50 minutes, before the 
reaction was inactivated by heating at 70˚C for 15 minutes. The cDNA was stored at -
20˚C until use in the Q-PCR gene expression studies. 
 
General analysis and statistical methods 
All genotyping data were analysed using freely available software PLINK [190, 191] 
implemented using the program BCgene (BC Platforms, Finland). 
 
Quality assurance (QA) was carried out on the genotyping data to ensure only the 
top quality data was used for analysis. Cut off values were assigned for each of the 
following values and are specified in each individual chapter:  
 Minor allele frequency - frequency of less common allele in a population 
(denoted in PLINK by --maf) 
 Exact Hardy-Weinberg equilibrium in controls (denoted in PLINK by --hwe) 
 SNP and individual call rates - number of SNPs that have alleles assigned 
(denoted in PLINK by --geno and --mind respectively).  
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Case control associations were performed on the genotype data using a standard 
case control allelic association unless otherwise detailed [192, 193]. This is a basic 
chi-squared test of association (using a 2x2 contingency table with 1 degree of 
freedom) of the allele counts between cases and controls, regardless of the 
genotype combination from which they arise. This assumes a multiplicative model 
of inheritance, so that the risk of the disease increases by factor r for each allele 
carried. For example with genotypes AA, AT and TT, the risk increases by r for each 
T allele carried – AA = 1, AT = r, TT = r2 [192, 194]. 
 
A Cochran-Mantel-Haenszel (CMH) test (2x2xK) was performed on the genotype 
data when a stratified analysis was needed [195, 196]. This is a cluster based 
analysis that generates an average odds ratio that controls for confounding factors 
between clusters. This is referred to as a stratified analysis. 
 
Meta-analyses use statistical methods to compare similar studies with a similar 
hypothesis to examine results as a whole and to make the best use of all the 
information from all samples available, increasing statistical power.  This analysis 
was used where appropriate to combine results across multiple breed analyses 
[197]. This was run in PLINK using the command line --meta-analysis with the 
appropriate association data files written in. 
 
 
  
- 59 - 
 
Haploview case control analysis was performed to determine haplotype 
associations within the genotype datasets [198]. This was implemented using PLINK 
and Haploview. The standard Gabriel method was used to define haplotype blocks 
[199]. 
 
Significance of the data was determined by p-values, a raw p-value of ≤0.05 or a 
corrected p-value (see below) was used to infer significance in the data unless 
otherwise stated.  
 
Corrections for multiple testing (where applicable) were applied to counteract 
multiple testing [200]. There are various methods to use to correct for multiple 
testing, Bonferroni, permutation testing, or the Benjamini & Hochberg false 
discovery rate (FDR). Bonferroni correction multiples the p-value by the number of 
tests being carried out to lower the chances of type 1 error (false positives). As the 
highest accepted individual raw p-value for the GWAS data would have to be 
0.00000025 (0.00000025 x 200,000 = 0.05) this makes the test very conservative, 
especially given that dogs have very high LD, so the actual number of independent 
tests will be less than 200,000. Permutation testing involves the cases and controls 
being rearranged randomly and re-analysed to assess significance. It is standard to 
use 1000 [201] or 100,000 [202] permutations for correction in genetic studies. FDR 
testing consists of sorting the p-values in ascending order, then dividing each 
observed p-value by its percentile rank to get an estimated FDR. FDR gives the 
 
  
- 60 - 
 
expected percentage of false positives among all the claimed positive associations. 
The three methods will all be used in this thesis and the results compared.  
 
Hardy-Weinberg equilibrium (HWE) states that in an outbred, randomly mating 
population the allele frequencies will remain constant from one generation to 
another [203, 204]. It is represented by the equation:               where p 
and q are the frequencies of alleles for a locus in the population, p2 and q2 
represent the proportions of each homozygote and 2pq represents the proportion 
of heterozygotes. In an inbred population (such as pure-breed dogs) the 
populations are non-randomly mated and therefore the allele frequencies will not 
conform to the HWE. The observed allele frequencies are compared to the 
expected allele frequencies using an exact test designed by Wiggington et al. 2005 
[205] in PLINK, to produce a p-value which denotes the deviation of the SNPs from 
HWE. 
 
The odds ratio (OR) is used to provide an estimation of relative risk of an allele in 
the population [206]. It is a measure of magnitude of association between the cases 
and controls and can be calculated by dividing the odds of the allele in the cases by 
the odds of the allele in the control population: 
OR = 
  (   )
  (   )
 
‘s’ is the frequency of a disease-associated variant in cases and ‘f ‘ is its frequency in 
controls. The OR is used to determine the direction of association: >1 indicates that 
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allele 1 increases the risk of disease compared to allele 2 and <1 allele 2 increases 
risk of disease compared to allele 1, if the OR is equal to 1 then there is no 
difference in allele frequency between cases and controls (null hypothesis) [206]. 
The 95% confidence interval (CI) is the range at which the true value is thought to 
lie; 95% of the population values will fall between the two numbers given (upper 
and lower limit). The 95% CI of the OR is used to determine significance of the 
results; If the 95% CI contains 1 (null hypothesis) then the result should be 
considered non-significant, if the 95% CI does not contain the null hypothesis then 
the p-value should be significant, but if the window is window is wide then the 
certainty that the results are meaningful is reduced.  
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Introduction 
High density whole genome scanning provides an unbiased approach for scanning 
the entire genome to identify novel candidate genomic regions of disease 
association. Previously, candidate genes were selected based on their perceived 
involvement in the disease or disease process. Many genes were not screened for 
disease association because their function was unknown or was not thought to be 
relevant to disease susceptibility, onset or progression [207]. Consequently many 
associations may have been missed for not being in obviously “associated” genes. 
 
Genome wide association studies (GWAS) have been successfully been conducted 
for many human diseases, the most prominent paper evaluating the use of GWAS in 
common human diseases is the Welcome Trust Case control Consortium (WTCCC) 
[208]. This paper evaluates genetic contribution in seven common genetic diseases 
using 14,000 cases and 3,000 controls. Considering the dog has a unique population 
structure (highly inbred, genetically isolated populations with extended LD) fewer 
genetic markers and smaller sample sizes are required to find disease associations 
in dogs than in human studies [144, 150]. In human studies, to achieve whole 
genome coverage you require 200,000 to 500,000 markers [144] but this has 
significantly increased in recent years – the newest generation of Affymetrix human 
arrays now contains nearly one million SNPs (906,600, Human SNP Array 6.0). In 
canine studies this number is much reduced with as little as 10,000 markers needed 
[142] and the newest canine SNP chip contains nearly 200,000 markers (Illumina 
CanineHD chip). 
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High density SNP arrays have been successfully used to determine genetic 
involvement in canine disorders including atopic dermatitis, epilepsy and pituitary 
dwarfism as well as non-disease traits such as coat colour [174, 177, 209, 210]. 
These arrays are available for genome wide analyses of many veterinary species 
including the dog and are commercially available from Illumina (www.illumina.com) 
and Affymetrix (www.affymetrix.com).  As these arrays offer so much in terms of 
screening the genome for regions of disease association and generate high quality 
data unobtainable by other means, a genome wide approach was used to examine 
the canine genome for SNP associations with CCL rupture in Newfoundland dogs. 
 
Causative mutation(s) may be ancient or quite modern in origin [168]. If they are 
ancient they will have survived the selective breeding pressures of breed creations 
to form modern dog breeds and as a result will have been fixed in distantly related 
dog breeds. If the mutation is relatively modern the mutation will only be present in 
discreet clusters of one or a few modern breeds. GWAS is a powerful and relatively 
inexpensive approach to screening multiple dogs from a variety of breeds to try and 
determine the origin of the mutation(s) and whether or not it/they is/are present in 
different dog breeds. Multiple breeds may share the same phenotype caused by the 
same causal genetic variant. This is the case for a number of conditions, such as 
chondrodysplasia (dwarfism) and the brachycephalic (short snout) trait [211, 212]. 
This phenotype sharing due to the same causal genetic variation/region of interest 
was identified through GWAS using multiple breeds. Although we are only 
investigating CCL rupture via GWAS in one breed, Newfoundlands, it would be 
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interesting to examine the associations in other breeds and to determine whether 
the same associations for CCL rupture are fixed in the different breeds – this is 
beyond the scope of the current project. 
 
This is the first GWA study that has been conducted on CCL rupture using the high 
density CanineHD array. It is hoped that this study will allow novel mutations that 
have not previously been associated with CCL rupture to be determined in a cohort 
of Newfoundland dogs.  
 
Methods 
Sample collection and preparation 
Samples collection was either via salivary swabs (Oragene™, DNA genotek, Ontario) 
or from residual blood excess from veterinary investigations already being carried 
out (for more details see the main methods Chapter 2). The DNA was extracted as 
described in the main methods (Chapter 2) and then normalised to 100ng/µl using a 
Nanodrop spectrophotometer. 
 
DNA from 96 Newfoundlands – 48 North American (NA) and 48 European (EU) 
Newfoundlands (24 cases and 24 controls in each of the populations) was sent to 
Roslin Institute for genotyping on the Illumina CanineHD array.  
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Illumina genotyping  
The genome wide SNP genotyping of Newfoundland dog DNA samples was 
performed using the Illumina CanineHD chip (San Diego, California, US), with the 
hybridisation being performed at the Roslin Institute in Edinburgh. The SNPs on the 
chip were selected from the CanFam2 assembly of the dog genome. The new SNP 
chip (CanineHD) contains many more SNPs than the original Canine SNP chip array 
from Illumina (CanineSNP20), which contained 22,362 validated SNP probes; it also 
has greater coverage across the whole genome.  The CanineHD SNP chip contains 
173,662 markers evenly spaced across the genome with an average coverage of 
greater than 70 markers per megabase (Mb). This allows an unbiased approach to 
screening the whole of the canine genome for differences associated with normal 
or disease phenotypes. 
 
The genotyping was carried out using the standard manufacturer’s protocol 
(www.illumina.com) at the Roslin Institute in Edinburgh. Briefly, the genomic DNA 
was denatured and neutralised before being isothermally genome wide amplified. 
The amplified DNA was enzymatically fragmented in a controlled process so as not 
to over fragment (and which does not require a gel electrophoresis). After alcohol 
precipitation the DNA was resuspended in hybridisation buffer. The DNA was 
annealed to specific probes attached to beads on the surface of a chip. Un-
hybridised DNA was washed off, before a single base extension of the probe with 
labelled nucleotides (to confer allelic specificity). Fluorescent intensities were 
detected by the Illumina software and turned into an automated genotype call.  
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The GWAS data were analysed using a freely available whole genome association 
analysis toolset PLINK [190, 191] implemented using the program BCGene (BC 
Platforms, Finland). Graphical representation of the data was performed using the 
GenABEL and ggplot packages in R [213].  
 
Quality Assurance 
Raw genotypes from the Illumina final report file were directly uploaded to the 
BCgene program. The GWAS data were then assessed and filtered for quality 
assurance (QA) before association testing. Samples and SNPs were excluded if the 
sample call rate was <85%, the genotype call rate <90%, the control population was 
not in Hardy-Weinberg equilibrium (p<0.05) and/or the minor allele frequency 
≤0.05. Following QA, 81 samples remained. The data were then assessed for 
population stratification and any outliers deviating from the main cluster(s) were 
removed from subsequent analyses – five samples were classed as outliers and 
removed, leaving 76 samples for further analysis. 
 
Assessing population structure 
As samples were sourced from two different geographical locations (North America 
and Europe), the data had to be assessed for population stratification. Underlying 
population stratification is a common confounder that could introduce bias to the 
analyses and reported allelic associations, resulting in higher numbers of false 
positive and false negative associations [214, 215]. By checking and accounting for 
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underlying population stratification, the number of spurious associations is greatly 
reduced [216]. Population stratification can be assessed in many ways [214, 217-
220] including; genomic control [221], Eigenstrat principle component analysis 
(PCA) [216], or multidimensional scaling (MDS) [222]. 
 
In the early genetic studies, genomic control [221] was the primary method for 
correcting population stratification. This is where the data is adjusted by the 
common genomic inflation factor (λ). The data is visualised on a quantile-quantile 
(Q-Q) plot by plotting observed data against the expected data. Any deviation from 
the straight line indicates stratification within the dataset. The lambda value (λ) is 
the estimation of the distribution of the p-values and whether they conform to 
expected data; any stratification within the results leads to deviation of this value 
away from one. The genomic control method has been criticised for being over 
conservative in its results and also for being poor in correcting for stratification if 
the stratification was large, if there were discrete structures within the subjects 
[214, 218], or if there is a high level of relatedness within the population (which is 
the case with pure-bred dog breeds) [223]. 
 
An alternative approach for correcting for population substructure is the Eigenstrat 
principle component analysis (PCA) [216, 219]. This works by computing principle 
components (clusters) within the datasets and the top two principle components 
are indicative of the structure within the dataset. The samples are assigned clusters 
based on their ancestry and variation of the markers to each other. They are 
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assigned an axis and are plotted as if in a three dimensional space, with related 
samples clustering together. The clusters within the data can be visualised 
graphically by plotting the first two axes of variation against each other on an XY 
scatter plot.  
 
A third approach for determining genetic heterogeneity within the datasets is MDS 
[224], which is similar to PCA. It uses a matrix of pairwise identity by state (IBS) 
values between individuals, to compute the principle components in the data, 
which are then plotted in the same way as the PCA. An increasingly popular 
approach to examining stratification in the analysis involves running an Efficient 
Mixed-Model Association eXpedited analysis (EMMAX) [217]. This takes into 
account the kinship structure within the subjects to correct for any stratification; it 
also performs a case control association analysis at the same time.  
 
The method chosen to correct for stratification in this study was the Eigenstrat 
principle component analysis (PCA), which is believed to be the most robust and 
powerful approach for correcting for substructure within genome wide association 
datasets [216, 225]. If any samples are visually seen to deviate from the main 
cluster(s) they are classed as outliers and are removed from all subsequent 
analyses. If it is clear that there are two or more separate clusters of data, then any 
further analyses should take the grouping into account. A stratified allelic 
association analysis using the clusters as the groups – such as a Cochran–Mantel–
Haenszel (CMH) 2x2xK, or by performing the analysis separately on each individual 
 
  
- 70 - 
 
cluster and combining results with a meta-analysis, or an EMMAX analysis can be 
run as an alternative. 
 
Assessing Significance 
To determine whether SNPs were significant or not, the significance level needed to 
be established. If the standard significance value was used (p-value ≤0.05) for the 
GWAS data there would be 10,000 SNPs that would reach statistical significance by 
chance alone (200,000 X 0.05). This is nonsensical and therefore a more 
appropriate level of significance is needed such that the number of SNPs reaching 
significance is more realistic. Human GWAS studies use a significance level that 
indicates a p-value of 1x10-7 as being very highly associated and a p-value of 1x10-5 
being reasonably associated [208]. In this project, the significance threshold was set 
so that any association below 1x10-5 was considered associated with CCL rupture 
susceptibility in dogs. This has been considered suitable in other canine GWAS 
studies [177]  because dogs have much higher LD than humans. 
 
Haplotype analysis of GWAS data 
Different combinations of alleles in a population that are inherited together are 
called a haplotype [226]. Using PLINK and Haploview, a case–control haplotype 
association analysis can be performed on the genome wide data. The linkage and 
recombination relationship between each SNP on the chromosomes is determined. 
A 1000 permutations test was used to correct the haplotype block raw p-values to 
counteract multiple testing issues.  
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Haplotype blocks were defined by the Haploview software (version 4.2), using the 
standard Gabriel method [199]. Recombination between the SNPs can be estimated 
using D’. If SNPs are in strong LD, D’ = 1, if SNPs are independent of each other D’ = 
0. The default Gabriel settings (as implemented by the Haploview software), are 
that if the upper 95% confidence bound on D’ is >0.98 and the lower bound is >0.7 
then there is LD between the SNPs. A haplotype block is formed when less than 5% 
of markers show recombination (i.e. 95% of markers are in strong LD with each 
other).  
 
The haplotype blocks can be visualised by using a heatmap, which is a triangular 
matrix of pairwise dependencies between SNPs that are within 500KB of each 
other. The colour depth of each block indicates the strength of the LD within each 
block/between each marker. Bright red indicates markers that have very high LD 
and are more likely to be inherited together (LOD = 2, D’ = 1), white indicates no LD 
between markers (LOD = <2, D’ = <1) and pink/pale red and blue are for markers 
that have intermediate LD or can be indicative of a monomorphic SNP (LOD = 2, D’ = 
<1, or LOD = <2, D’ = 1). The number shown in each diamond on the heatmap is 
indicative of the D’ value between each SNP. Each SNP is listed above the heatmap 
and they are ordered by position on chromosome. The upward facing sides of the 
diamond indicate which SNPs are in LD with one another; an example heat map 
with explanation of the details is shown in Figure 3.1 
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Figure 3.1. Haplotype LD plot example. Number circled in green is D’ value 
between SNPs circled in blue. Colour is rough measure of significance. Block 
number (and size) is shown and detailed by black triangle. The numbers along the 
top block indicate the sequential order of SNPs along the chromosome. The SNP is 
shown vertically above each diamond. 
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Overview of genome wide data analyses 
The overview of the workflow analyses for the genome wide association study is 
summarised diagrammatically in Figure 3.2 
 
Figure 3.2. Workflow methodology for the GWAS study. GWAS data were 
imported into the BCgene program and subjected to QA testing. Data were 
excluded if the sample call rate was <85%, the genotype call rate <90%, the 
control population was not in Hardy-Weinberg equilibrium (p<0.05) and/or the 
minor allele frequency ≤0.05. Population stratification was then assessed and 
outliers removed before data were analysed either using the CMH stratified 
analysis or a case control chi squared test. Haplotype association tests were also 
conducted on the data. 
 
  
- 74 - 
 
Results 
Population stratification within the Newfoundland dogs 
PCA analysis of the GWAS data as a whole (without regard to CCL rupture status), 
identified two discreet clusters evident within the dataset (Figure 3.3) which were 
indicative of the country of origin of the Newfoundland dog. The QQ plots of the 
data and their respective λ values are shown in Figure 3.4. For the unadjusted 
dataset, λ was 1.31 and when the data were stratified by country using a CMH test, 
this was reduced to 1.27, after conducting an EMMAX analysis on the data, the λ 
was further reduced to 1.02.  
 
Figure 3.3. Eigenstrat PCA plot of the 81 Newfoundland dogs that satisfied the QA 
criteria. Outliers (n=5, circled) were excluded from any subsequent analyses of 
the data, as they deviated from the main clusters. Black squares represent North 
American dogs, white diamonds indicate European dogs. 
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Figure 3.4. QQ plots and λ values of the GWAS data; A = unadjusted data, B = 
Stratified by country (CMH test), C = EMMAX analysis 
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High Density Illumina Array - Newfoundlands 
Manhattan plots were produced for each GWAS analysis: CMH stratified (Figure 
3.5), European (Figure 3.6), North American (Figure 3.7) and EMMAX (Figure 3.8). 
This data representation displays p-values for each SNP based on the genotype 
frequencies when comparing their incidence in healthy dogs to those with CCL 
rupture. Each SNP is visually represented with its -log p-value against chromosomal 
location. Anything with a p-value of ≤ 1x10-5 (above dotted line of significance) was 
considered to have genome wide statistical significance indicating whether it was 
over or under represented in the CCL rupture group of dogs.  
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Figure 3.5. Manhattan plot for all Newfoundland dogs following the CMH stratified GWAS analysis. The dotted line represents the p-value 
threshold of 1x10-5 to indicate genome wide significance of SNPs associated with CCL rupture. 
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Figure 3.6. Manhattan plot for EU Newfoundland dogs following genome wide association analyses. The dotted line represents the p-value 
threshold of 1x10-5 for suggested genome wide significance of SNPs associated with CCL rupture. 
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Figure 3.7. Manhattan plot for NA Newfoundland dogs following genome wide association analyses. The dotted line represents the p-value 
threshold of 1x10-5 for suggested genome wide significance of SNPs associated with CCL rupture. 
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Figure 3.8. Manhattan plot for all Newfoundland dogs tested after genome wide association analyses stratified by EMMAX. The dotted line 
represents the p-value threshold of 1x10-5 for suggested genome wide significance of SNPs associated with CCL rupture. 
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A comparison of the different analyses (stratified, meta- and EMMAX) showed that 
variation was low and that similar SNPs reached statistical significance (p ≤ 1x10-5) 
although their rank order was different - Table 3.1 shows this point by ranking the 
ten most associated SNPs in each of the 3 different analyses.  
 
Table 3.1. The ten most significant SNPs ranked by p-value from each different 
analyses of the GWAS data.  
SNP Chromosome 
Rank in 
CMH 
stratified 
Rank in 
Meta 
Rank in 
EMMAX 
BICF2S23133650 33 1 1 1 
BICF2P1311062 33 2 2 3 
BICF2P59100 1 3 3 2 
BICF2P797863 33 4 4 4 
BICF2G630343527 3 5 8 9 
TIGRP2P8419_ 
rs8959368 
1 6 9 - 
BICF2P486041 33 7 - 6 
BICF2G63080008 33 8 - 8 
BICF2P1008542 1 9 5 5 
BICF2P212467 33 10 7 - 
BICF2S2318592 1 - 6 7 
BICF2P1457397 33 - 10 - 
BICF2P893554 1 - - 10 
 
 
The 40 SNPs showing greatest association (raw p-values <0.05) from the CMH 
stratified analysis are shown in Table 3.2 
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Table 3.2. The 40 SNPs showing greatest association (by raw p-value) from the CMH genome wide association stratified analysis. 
Rank CHR SNP Position A1 MAF A2 p (raw) p (BONF) p (PERM) 
FDR Benjamini 
and Hochberg p 
OR 95% CI 
1 33 BICF2S23133650 25987425 G 0.32 A 9.08E-09 0.0009 0.0003 0.0009 0.10 0.04 - 0.24 
2 33 BICF2P1311062 26001662 G 0.35 A 5.76E-08 0.0058 0.0014 0.0029 0.13 0.06 - 0.28 
3 1 BICF2P59100 10792454 A 0.43 C 8.90E-07 0.0901 0.0213 0.0300 5.96 2.85 - 12.46 
4 33 BICF2P797863 26063962 C 0.50 T 1.25E-06 0.1268 0.0296 0.0317 0.18 0.09 - 0.37 
5 3 BICF2G630343527 59316812 A 0.39 T 1.99E-06 0.2019 0.0473 0.0404 0.17 0.08 - 0.36 
6 1 TIGRP2P8419_ rs8959368 11497808 G 0.28 A 2.88E-06 0.2912 0.0668 0.0485 0.16 0.07 - 0.36 
7 33 BICF2P486041 25983710 C 0.47 T 3.42E-06 0.3465 0.0791 0.0495 0.19 0.09 - 0.40 
8 33 BICF2G63080008 19430035 G 0.33 A 4.10E-06 0.4156 0.0952 0.0507 0.18 0.09 - 0.39 
9 1 BICF2P1008542 10756573 C 0.38 T 4.51E-06 0.4566 0.1032 0.0507 5.65 2.62 - 12.2 
10 33 BICF2P212467 25923850 A 0.38 G 5.26E-06 0.5327 0.1179 0.0533 0.19 0.09 - 0.40 
11 33 BICF2P1072408 24536212 T 0.34 A 7.49E-06 0.7588 0.1621 0.0669 0.18 0.09 - 0.40 
12 1 BICF2S2318592 10822495 G 0.37 A 7.92E-06 0.8022 0.1702 0.0669 5.49 2.53 - 11.91 
13 33 BICF2P325662 23291566 C 0.46 T 9.13E-06 0.9244 0.1947 0.0678 0.22 0.11 - 0.43 
14 3 BICF2G630343620 59381030 C 0.39 T 9.37E-06 0.9490 0.1994 0.0678 0.20 0.09 - 0.41 
15 33 BICF2G63079918 19502373 T 0.28 C 1.21E-05 1.0000 0.2486 0.0817 0.18 0.08 - 0.40 
16 33 BICF2S23216989 19794189 C 0.43 T 1.62E-05 1.0000 0.3135 0.1027 0.22 0.11 - 0.45 
17 1 BICF2G630711545 10238823 T 0.43 C 1.79E-05 1.0000 0.3385 0.1068 4.58 2.25 - 9.34 
18 33 BICF2P1457397 24386039 T 0.36 G 2.00E-05 1.0000 0.3681 0.1126 0.22 0.11 - 0.45 
19 33 BICF2P774690 22930550 T 0.45 C 2.13E-05 1.0000 0.3858 0.1138 0.22 0.11 - 0.45 
20 10 BICF2S23060690 58719181 T 0.14 C 2.74E-05 1.0000 0.4579 0.1329 0.08 0.02 - 0.32 
21 33 BICF2S23241903 26080255 C 0.23 T 2.75E-05 1.0000 0.4588 0.1329 0.17 0.07 - 0.40 
22 12 BICF2S24413446 14748689 T 0.09 G 3.18E-05 1.0000 0.5038 0.1444 0.00 0.00 - 0.00 
23 1 BICF2G630711540 10231948 G 0.43 A 3.28E-05 1.0000 0.5122 0.1444 4.43 2.16 - 9.10 
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Rank CHR SNP Position A1 MAF A2 p (raw) p (BONF) p (PERM) 
FDR Benjamini 
and Hochberg p 
OR 95% CI 
24 1 BICF2S23354689 13375903 T 0.32 C 3.89E-05 1.0000 0.5660 0.1607 0.22 0.11 - 0.47 
25 33 TIGRP2P389380_rs8613571 24503510 A 0.37 G 4.44E-05 1.0000 0.6104 0.1607 0.23 0.11 - 0.47 
26 3 BICF2G630343137 58878743 A 0.48 G 4.64E-05 1.0000 0.6244 0.1607 4.10 2.06 - 8.17 
27 33 TIGRP2P389430_rs9122813 24703426 C 0.42 T 4.72E-05 1.0000 0.6301 0.1607 0.25 0.12 - 0.49 
28 1 BICF2P893554 12724538 T 0.42 G 4.73E-05 1.0000 0.6312 0.1607 4.33 2.10 - 8.89 
29 33 TIGRP2P388471_rs9063975 19813762 A 0.46 G 5.08E-05 1.0000 0.6525 0.1607 0.25 0.13 - 0.49 
30 33 BICF2G63081807 16640349 C 0.38 T 5.09E-05 1.0000 0.6533 0.1607 0.23 0.11 - 0.48 
31 10 BICF2S237368 57091773 G 0.13 A 5.24E-05 1.0000 0.6626 0.1607 0.08 0.02 - 0.33 
32 10 BICF2S23110665 57419768 A 0.13 G 5.24E-05 1.0000 0.6626 0.1607 0.08 0.02 - 0.33 
33 10 BICF2P1370043 57892601 A 0.13 G 5.24E-05 1.0000 0.6626 0.1607 0.08 0.02 - 0.33 
34 33 TIGRP2P388138_rs8754330 18223573 G 0.26 A 6.43E-05 1.0000 0.7292 0.1873 0.21 0.09 - 0.46 
35 10 BICF2P1384039 57622160 G 0.16 A 6.47E-05 1.0000 0.7308 0.1873 0.14 0.05 - 0.41 
36 1 BICF2G630711764 14988276 C 0.38 T 6.91E-05 1.0000 0.7505 0.1944 0.25 0.12 - 0.50 
37 22 BICF2G630317860 10772478 T 0.40 C 7.63E-05 1.0000 0.7807 0.2079 0.25 0.13 - 0.51 
38 33 BICF2P29702 22652694 T 0.41 C 7.80E-05 1.0000 0.7871 0.2079 0.25 0.13 - 0.51 
39 3 BICF2G630343157 58927121 C 0.47 T 9.23E-05 1.0000 0.8319 0.2303 3.84 1.94 - 7.61 
40 1 BICF2P1077045 12732415 T 0.41 C 9.27E-05 1.0000 0.8328 0.2303 4.05 1.98 - 8.27 
 
KEY: MAF = minor allele frequency, A1 = base for allele 1, A2 = base for allele 2, OR = odds ratio of A1, CI = confidence interval of the odds 
ratio.  The position is the chromosomal position on the CanFam3 genome annotation. Three methods of correction for multiple testing are 
shown, BONF = Bonferroni, FDR and PERM = 100,000 permutations.
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SNPs positively or negatively associated with CCL rupture were present on 
chromosomes 33, 1, 3, 10, 12 and 22. Chromosome 33, in particular showed a 
strong linkage with CCL rupture; 19 of the 40 SNPs showing greatest association 
with CCL rupture (by raw p-value) were located to that chromosome. Of the ten 
most associated SNPs (all below the standard p-value cut-off of praw ≤ 1x10
-5), six 
SNPs located to chromosome 33, three SNPs to chromosome 1 and one SNP to 
chromosome 3.  
 
The two highest ranking CCL rupture associated SNPs both located to chromosome 
33 and were significant after correction for multiple testing using Bonferroni. When 
100,000 permutations were run on the data, five SNPs showed significance (three 
on chromosome 33 and one SNP on chromosome 1 and 3). When FDR was applied 
seven SNPs were significant (four on chromosome 33, two on chromosome 1 and 
one on chromosome 3).   
 
Haplotype associations 
Haplotype analyses were performed on each of the three main chromosomes 
showing regions of association with CCL rupture (chromosome 1, 3 and 33). 
Significant haplotype blocks were identified in two of the three chromosomes 
(chromosome 33 - Figure 3.9, and chromosome 1 - Figure 3.10). Chromosome 3 did 
not have any associated haplotype blocks that reached statistical significance (raw 
p= ≤1x10-5). A representation of the haplotype blocks for each chromosome is 
shown to indicate the physical distances between each of the blocks and their 
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position on the chromosome (chromosome 33 - Figure 3.11 and chromosome 1 - 
Figure 3.12). The haplotype frequencies for each allele combination are shown in 
Table 3.3 for chromosome 33 and Table 3.4 for chromosome 1. 
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Figure 3.9. LD plots showing haplotype blocks reaching statistical significance (raw 
p= ≤1x10-5) on chromosome 33 
 
  
- 87 - 
 
 
Figure 3.10. LD plots showing haplotype blocks reaching statistical significance 
(raw p= ≤1x10-5) on chromosome 1. 
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Figure 3.11. Representation of haplotype blocks on chromosome 33 
 
 
Figure 3.12. Representation of haplotype blocks on chromosome 1 
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Table 3.3. Haplotype blocks in chromosome 33.  
Block Haplotype Freq. 
Case, Control Ratio 
Counts 
Case, 
Control 
Frequencies 
p-value 
(raw) 
p-value 
(permutation) 
Block 
159 
GG 0.32 10.0 : 80.0, 45.0 : 37.0 0.11, 0.55 7.90E-10 <0.001 
AA 0.64 76.0 : 14.0, 34.0 : 48.0 0.84, 0.42 4.52E-09 <0.001 
AG 0.04 4.0 : 86.0,      3.0 : 79.0 0.04, 0.04 7.94E-01 1.000 
Block 
161 
TT 0.51 62.7 : 29.3, 27.3 : 56.7 0.68, 0.33 2.42E-06 <0.001 
CC 0.23 8.9 : 83.1,    31.4 : 52.6 0.10, 0.37 1.29E-05 0.010 
CT 0.26 20.4 : 71.6, 25.3 : 58.7 0.22, 0.30 2.33E-01 1.000 
Block 
112 
CTTCGAG 0.18 6.1 : 85.9,    25.0 : 59.0 0.07, 0.30 5.96E-05 0.020 
ATCCTGG 0.28 30.9 : 61.1, 19.0 : 65.0 0.34, 0.23 1.07E-01 1.000 
CCTCGAG 0.06 7.4 : 84.6,      3.0 : 81.0 0.08, 0.04 2.10E-01 1.000 
CCTTGAT 0.42 40.0 : 52.0, 33.0 : 51.0 0.44, 0.39 5.73E-01 1.000 
CCTCGAT 0.05 5.5 : 86.5,      4.0 : 80.0 0.06, 0.05 7.21E-01 1.000 
Block 
124 
GAC 0.57 66.8 : 25.2, 33.7 : 50.3 0.73, 0.40 1.42E-05 0.010 
AGC 0.17 10.4 : 81.6, 20.0 : 64.0 0.11, 0.24 2.74E-02 1.000 
AGT 0.17 6.0 : 86.0,    24.0 : 60.0 0.07, 0.29 1.00E-04 0.030 
AAC 0.08 7.8 : 84.2,      6.1 : 77.9 0.08, 0.07 7.79E-01 1.000 
Block 
156 
TC 0.43 26.0 : 66.0, 47.4 : 32.6 0.28, 0.59 4.13E-05 0.020 
AT 0.50 56.9 : 35.1, 29.0 : 51.0 0.62, 0.36 8.00E-04 0.250 
AC 0.07 9.1 : 82.9,      3.6 : 76.4 0.10, 0.05 1.74E-01 1.000 
Block 
170 
ATCAC 0.25 12.0 : 80.0, 30.9 : 51.1 0.13, 0.38 2.00E-04 0.050 
GCCAC 0.08 11.0 : 81.0,    2.1 : 79.9 0.12, 0.03 1.97E-02 0.990 
GCTGT 0.37 40.5 : 51.5, 23.2 : 58.8 0.44, 0.28 3.10E-02 1.000 
GTCAC 0.03 3.0 : 89.0,      2.0 : 80.0 0.03, 0.02 7.52E-01 1.000 
GCTGC 0.25 22.4 : 69.6, 21.7 : 60.3 0.24, 0.26 7.53E-01 1.000 
ATTGC 0.01 1.0 : 91.0,      1.1 : 80.9 0.01, 0.01 8.73E-01 1.000 
Those in red are statistically significant haplotypes (raw p= ≤1x10-5). The one that 
is highlighted yellow is of greatest importance/statistical significance.  
 
KEY – freq. = frequency of haplotype in population. Case, control ratio counts = 
number of cases with and without and then the number of controls with and 
without the haplotype. Case, control frequency = frequency of haplotype in cases 
and controls. Permutation p-value = 1000 permutations p-value 
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Table 3.4. Haplotype blocks in chromosome 1. 
Block Haplotype Freq. 
Case, Control Ratio 
Counts 
Case, 
Control 
Frequencies 
p-value 
(raw) 
p-value 
(permutation) 
Block 
48 
AA 0.45 55.7 : 34.3, 22.7 : 61.3 0.62, 0.27 3.87E-06 0.001 
CC 0.39 25.7 : 64.3, 42.7 : 41.3 0.29, 0.51 2.60E-03 0.835 
CA 0.16 8.5 : 81.5, 18.5 : 65.5 0.10, 0.22 2.21E-02 1.000 
Block 
45 
CGTCA 0.43 52.0 : 38.0, 22.0 : 60.0 0.58, 0.27 4.25E-05 0.031 
CACTG 0.19 11.4 : 78.6, 20.8 : 61.2 0.13, 0.25 3.34E-02 1.000 
CACCA 0.12 7.0 : 83.0, 13.9 : 68.1 0.08, 0.17 6.63E-02 1.000 
AACTG 0.24 17.6 : 72.4, 24.2 : 57.8 0.20, 0.30 1.27E-01 1.000 
AATTA 0.01 1.0 : 89.0,  1.1 : 80.9 0.01, 0.01 9.09E-01 1.000 
Block 
58 
GTTC 0.42 50.6 : 39.4, 21.9 : 60.1 0.56, 0.27 9.36E-05 0.076 
GGCC 0.33 17.4 : 72.6, 39.1 : 42.9 0.19, 0.48 7.70E-05 0.064 
TGCT 0.24 21.6 : 68.4, 19.7 : 62.3 0.24, 0.24 9.96E-01 1.000 
Block 
66 
TGGTAT 0.40 49.9 : 42.1, 21.0 : 63.0 0.54, 0.25 7.67E-05 0.064 
AACGTT 0.15 8.3 : 83.7, 17.8 : 66.2 0.09, 0.21 2.27E-02 1.000 
AACGTC 0.37 29.7 : 62.3, 36.0 : 48.0 0.32, 0.43 1.48E-01 1.000 
AAGTTT 0.03 1.0 : 91.0,  3.3 : 80.7 0.01, 0.04 2.25E-01 1.000 
TGCGTT 0.03 2.0 : 90.0,  3.0 : 81.0 0.02, 0.04 5.81E-01 1.000 
Those in red are statistically significant haplotypes (raw p= ≤1x10-5). The one that 
is highlighted yellow is of greatest importance/statistical significance. 
 
KEY – freq. = frequency of haplotype in population. Case, control ratio counts = 
number of cases with and without and then the number of controls with and 
without the haplotype. Case, control frequency = frequency of haplotype in cases 
and controls. Permutation p-value = 1000 permutations p-value 
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The most significant haplotype was a 14KB region (block 159) on chromosome 33 
which contained two SNPs (BICF2S23133650 and BICF2P1311062), that were the 
two highest ranking hits (had the smallest raw p-values) in the CMH stratified 
dataset. The second most important haplotype block was a 15KB region on 
chromosome 1 (block 48), which contained the third most significant SNP in the 
CMH stratified dataset (BICF2P59100 raw p-value = 8.90E-07). 
 
Chromosome 33 contained five haplotype blocks that reached statistical 
significance after 1000 permutation (Figure 3.9 A-E, blocks 159, 161, 112, 124 and 
156)  and one block (block 170) that neared significance after multiple correction 
testing (permutation p-value = 0.053) - Figure 3.9 F.  On chromosome 33 (see Figure 
3.9), the largest haplotype block (Block 170, 72KB) contained five SNPs 
(BICF2G63077271, BICF2G63077266, BICF2S23214572, BICF2P778764 and 
BICF2S23431355) all of which showed high pairwise LD in addition to extended LD 
across all of the SNPs in the block. Block 112 (68Kb) contained the largest number 
of SNPs (7) within a block (BICF2P1228306, BICF2P328516, BICF2P508171, 
BICF2P147184, BICF2P754969, BICF2S23215488 and BICF2P533530). 
 
Chromosome 1 had two associated haplotype blocks (blocks 48 and 45) that were 
significant after permutation testing (Figure 3.10 A & B) and two blocks (blocks 58 
and 66) that neared multiple correction significance Figure 3.10 C & D (permutation 
p-values for each = 0.06).  On chromosome 1 (see Figure 3.10), the largest 
haplotype block was Block 66 (96KB); the SNPs in LD in this block were 
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BICF2P1362061, BICF2P1240331, BICF2P1038853, BICF2S23513984, 
BICF2S23224159 and BICF2P263531. 
 
Low density Illumina Array – Labrador Retrievers and Golden Retrievers 
Genotype data from a previous unrelated study (performed on an Illumina low 
density SNP20 canine chip containing 22,362 SNPs) was made available for analysis 
purposes within this project. The data included cruciate cases and controls from 
two breeds – Labrador Retrievers (n=49) and Golden Retrievers (n=38). The SNPs 
were selected from the CanFam2 genome assembly. 
 
These data were also assessed for stratification by the Eigenstrat PCA method to 
check for any underlying population stratification. Two Labrador Retriever samples 
were removed for being outliers on the plots leaving 85 samples for analysis. PCA 
analysis showed that the two breeds segregated separately on the principle 
component plot (Figure 3.13) 
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Figure 3.13. Eigenstrat population stratification plot of the low density (Illumina 
canine SNP20 chip) genome wide association data for Labrador Retrievers (n=47) 
(white squares) and Golden Retrievers (n=38) (black diamonds). Outliers have 
been removed from the plot. 
 
The Manhattan plots for each individual breed are shown in Figure 3.14 and Figure 
3.15 and the 40 most significant SNPs from the Golden retrievers and Labrador 
Retrievers are shown in Table 3.5 and Table 3.6 
.  
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Figure 3.14. Manhattan plot showing the SNP position on each chromosome for the Golden Retrievers. The dotted line represents the p-
value threshold of 1x10-5 to indicate genome wide significance of SNPs associated with CCL rupture. 
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Figure 3.15. Manhattan plot showing the SNP position on each chromosome for the Labrador Retrievers. The dotted line represents the p-
value threshold of 1x10-5 to indicate genome wide significance of SNPs associated with CCL rupture. 
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Table 3.5. The 40 most associated SNPs from Golden Retriever low density GWA data. 
SNP CHR POSITION (bp) A1 A2 p (raw) p (BONF) p (FDR) p (perm) OR 
BICF2P1262009 28 36603096 A G 0.00005 0.690 0.269 0.235 0.10 
BICF2G63088517 7 83386719 G A 0.00007 1.000 0.269 0.325 7.60 
BICF2S23118727 23 50062261 A T 0.00009 1.000 0.269 0.424 0.10 
BICF2S23316643 X 26644787 T C 0.00016 1.000 0.269 0.560 0.00 
BICF2P566020 5 20811822 C G 0.00016 1.000 0.269 0.544 13.10 
BICF2G63067880 38 24803437 T C 0.00016 1.000 0.269 0.544 13.10 
BICF2P257904 18 50409186 G A 0.00020 1.000 0.269 0.673 6.40 
BICF2P678005 37 18333740 A G 0.00020 1.000 0.269 0.673 0.20 
BICF2G630535123 X 21076817 T C 0.00024 1.000 0.269 0.719 6.10 
BICF2G630535042 X 21634355 A C 0.00024 1.000 0.269 0.727 0.20 
BICF2P196724 X 18993861 T C 0.00025 1.000 0.269 0.746 0.10 
BICF2P756453 31 5469008 G A 0.00035 1.000 0.269 0.834 11.70 
BICF2G630727337 31 5487351 A G 0.00035 1.000 0.269 0.834 11.70 
BICF2P1153207 35 11394748 A G 0.00035 1.000 0.269 0.834 11.70 
BICF2G630532723 X 27757945 A G 0.00038 1.000 0.269 0.857 0.10 
BICF2G630772450 35 11171254 A G 0.00038 1.000 0.269 0.857 19.20 
BICF2S23032956 6 51890820 A G 0.00040 1.000 0.269 0.884 0.10 
BICF2P680952 23 36495440 T C 0.00040 1.000 0.269 0.884 7.70 
BICF2G630128194 37 13737113 T C 0.00040 1.000 0.269 0.884 0.10 
BICF2G630538696 X 7380657 A T 0.00046 1.000 0.269 0.903 5.80 
BICF2S23055953 17 54963129 G A 0.00046 1.000 0.269 0.903 5.80 
BICF2S23356422 23 48919581 T C 0.00046 1.000 0.269 0.903 5.80 
BICF2P1209319 X 15247146 C T 0.00052 1.000 0.269 0.920 0.20 
BICF2P778313 18 49588963 A G 0.00055 1.000 0.269 0.930 6.60 
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SNP CHR POSITION (bp) A1 A2 p (raw) p (BONF) p (FDR) p (perm) OR 
BICF2G630373728 23 35041979 A G 0.00055 1.000 0.269 0.930 6.60 
BICF2S23219696 X 20942865 C T 0.00056 1.000 0.269 0.939 5.40 
BICF2S23060383 X 21107246 G A 0.00056 1.000 0.269 0.939 5.40 
BICF2G630575388 6 54336831 C T 0.00056 1.000 0.269 0.939 0.20 
BICF2G630549539 7 6917459 A G 0.00057 1.000 0.269 0.948 0.10 
BICF2G63052930 19 35337964 A G 0.00057 1.000 0.269 0.948 8.50 
BICF2S23227907 7 83313016 C A 0.00058 1.000 0.269 0.954 0.20 
BICF2G630726990 31 4334718 A G 0.00058 1.000 0.269 0.954 0.20 
BICF2P477037 35 12153431 T C 0.00069 1.000 0.297 0.962 NaN 
BICF2G630578492 6 50788895 A G 0.00073 1.000 0.297 0.974 0.10 
BICF2P1170982 5 75258257 A G 0.00081 1.000 0.297 0.980 17.10 
BICF2P862614 25 23258426 T C 0.00081 1.000 0.297 0.980 0.10 
BICF2S24112448 1 16271092 C T 0.00085 1.000 0.297 0.984 6.90 
BICF2P1370375 14 17971222 C G 0.00085 1.000 0.297 0.984 6.90 
BICF2G630128293 37 13794179 T C 0.00085 1.000 0.297 0.984 0.10 
BICF2G630128407 37 13923230 G A 0.00085 1.000 0.297 0.984 0.10 
 
KEY: OR = odds ratio. KEY: A1 = base for allele 1, A2 = base for allele 2, OR = odds ratio for A1. The data is from the CanFam2 genome 
annotation and the low density Illumina array 
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Table 3.6  The 40 most associated SNPs from Labrador Retriever low density GWA data. 
SNP CHR POSITION (bp) A1 A2 p (raw) p (BONF) p (FDR) p (perm) OR 
BICF2S2356933 8 53525876 A C 0.0000004 0.008* 0.008* 0.004* 10.30 
BICF2P824055 6 57929723 C T 0.0000135 0.238 0.119 0.140 7.50 
BICF2G630573645 6 57338843 T C 0.0000326 0.576 0.174 0.288 6.50 
BICF2S23217009 6 60904209 A G 0.0000393 0.694 0.174 0.364 11.30 
BICF2S23213970 6 58426144 A G 0.0000684 1.000 0.210 0.504 5.90 
BICF2P115992 19 11296216 T C 0.0000928 1.000 0.210 0.642 22.70 
BICF2S2439360 19 11304497 T G 0.0000928 1.000 0.210 0.642 22.70 
BICF2P1267480 6 60820837 G A 0.0000995 1.000 0.210 0.678 10.20 
BICF2G630706178 3 33472405 A G 0.0001700 1.000 0.210 0.820 0.10 
BICF2P814871 18 34563332 A G 0.0001740 1.000 0.210 0.833 5.30 
BICF2P783963 31 24917345 A G 0.0001930 1.000 0.210 0.842 0.20 
BICF2P178000 2 30099000 T C 0.0001950 1.000 0.210 0.852 6.50 
BICF2S23651052 6 57316517 C G 0.0001950 1.000 0.210 0.852 6.50 
BICF2S23714172 19 18607492 A G 0.0001950 1.000 0.210 0.852 6.50 
BICF2G630816155 16 51480795 T G 0.0002120 1.000 0.210 0.872 5.30 
BICF2P681116 2 30117462 C T 0.0002150 1.000 0.210 0.878 6.10 
BICF2G63078520 33 24890251 A G 0.0002240 1.000 0.210 0.892 5.40 
BICF2S23737289 8 53570064 A G 0.0002260 1.000 0.210 0.898 5.80 
BICF2P778506 18 32131688 T C 0.0002260 1.000 0.210 0.898 5.80 
BICF2P721935 23 27073235 G A 0.0002730 1.000 0.241 0.939 0.20 
BICF2P1010365 17 8058457 G A 0.0003080 1.000 0.259 0.950 0.20 
BICF2S2379941 18 35534955 T C 0.0003730 1.000 0.300 0.969 4.80 
BICF2P638159 3 59502464 A G 0.0004400 1.000 0.314 0.984 0.20 
BICF2P695795 8 54831607 A G 0.0004650 1.000 0.314 0.986 5.90 
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SNP CHR POSITION (bp) A1 A2 p (raw) p (BONF) p (FDR) p (perm) OR 
BICF2P1307704 5 77056386 T C 0.0005100 1.000 0.314 0.991 0.20 
BICF2P592926 15 58282077 C G 0.0005120 1.000 0.314 0.992 0.20 
BICF2P95470 17 8860568 T C 0.0005130 1.000 0.314 0.992 0.10 
BICF2P1240005 8 53680922 C T 0.0005150 1.000 0.314 0.993 0.20 
BICF2P759679 27 27664279 C G 0.0005150 1.000 0.314 0.993 0.20 
BICF2S23514041 27 47718008 C G 0.0005350 1.000 0.315 0.994 5.20 
BICF2P526433 21 48157647 G C 0.0006740 1.000 0.384 0.999 0.10 
BICF2P883484 13 36084406 T C 0.0007280 1.000 0.399 0.999 0.10 
BICF2P703258 11 19340622 T C 0.0007750 1.000 0.399 0.999 6.70 
BICF2S23547520 17 50927494 C G 0.0009050 1.000 0.399 1.000 0.10 
BICF2P1340532 6 58060674 T C 0.0009400 1.000 0.399 1.000 5.90 
BICF2G63037067 19 14230616 C T 0.0009400 1.000 0.399 1.000 5.90 
BICF2G630394788 30 41936591 C A 0.0009430 1.000 0.399 1.000 0.20 
BICF2S23525565 22 55319287 A G 0.0009520 1.000 0.399 1.000 9.90 
BICF2S23260589 4 84261092 G A 0.0009560 1.000 0.399 1.000 0.20 
BICF2P1266966 4 53505610 C T 0.0010430 1.000 0.399 1.000 4.20 
 
KEY: OR = odds ratio. KEY: A1 = base for allele 1, A2 = base for allele 2, OR = odds ratio for A1. The data is from the CanFam2 genome 
annotation and the low density Illumina array. Asterix (*) = significant after correction for multiple testing. 
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To compare the Labrador Retrievers and Golden Retrievers together as a whole 
cohort, a meta-analysis was carried out on the two datasets. The corresponding 
Manhattan plot and the 20 most associated SNPs are shown below in Figure 3.16 
and Table 3.7 respectively. 
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Figure 3.16. Manhattan plot of each SNP on each chromosome, for the meta-analysis of Labrador Retrievers and Golden Retrievers low 
density GWAS data. The dotted line represents the p-value threshold of 1x10-5 to indicate genome wide significance of SNPs associated with 
CCL rupture. 
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Table 3.7. The 20 most associated SNPs (raw p<0.05) from a meta-analysis of the 
Golden Retriever data and the Labrador Retriever low density GWAS data  
SNP CHR Position (bp) A1 A2 Raw p 
Estimated 
p (BONF) 
OR 
BICF2S23118727 23 50062261 T A 0.00002 0.32 4.2 
BICF2P280650 3 91785665 A G 0.00018 1.00 3.6 
BICF2P990180 15 26091657 C T 0.00019 1.00 3.4 
BICF2G630522197 14 15582285 G A 0.00021 1.00 0.2 
BICF2P209484 14 22304055 G A 0.00024 1.00 0.3 
BICF2P695795 8 54831607 A G 0.00026 1.00 3.8 
BICF2G630128293 37 13794179 T C 0.00028 1.00 0.2 
BICF2G630128194 37 13737113 T C 0.00029 1.00 0.2 
BICF2P1240005 8 53680922 C T 0.00043 1.00 0.2 
BICF2G630492949 10 71446224 G A 0.00049 1.00 0.3 
BICF2G630530271 14 44484835 G T 0.00050 1.00 3.4 
BICF2P1285690 21 39448116 A G 0.00054 1.00 0.2 
BICF2S23032956 6 51890820 A G 0.00057 1.00 0.3 
BICF2P331356 4 27447828 G A 0.00063 1.00 4.9 
BICF2P1340532 6 58060674 T C 0.00066 1.00 4.6 
BICF2S23623203 25 15609495 G A 0.00077 1.00 0.3 
BICF2P562824 8 67905258 A G 0.00079 1.00 0.3 
BICF2P1210287 21 39467303 A G 0.00081 1.00 0.2 
BICF2P759679 27 27664279 C G 0.00092 1.00 0.3 
BICF2G630486552 10 41050419 G A 0.00096 1.00 3.0 
KEY: A1 = base for allele 1, A2 = base for allele 2, OR = odds ratio for A1. Based on 
the CanFam2 annotation of genome. p (BONF) = Correction for multiple testing. 
This has been estimated by correcting for 16163 tests (unique tests run in the 
meta-analysis). 
 
None of the SNPs reached significance (raw p-value ≤ 1x10-5) in the meta-analysis of 
the low density Labrador Retrievers and Golden Retriever data, although the SNP 
showing greatest association (BICF2S23118727) on chromosome 23 generated a 
raw p-value of 1.5x10-5. These SNPs are different to those identified using the high 
density Newfoundland data. 
 
 
  
- 103 - 
 
In order for a comparison to be made between the Newfoundlands, Labrador  
Retrievers and Golden Retrievers, a meta-analysis was run include the high density 
data of the Newfoundlands along with the low density data of the Labrador 
Retrievers and Golden Retrievers. Only the SNPs common to both arrays were 
assessed (16163 SNPs). 
 
The Manhattan plot of the data is shown in Figure 3.17 and the 20 most significant 
SNPs from the combined meta-analysis of the high density and low density data for 
the three breeds are shown in Table 3.8 
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Figure 3.17. Manhattan plot of each SNP on each chromosome, for the meta-analysis of (low density array) Labrador Retrievers, Golden 
Retrievers and the (high density array) Newfoundlands. The dotted line represents the p-value threshold of 1x10-5 to indicate genome wide 
significance of SNPs associated with CCL rupture 
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Table 3.8. Twenty most significant SNPs from the meta-analysis of the low density 
Golden Retriever data and Labrador Retriever data and the high density 
Newfoundland data . 
SNP CHR Position (bp) A1 A2 Raw p 
Estimated 
p (BONF) 
OR 
BICF2S22956692 33 24532210 G T 6.33E-05 0.66 2.75 
BICF2P174661 4 52672382 T A 1.09E-04 1.00 0.29 
BICF2S23756043 8 55368579 G C 2.43E-04 1.00 2.53 
BICF2P695795 8 54831607 A G 2.64E-04 1.00 3.82 
BICF2P1240331 1 16482671 G A 2.78E-04 1.00 2.46 
BICF2P562824 8 67905258 A G 2.87E-04 1.00 0.40 
BICF2P355991 39 38928542 C T 2.96E-04 1.00 2.84 
BICF2G630434646 15 30579673 T C 2.97E-04 1.00 0.37 
BICF2P990180 15 26091657 C T 2.97E-04 1.00 2.33 
BICF2G630434636 15 30593836 A C 3.00E-04 1.00 0.37 
BICF2G63093243 22 63949304 A G 3.41E-04 1.00 0.38 
BICF2P227876 39 109116340 A C 3.68E-04 1.00 3.05 
BICF2P1240005 8 53680922 C T 4.26E-04 1.00 0.24 
BICF2S23510607 28 32230015 C G 4.36E-04 1.00 0.38 
BICF2G630492949 10 71446224 G A 4.87E-04 1.00 0.27 
BICF2P1049530 24 19875480 A C 4.90E-04 1.00 2.38 
BICF2P676783 24 19944160 C T 4.90E-04 1.00 2.38 
BICF2P779428 1 14732079 T C 5.37E-04 1.00 0.33 
BICF2P1285690 21 39448116 A G 5.37E-04 1.00 0.17 
BICF2P1267480 6 60820837 G A 5.73E-04 1.00 2.93 
KEY: A1 = base for allele 1, A2 = base for allele, OR = odds ratio. Based on the 
CanFam2 annotation of genome P (BONF) = Correction for multiple testing. This 
has been estimated by correcting for 10432 tests (unique tests run in the meta-
analysis). 
 
 
None of the SNPs reached significance (raw p-value ≤ 1x10-5) in the meta-analysis of 
the high and low density data combined for the three individual breeds. The 
significant SNPs identified in the Labrador Retriever and Golden Retriever are 
different from the high density Newfoundland data. 
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Discussion 
Investigations using 96 Newfoundland dogs (irrespective of disease status) 
identified population stratification within the dataset, due to the geographical 
region of origin of the dogs (Europe or North American). Population stratification is 
well documented as causing spurious genetic associations and is an important 
confounder in both human and canine genetic analyses [216, 219, 220, 227-229]. 
This effect has been reported previously in dogs that have originated from different 
geographical regions [170, 177, 230, 231] but has not previously been documented 
within the Newfoundland breed.  
 
The data were assessed in the individual populations to evaluate if the results 
differed by country. A case control study was conducted separately on the 
European and the North American dogs. A meta-analysis was carried out to 
examine the effects of the combined European and North American case control 
studies and an EMMAX analysis was also conducted. This enabled a thorough 
comparison of the different analysis methods used for correcting population 
stratification. The variation in the most significant SNPs between each of the 
methods was minimal (Table 3.1) and the same significant associations were 
identified. Therefore only the stratified CMH analysis will be discussed in detail. 
 
An analysis of the three methods used for correction for multiple testing shows that 
Bonferroni is the most conservative of the three methods, with FDR being the least 
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stringent. Permutation testing with 100,000 permutations shows intermediate 
stringency when used on the GWAS data.  
 
From the stratified GWAS data in the high density array, there are three significant 
regions of association (seen as straight line vertical peaks, rising above the 
background noise on the Manhattan plot - Figure 3.5). The regions on 
chromosomes 1, 3 and 33 indicate a genetic association with CCL rupture and justify 
further investigation. The two most significant SNPs (on chromosome 33) are 
contained within the gene Semaphorin 5b (SEMA5B), which has functions involved 
in axonal regulation and neural development [232]. These two SNPs are both 
intronic and are present in one haplotype block – block 159 on chromosome 33. 
This block also reaches significance with a permutation p-value of ≤0.0001 for the 
most common allele combination. The three combinations are GG, AA or AG; the 
frequency of GG haplotype in the population is 32%, the AA 64% and the much 
rarer AG haplotype only has a 4% frequency in the population. The dogs that have 
the GG haplotype are at a reduced risk of CCL rupture 11% frequency in cases and 
55% frequency in controls. The risk haplotype AA has a much higher frequency in 
the population (64%) than the protective haplotype with 84% frequency in cases 
and 42% frequency in the controls. 
 
The third most associated SNP in the stratified analysis (BICF2P59100 on 
chromosome 1), was located in a haplotype block with one other SNP which did not 
reach statistical significance (ranked 839). With a frequency of 45% in the 
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population (62% frequency in cases and 27% frequency in controls) the AA allele 
combination is the only allele combination to show significance. Both SNPs in the 
haplotype block are intergenic and the nearest gene is CDH19 which is 0.27Mb 
upstream. CDH19 is a cadherin gene that is involved in cell-cell adhesion, it is not 
known whether the identified SNPs impact on the function of CDH19. 
 
To date, there have been no other reported GWAS screens that have used any high 
density SNP chips to test the hypothesis that there is a genetic basis to CCL rupture 
in dogs. The only previous studies that have investigated the genetic basis of CCL 
rupture are microsatellite (MSAT) studies [2] and candidate gene studies [6, 233-
235]. In the MSAT report the study assessed 495 MSATs in total for potential 
genome wide significance with CCL in the Newfoundland dog. From these markers, 
86 were found to be significant with a p-value of ≤0.05. After correcting for multiple 
testing, four markers showed significance. The four markers were on different 
chromosomes and after validation using other markers nearby, three of the four 
chromosomes remained significant on chromosome 3, 5 and 13. We did not find 
any significant associations on either chromosome 5 or 13, but we did identify five 
SNPs on chromosome 3 that had a position of 68.2MB (the same position as the 
CPH19 MSAT) which could potentially be associated with CCL rupture although 
none were statistically significant (Table 3.9). 
 
 
  
- 109 - 
 
Table 3.9. SNPs on chromosome 3 at position 68.2MB in the GWAS study. Our 
results at this position are not significant and do not replicate the results of Wilke 
et al. (2009). 
CHR SNP Position p-value 
3 BICF2S23344482 68205869 0.64 
3 BICF2P439249 68209925 0.29 
3 BICF2P7565 68219772 0.29 
3 BICF2S23143373 68260652 0.16 
3 BICF2S23345176 68267363 0.33 
 
 
The MSATs that Wilke et al. (2009) used were spaced on average 5.5 centimorgans 
(cM) apart across all 38 chromosomes. The number of bases per centimorgan varies 
between species, but is thought to be around 1cM to 1Mb in humans [236] and in 
dogs is thought to be 106bp to 1cM [237]. On the Illumina CanineHD chip there are 
only 21 gaps that are larger than 200kB [238] and the markers on the Illumina 
CanineHD chip are spaced on average 13Kb apart. Therefore, as the number and 
size of gaps in the MSAT study is much greater than the Illumina scan, important 
regions and causative mutations are likely to have been missed by the MSAT study. 
Thus using the Illumina CanineHD arrays, the whole of the canine genome is 
genotyped with high coverage, depth and in more detail than any previous MSAT or 
low density GWA screen has been able to achieve.  
 
Low density data  
Within the meta-analysis of the low density data there were no significant 
associations, however one SNP - BICF2S23118727 (chromosome 23) neared 
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statistical significance (raw p=0.00002). This is an intergenic SNP, 0.1MB upstream 
of the gene MBNL2 that may have an involvement in myotonic dystrophy disease in 
humans [239, 240]. This disease causes muscle wasting and weakness and so 
functionally it is possible that this may play a role in CCL rupture susceptibility.  
 
The lack of SNPs reaching statistical significance on the low density chip may be 
explained by the limited sample size (49 Labrador Retrievers and 38 Golden 
Retrievers) and the relatively low number of SNPs (22,362). As a consequence the 
gap size between markers is larger, and many SNPs will not have been tested. The 
causal genetic variant may have been missed as it may have fallen between the 
markers on the array. To determine whether there is sharing of causal 
mutations/regions involved in susceptibility to CCL rupture between different dog 
breeds it would be useful to perform a case control GWAS on multiple breeds using 
the high density Illumina CanineHD chip and large numbers of dogs from a number 
of susceptible breeds. 
 
In isolation, the three regions of association, important SNPs and several key 
haplotypes found in the Newfoundland GWAS, cannot be taken as substantial 
evidence for genetic susceptibility to CCL rupture. Further replication and validation 
are needed in order for them to validated and confirmed as true associations. 
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Replication and validation of GWAS data 
The 40 most associated SNPs found in the high density GWAS data were re-
genotyped on another genotyping platform (Sequenom iPlex), with a separate 
cohort of Newfoundlands to determine if the genotyping results were consistent 
and could be replicated in a larger number of dogs.  
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Introduction 
The GWAS SNP data generated for the Newfoundlands as described in Chapter 3 
was of considerable interest. It revealed three promising chromosome association 
signals associated with CCL rupture on chromosomes 1, 3 and 33. These associated 
regions, in addition to other SNPs with the lowest p-values in the individual GWAS 
analyses (a total of 70 unique SNPs) were chosen for additional genotyping. This 
hoped to confirm (or not) the significance of association of the SNPs with CCL 
rupture. As well as validating the GWAS identified SNPs in the test population of 
Newfoundlands, there was also the opportunity to examine SNP associations in an 
additional cohort of Newfoundlands and in other breeds where CCL rupture is also 
considered to be a major problem.  Any reproducibility would suggest a common 
pathogenesis and a possible shared aetiology between breeds.  
 
Replication and validation of any biological data (including genotyping data) is 
essential to confirm that the associations seen are accurate and are not artefacts of 
bias in the original study [241]. It may also confirm the statistical associations of the 
data to validate the preliminary associations in a larger cohort of subjects [242].  
 
Validation could be achieved by directly replicating the previous work by running a 
second GWAS on a further cohort of Newfoundlands and other breeds. The cost 
implication of whole genome genotyping (using hundreds of thousands of SNPs on 
an array) makes genotyping large numbers of dogs expensive; so genotyping a 
second cohort of dogs on the same platform (Illumina Canine HD chip) is 
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impractical. An alternative approach for validating associations could be to re-
sequence any previously identified regions of association. If one does not know 
whether the areas being re-sequenced are real associations, re-sequencing a 
wrongly identified region would be a costly mistake. In-vitro and in-vivo functional 
analysis (including knock-out mice models) using the SNPs could also be run. These 
approaches are time consuming, expensive and are not worthwhile unless SNPs are 
confirmed as associated with the disease. Thus these would not be appropriate at 
this stage of the project.  
 
Replication in this study was possible because of the availability of a second 
genotyping method – MALDI-TOF mass spectrometry (Sequenom iPlex) which 
enables high throughput of samples for specific SNP genotyping and is also 
relatively inexpensive to run. This technique targets specific SNPs, previously 
identified as potentially associated, by a cost-effective methodology which lends 
itself to studies of larger dog cohorts. This approach is suitable for genotyping small 
numbers of potentially important SNPs in a relatively large population of samples. 
This two stage approach (GWAS followed by Sequenom genotyping) has been 
widely accepted as a replication/validation method used by many researchers, 
including Wood et al. [177] who genotyped 25 atopic canine cases and 23 canine 
controls on the Illumina SNP20 GWAS chip. They validated their most significant 
associations in a total of 659 samples across eight different dog breeds using the 
Sequenom assay. Guo et al. [243] also used this approach to identify a novel 
susceptibility gene for osteoporosis in humans. They used the Affymetrix 500K 
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human SNP chip for the GWAS study and validated the most associated SNPs using 
Sequenom analysis. More recently, Tengvall et al. [244] also used this design to 
determine genetic associations with canine atopic dermatitis in German Shepherd 
dogs using the high density CanineHD GWAS array and then validating their 54 most 
significant associations in 185 German Shepherd dogs. 
 
This chapter describes the use of a Sequenom genotyping platform to confirm (or 
refute) GWAS-identified SNPs from the previously genotyped Newfoundlands. It 
assesses the SNP associations in additional Newfoundlands and also in other breeds 
of dogs with high susceptibility for CCL rupture (Labrador Retriever, Rottweiler and 
Staffordshire Bull terrier). 
 
Methods 
Sample selection 
Additional samples and breeds were included to determine whether the GWAS 
associations could be replicated in (a) a larger cohort of Newfoundlands and (b) 
different breeds of dog. Along with the 96 Newfoundlands previously analysed by 
GWAS, another 175 Newfoundlands were genotyped. Three other dog breeds at 
high risk for cruciate rupture were also included; Labrador Retrievers (n = 289), 
Rottweilers (n = 138) and Staffordshire Bull Terriers (n = 51). The samples were 
obtained from the UK companion animal DNA archive and the VLA database as 
described previously in the “Sample Collection for DNA extraction” section of the 
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Methods. A breakdown of the cases and controls is shown below in Table 4.1. A full 
table detailing the age and sex of the dogs is shown in the Appendix (Appendix 1) 
Table 4.1. Cases and controls used for the replication/validation of GWAS study 
Breed Case Control Total 
Newfoundlands (Total) 99 172 271 
Newfoundlands (EU) 56 72 128 
Newfoundlands (NA) 43 100 143 
Labrador Retrievers 124 165 289 
Rottweilers 57 81 138 
Staffordshire Bull Terriers 13 38 51 
 
Sequenom genotyping  
Sequenom iPlex is a multiplex, high quality customised genotyping platform, 
capable of running up to 40 SNPs in one reaction (plex). Samples are processed on 
384 well plates. Each SNP is chosen by the user and primers are designed and 
automatically assigned into plexes using the Sequenom assay design software 
(www.mysequenom.com). The DNA undergoes a multiplex, locus specific PCR 
reaction followed by a single base, allele specific primer extension using modified 
oligos. The PCR product is nanospotted onto a silica chip and placed into a Matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer; 
each spot is shot with a laser which ionizes the samples. The ions travel through a 
vacuum tube to an ion detector. Time of flight measures the difference in time 
different molecules hit the detector and the software calculates the mass of the 
fragment. Smaller molecules travel faster than larger ones; this happens in real time 
and the software analyses this and produces the allele calls.  
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Assay design 
A total of 70 SNPs were chosen for replication from the 40 most associated SNPs in 
each of the GWAS analyses carried out (meta, EMMAX and CMH stratified), as 
detailed in Chapter 3. 
 
The SNPs of interest (including 100bp flanking sequence) were retrieved from 
Ensembl, using the mining tool Biomart [245] and exported in FASTA format. Files 
were converted to a suitable format for use in the Sequenom assay design software 
(version 1.0) using a customised PERL script. ProxSNP and Prextend quality control 
procedures were run on the sequences as part of the design process. Any 
unsuitable primers, i.e. those that may form primer-dimers were rejected, as were 
sequences that could not have suitable primers designed. SNP primers that could 
not be plexed with others were also rejected. Five SNPs were excluded in this 
process leaving 65 SNPs for running and analyses. 
 
Primers and probes were ordered from Sigma Aldrich (Dorset, UK) in the lyophilised 
form on 96 deep well plates. The primers were diluted to 50µM and pooled 
together into their respective plexes; each primer in the pool was at a working 
concentration of 0.5µM. The 65 SNPs were pooled into three plexes, 2x22plex and 
1x21plex. The probes were diluted to 300µM. 
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The Sequenom laboratory work was carried out at the Wolfson Centre for 
Personalised Medicine in the Pharmacology Department at the University of 
Liverpool.  
 
The primer and probe sequences for the 65 SNPs used for replication are shown in 
Appendix III. 
 
PCR  
PCR reactions were carried out in 384 well plates using a Veriti® 384-Well Thermal 
Cycler (Applied Biosystems, California, US). The PCR mix for each well consisted of 
0.10µl Hot start Taq (5U/µl, Sequenom, Hamburg, Germany), 1µl of the primer pool 
mix (0.5µM), 0.10μl dNTP mix (25mM, Sequenom, Hamburg, Germany), 0.33µl 
MgCl2 (25mM, Sequenom, Hamburg, Germany), 0.63µl PCR buffer (10x, Sequenom, 
Hamburg, Germany) and 2.85µl of nanopure water. The reaction mixture was 
added to wells containing DNA that had been dried down previously (2µl of 20ng/µl 
DNA). The amplification reaction was carried out using the following amplification 
conditions: 
94˚C – 15 minutes 
94˚C – 20 seconds 
56˚C – 30 seconds 
72˚C – 1 minute 
72˚C – 3 minutes 
4˚C - ∞ 
 
X45 
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Unincorporated dNTPs were neutralised by the addition of shrimp alkaline 
phosphatase (SAP) enzyme (1.7 U/μl, Sequenom, Hamburg, Germany). This was 
prepared by adding 1.53µl of nanopure water, 0.17µl of hME buffer (10x, 
Sequenom, Hamburg, Germany), 0.30µl of SAP enzyme was added to each well 
making a total reaction volume of 7µl. This was then cycled at 37˚C for 40 minutes 
and 85˚C for 5 minutes. 
 
iPLEX extension reaction  
Due to the inverse relationship between peak intensity and mass of product [246] it 
was important to amend the concentration of the extension primers with a four 
stage adjustment to level out the analyte peaks in the final spectra. To do this, the 
lowest mass primers were mixed to a final concentration of 7µM, second lowest at 
9.3µM, the next at 11.66µM and the highest mass group at 14µM. The iPLEX 
cocktail mixture was made by adding 0.76µl of nanopure water, 0.2µl iPLEX buffer 
(10x, Sequenom, Hamburg, Germany), 0.2µl iPLEX-termination mix (Sequenom, 
Hamburg, Germany), 0.04µl of iPLEX enzyme (Sequenom, Hamburg, Germany) with 
0.80µl of the primer mix. This reaction mixture was added to each well of the 384 
well plate to make a final reaction volume of 9µl, which was thermocycled using the 
following conditions: 
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94˚C – 30 seconds 
94˚C – 5 seconds 
52˚C – 5 seconds 
80˚C – 5 seconds 
52˚C – 5 seconds 
80˚C – 5 seconds 
72˚C – 3 minutes 
4˚C - ∞ 
 
The iPLEX reaction products were cleaned by adding 6mg of resin (Sequenom, 
Hamburg, Germany) to each well. Nanopure water (16µl) was added to each well 
and the 384 well plate was then rotated 360˚ along its long axis for 10 minutes 
before centrifugation for 5 minutes at 1500g. 
 
Mass Spectrometry  
The Sequenom chip was spotted with the PCR product using the nanodispenser 
(Sequenom, Hamburg, Germany) and placed in a MALDI-TOF mass spectrometer to 
acquire the spectra. A biallelic SNP can yield three different genotypes. For 
example, an A/G marker could produce the genotype of A homozygote, G 
homozygote and A/G heterozygote. Representative images of the spectra is shown 
in Figure 4.1 
X50 
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Figure 4.1. An example spectra from MALDI-TOF showing genotype calls for a 
bialleleic SNP A/G. The unextended primer (UEP) is shown in green, the alleles are 
shown in red and yellow - yellow peaks indicate the allele call for the sample. If 
the sample is homozygous there is one large peak as indicated by figures A & B, 
hetrozygote samples shows two peaks at both allele sites. The remaining peaks 
on the spectra are either from other SNPs in the plex or undetermined products. 
If the iplex extension failed then there would be a large peak at the UEP position. 
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The data were checked in the massARRAY TYPER program, which uses a “traffic 
light” system to show the quality of each reaction. The clusters and call rates for 
each SNP were visually assessed for correct genotype calls. The data were exported 
in a format suitable for input into the data analysis program PLINK [190, 191] 
implemented by BCgene (BC Platforms, Finland). 
 
Quality Assurance 
Before statistical analyses were performed, data were assessed for QA and 
excluded if the sample call rate was <75%, the genotype call rate <75%, the control 
population was not in Hardy-Weinberg equilibrium (p<0.001) and/or the minor 
allele frequency ≤0.01. Following QA, the samples and SNPs that remained for 
analyses differed for each breed and are shown in Table 4.2 
 
Table 4.2. Numbers of SNPs and CCL rupture cases and controls remaining for 
analyses after QA 
BREED SNPs 
SAMPLES 
Case Control Total  
Newfoundlands (Total) 58 78 136 214 
Newfoundlands (EU) 59 46 56 102 
Newfoundlands (NA) 59 32 80 112 
Labrador Retriever 53 91 126 217 
Rottweilers 53 50 64 114 
Staffordshire Bull Terriers 56 10 21 31 
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The call rate used to filter samples during QA for the Sequenom genotyping was 
lower than that used for the GWAS investigation (Chapter 3) because some of the 
samples that were used for Sequenom were of marginally lower quality due to 
differences in the sample collection methods. The majority of the DNA samples that 
were used for the Illumina genotyping were extracted from EDTA blood samples, 
whereas the DNA that was used in the Sequenom genotyping was mainly extracted 
from Oragene™ swabs.  Despite methods to clean up the DNA and remove 
contaminants from the salivary samples, the DNA from the Oragene™ kits was of 
lower quality than the DNA extracted from the EDTA blood samples. It was, 
however, adequate to be used for Sequenom genotyping, as documented 
previously [247] [181]. 
 
Results 
Concordance between Illumina and Sequenom genotyping 
Sixty-five SNPs in 96 samples were genotyped using both the Illumina and 
Sequenom platforms to check the consistency of the genotypes between the two 
platforms. Concordance between the two platforms was found to be 93%.  
 
Sequenom genotyping data 
The Sequenom data were examined on a breed by breed, case control basis. The 
Newfoundland group was analysed using the CMH test (stratified by country) in 
addition to separate European and North American case control studies. The 
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significantly associated SNPs  (p<0.05) that replicated in the Newfoundland breed 
analyses (stratified, European, North American) are shown in Table 4.3 - Table 4.5 
and the significant SNPs in the other breed analyses (Labradors Retrievers, 
Rottweilers and Staffordshire Bull Terriers) are shown in Table 4.6. 
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Table 4.3. Significantly-associated CCL rupture SNPs (p<0.05)  in Newfoundlands (Stratified analysis).  
Chr SNP 
Gene or 
intergenic 
Position 
(bp) 
A1 MAF A2 
p 
(raw) 
p 
(BONF) 
p 
(perm) 
p 
(FDR) 
OR 95% CI 
Gene 
function 
3 rs23569097 SORCS2 59381030 C 0.47 T 0.0006 0.03* 0.04* 0.02* 0.48 0.32 - 0.74  
3 rs23566023 Intergenic 58878743 A 0.43 G 0.0010 0.06 0.06 0.02* 2.00 1.32 - 3.02 - 
33 rs23829198 Intergenic 19430035 G 0.39 A 0.0011 0.06 0.06 0.02* 0.48 0.31 - 0.75 - 
33 rs8754330 ZDHHC23 18223573 G 0.29 A 0.0023 0.13 0.11 0.03* 0.47 0.29 - 0.77  
33 rs23835082 SEMA5B 25987425 G 0.28 A 0.0024 0.14 0.12 0.03* 0.47 0.29 - 0.77  
1 rs21977372 Intergenic 10792454 A 0.47 C 0.0039 0.23 0.18 0.04* 1.84 1.22 - 2.79 - 
15 rs22346338 STAB2 42269107 T 0.18 C 0.0044 0.25 0.19 0.04* 0.42 0.23 - 0.77  
15 rs22418471 Intergenic 37221186 G 0.33 T 0.0073 0.42 0.28 0.05* 0.55 0.35 - 0.85 - 
33 rs23806044 Intergenic 19502373 T 0.29 C 0.0073 0.42 0.28 0.05* 0.52 0.32 - 0.84 - 
1 rs22014075 Intergenic 10756573 C 0.42 T 0.0086 0.50 0.32 0.05* 1.75 1.15 - 2.66 - 
33 rs23801537 DIRC2 25923850 A 0.31 G 0.0097 0.56 0.34 0.05* 0.54 0.34 - 0.86  
33 rs23811087 Intergenic 26105553 T 0.29 C 0.0107 0.62 0.37 0.05* 0.53 0.32 - 0.86 - 
33 rs23827731 SEMA5B 26001662 G 0.30 A 0.0128 0.74 0.42 0.05* 0.55 0.34 - 0.88  
1 rs9094558 RNF152 14988276 G 0.37 A 0.0132 0.77 0.43 0.05* 0.58 0.38 - 0.89  
33 rs23835584 Intergenic 26080255 C 0.21 T 0.0137 0.79 0.44 0.05* 0.51 0.30 - 0.87 - 
33 rs8613571 STXBP5L 24503510 T 0.30 C 0.0139 0.81 0.44 0.05* 0.55 0.34 - 0.89  
4 rs24114482 LRRTM3 18350538 T 0.27 C 0.0152 0.88 0.47 0.05* 0.56 0.35 - 0.90  
1 rs21956708 Intergenic 10822495 G 0.41 A 0.0186 1.00 0.53 0.06 1.64 1.09 - 2.47 - 
1 rs21960910 Intergenic 10408315 G 0.40 A 0.0191 1.00 0.54 0.06 0.60 0.39 - 0.92 - 
33 rs23801997 Intergenic 26063962 C 0.42 T 0.0207 1.00 0.56 0.06 0.61 0.40- 0.93 - 
15 rs22383474 ANO4 39884807 G 0.25 A 0.0234 1.00 0.60 0.06 0.56 0.34 - 0.93  
33 rs8748659 STXBP5L 24536212 A 0.30 T 0.0247 1.00 0.61 0.06 0.59 0.37 - 0.93  
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Chr SNP 
Gene or 
intergenic 
Position 
(bp) 
A1 MAF A2 
p 
(raw) 
p 
(BONF) 
p 
(perm) 
p 
(FDR) 
OR 95% CI 
Gene 
function 
1 rs21987554 Intergenic 10403384 G 0.40 A 0.0251 1.00 0.62 0.06 0.61 0.39 - 0.94 - 
33 rs23798518 STXBP5L 24386039 T 0.30 G 0.0269 1.00 0.64 0.06 0.59 0.37 - 0.94  
8 rs24496570 Intergenic 11069517 T 0.30 A 0.0274 1.00 0.65 0.06 0.58 0.36 - 0.95 - 
27 rs23333120 CLSTN3 37900799 G 0.19 A 0.0287 1.00 0.66 0.06 0.55 0.32 - 0.95  
36 rs23935034 Intergenic 24968515 A 0.28 G 0.0289 1.00 0.67 0.06 1.66 1.05 - 2.63 - 
33 rs9122813 Intergenic 24703426 G 0.33 A 0.0350 1.00 0.72 0.07 0.62 0.40 - 0.97 - 
33 rs23795335 POPDC2 23291566 C 0.40 T 0.0454 1.00 0.80 0.09 0.65 0.43 - 0.99  
1 rs21998646 Intergenic 13375903 T 0.28 C 0.0457 1.00 0.80 0.09 0.61 0.38 - 0.99 - 
33 rs23800347 KALRN 27503643 A 0.20 G 0.0466 1.00 0.81 0.09 0.58 0.34 - 0.99  
1 rs21882298 Intergenic 10231948 G 0.49 A 0.0499 1.00 0.83 0.09 1.50 1.00 - 2.25 - 
1 rs8959368 Intergenic 11497808 G 0.04 A 0.0520 1.00 0.84 0.09 0.23 0.04 - 1.08 - 
33 rs23828846 SEMA5B 25983710 C 0.39 T 0.0532 1.00 0.85 0.09 0.66 0.43 - 1.01  
KEY: A1 = base for allele 1, A2 = base for allele 2, MAF = minor allele frequency, p(raw) = raw p-value. Three different tests for correction for 
multiple testing were performed: p (BONF) = Bonferroni p-value, p (FDR) = p-value for FDR, p(perm) = p-value for 100,000 permutations. OR 
= Odds Ratio (≥1 implies A1 increases risk compared to A2, if ≤1 A2 increases risk compared to A1).  An asterix (*) means significance after 
correction for multiple testing. The row highlighted in yellow is of most significance. 
 Function of the genes are colour coded: 
Purple - gene function involved in neuronal systems and development and maintenance of nervous system (KALRN, LRRTM3, SEMA5B, 
SORCS2, STXBP5L).  
Blue - synaptic junctions and synaptic signalling (ANO4, CLSTN3, ZDHHC23).  
Green - polyubiquination and apoptosis or were apoptosis enhancers (RNF152, STAB2).  
Orange – miscellaneous function (cancer and cellular transport; DIRC2) and (heart development; POPDC2) 
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Thirty-four of the 58 SNPs that replicated in the Newfoundland group as a whole 
(CMH stratified) had a raw p-value of ≤0.05. From the 34 SNPs, 18 were intergenic 
and the rest fall within 12 genes (KALRN, LRRTM3, SEMA5B, SORCS2, STXBP5L, 
ANO4, CLSTN3, ZDHHC23, RNF152, STAB2, DIRC2 and POPDC2). The twelve genes 
included five genes involved in neuronal systems and the development and 
maintenance of the nervous system. They are KALRN (Kalirin), LRRTM3 (leucine rich 
repeat transmembrane neuronal 3), SEMA5B (Semaphorin 5b), SORCS2 (sortillin-
related vacuolar protein sorting 10-domain containing protein) and STXBP5L 
(Syntaxin binding protein 5 like). Also identified as CCL rupture-associated were 
three genes that are involved in synaptic junctions and synaptic signalling: ANO4 
(Anoctamin 4), CLSTN3 (Calsytenin 3) and ZDHHC23 (Zinc finger DHHC-type 
containing 23). Two genes were involved in polyubiquination and apoptosis or were 
apoptosis enhancers RNF152 (Ring finger protein 152) and STAB2 (Stabilin 2). Two 
genes with miscellaneous functions were involved in cancer and cellular transport; 
DIRC2 (Disrupted in Renal Carcinoma 2) and heart development; POPDC2 (Popeye 
domain containing 2). 
 
The most associated SNP that replicated in this breed was rs23569097 on 
chromosome 3, in gene SORCS2. This is highlighted in yellow in Table 4.3. It showed 
significance after correction for multiple testing in each of the three different tests 
(Bonferroni p-value = 0.03, permutation p-value = 0.04 and FDR p-value = 0.02).  
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Table 4.4. Significantly associated CCL rupture SNPs (p≤0.05) in European Newfoundlands . 
Chr SNP 
Gene or 
intergenic 
A1 F_A F_U A2 p (raw) p (BONF) 
p 
(perm) 
p (FDR) OR 95% CI 
Gene 
function 
3 rs23569097 SORCS2 T 0.57 0.32 C 0.0005 0.03* 0.03* 0.03* 2.74 1.55 - 4.86  
3 rs23566023 Intergenic A 0.51 0.28 G 0.0012 0.07 0.07 0.04* 2.63 1.45 - 4.76 - 
33 rs23829198 Intergenic G 0.31 0.52 A 0.0036 0.21 0.18 0.07 0.42 0.23 - 0.76 - 
15 rs22418471 Intergenic G 0.27 0.46 T 0.0054 0.32 0.23 0.08 0.43 0.24 - 0.78 - 
1 rs22014075 Intergenic C 0.52 0.33 T 0.0086 0.51 0.33 0.08 2.20 1.22 - 3.96 - 
8 rs8987872 Intergenic T 0.26 0.44 C 0.0088 0.52 0.33 0.08 0.45 0.25 - 0.82 - 
33 rs8754330 ZDHHC23 G 0.20 0.38 A 0.0099 0.58 0.36 0.08 0.42 0.21 - 0.82  
8 rs24496570 Intergenic T 0.22 0.39 A 0.0150 0.89 0.47 0.09 0.43 0.22 - 0.86 - 
15 rs22346338 STAB2 T 0.17 0.32 C 0.0167 0.99 0.51 0.09 0.43 0.21 - 0.87  
8 rs24526391 Intergenic G 0.27 0.43 A 0.0169 1.00 0.51 0.09 0.48 0.27 - 0.88 - 
33 rs23806044 Intergenic T 0.20 0.35 C 0.0184 1.00 0.53 0.09 0.45 0.23 - 0.88 - 
1 rs21956708 Intergenic G 0.52 0.36 A 0.0185 1.00 0.54 0.09 1.97 1.12 - 3.47 - 
4 rs24114482 LRRTM3 T 0.25 0.40 C 0.0221 1.00 0.59 0.09 0.50 0.27 - 0.91  
15 rs22380841 Intergenic A 0.26 0.42 G 0.0231 1.00 0.60 0.09 0.50 0.27 - 0.91 - 
1 rs21977372 Intergenic A 0.51 0.35 C 0.0233 1.00 0.60 0.09 1.95 1.09 - 3.50 - 
27 rs23333120 CLSTN3 G 0.13 0.25 A 0.0275 1.00 0.65 0.10 0.44 0.21 - 0.92  
1 rs21882298 Intergenic G 0.55 0.41 A 0.0410 1.00 0.78 0.14 1.79 1.02 - 3.12 - 
15 rs22383474 ANO4 G 0.20 0.33 A 0.0463 1.00 0.81 0.15 0.51 0.26 - 0.99  
For key please see next page. 
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KEY: A1 = base for allele 1, A2 = base for allele 2, F_A/U = frequency of allele in affected/unaffected animals, p(raw) = raw p-value. Three 
different tests for correction for multiple testing were performed: p (BONF) = Bonferroni p-value, p (FDR) = p-value for FDR, p(perm) = p-
value for 100,000 permutations. OR = Odds Ratio (≥1 implies A1 increases risk compared to A2, if ≤1 A2 increases risk compared to A1).  An 
asterix (*) means significance after correction for multiple testing. The row highlighted in yellow is of most significance. 
Function of the genes are colour coded: 
Purple - gene function involved in neuronal systems and development and maintenance of nervous system (LRRTM3,  SORCS2).  
Blue - synaptic junctions and synaptic signalling (ANO4, CLSTN3, ZDHHC23).  
Green - polyubiquination and apoptosis or were apoptosis enhancers (STAB2).  
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Table 4.5. Significantly associated CCL rupture SNPs (p≤0.05) in North American Newfoundlands.  
Chr SNP Gene or intergenic A1 F_A F_U A2 p (raw) p (BONF) p (perm) p (FDR) OR 95% CI Gene function 
33 rs23827731 SEMA5B G 0.15 0.32 A 0.0107 0.63 0.37 0.22 0.37 0.17 - 0.81  
33 rs23811087 Intergenic T 0.17 0.34 C 0.0141 0.83 0.44 0.22 0.40 0.19 - 0.84 - 
33 rs23835082 SEMA5B G 0.16 0.33 A 0.0147 0.87 0.44 0.22 0.40 0.19 - 0.85  
33 rs23801537 DIRC2 A 0.21 0.38 G 0.0181 1.00 0.50 0.22 0.44 0.22 - 0.88  
33 rs23795335 POPDC2 C 0.26 0.42 T 0.0223 1.00 0.57 0.22 0.47 0.25 - 0.91  
33 rs23835584 Intergenic C 0.12 0.25 T 0.0316 1.00 0.69 0.22 0.40 0.17 - 0.94 - 
33 rs23798518 STXBP5L T 0.20 0.35 G 0.0320 1.00 0.70 0.22 0.46 0.23 - 0.95  
33 rs8748659 STXBP5L A 0.20 0.35 T 0.0320 1.00 0.70 0.22 0.46 0.23 - 0.95  
33 rs8613571 STXBP5L T 0.20 0.35 C 0.0343 1.00 0.71 0.22 0.47 0.23 - 0.95  
33 rs23828846 SEMA5B C 0.27 0.43 T 0.0381 1.00 0.74 0.22 0.51 0.27 - 0.97  
1 rs8959368 Intergenic G 0.00 0.07 A 0.0418 1.00 0.78 0.22 0.00 0.00 – 0.00 - 
33 rs23800347 KALRN A 0.11 0.23 G 0.0472 1.00 0.82 0.23 0.42 0.18 - 1.01  
1 rs9094558 RNF152 G 0.25 0.39 A 0.0510 1.00 0.84 0.23 0.53 0.28 - 1.01  
1 rs21998646 Intergenic T 0.17 0.29 C 0.0541 1.00 0.85 0.23 0.48 0.22 - 1.02 - 
KEY: A1 = base for allele 1, A2 = base for allele 2, F_A/U = frequency of allele in affected/unaffected animals, p(raw) = raw p-value. Three 
different tests for correction for multiple testing were performed: p (BONF) = Bonferroni p-value, p (FDR) = p-value for FDR, p(perm) = p-
value for 100,000 permutations. OR = Odds Ratio (≥1 implies A1 increases risk compared to A2, if ≤1 A2 increases risk compared to A1).  An 
asterix (*) means significance after correction for multiple testing. 
The row highlighted in yellow is of most significance. 
Function of the genes are colour coded: 
Purple - gene function involved in neuronal systems and development and maintenance of nervous system (KALRN, SEMA5B, STXBP5L).  
Green - polyubiquination and apoptosis or were apoptosis enhancers (RNF152).  
Orange – miscellaneous function (cancer and cellular transport; DIRC2) and (heart development; POPDC2) 
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In the European Newfoundlands (Table 4.4), 18 of the 59 SNPs replicated with a raw 
p-value of ≤0.05 and were associated with CCL rupture. The most associated SNP, 
rs23569097 on chromosome 3 and in gene SORCS2, showed significance after 
correcting for multiple testing in all three tests (p = 0.03 in each). 
 
In the North American Newfoundlands Table 4.5), 14 of the 59 SNPs replicated with 
a raw p-value of ≤0.05 and were significantly associated with CCL rupture. After 
correcting for multiple testing, no SNPs were significant. 
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Table 4.6. Significant CCL rupture associated SNPs for the Labrador Retrievers, Rottweilers and Staffordshire Bull Terriers  
Breed Chr SNP 
Gene or 
intergenic 
A1 F_A F_U A2 
p    
(raw) 
p 
(BONF) 
p 
(perm) 
p 
(FDR) 
OR 95% CI 
Gene 
function 
La
b
ra
d
o
r 
R
et
ri
ev
er
s 8 rs24526391  Intergenic G 0.29 0.15 A 0.0003 0.02* 0.02* 0.02* 2.37 1.47 - 3.80 - 
1 rs21895425 SERPINB13 C 0.38 0.29 G 0.0347 1.00 0.85 0.51 1.55 1.03 - 2.33  
8 rs8987872  Intergenic T 0.37 0.28 C 0.0393 1.00 0.88 0.51 1.53 1.02 - 2.31 - 
3 rs23569097 SORCS2 T 0.24 0.16 C 0.0406 1.00 0.89 0.51 1.64 1.02 - 2.64  
R
o
tt
w
ei
le
rs
 8 rs24526391  Intergenic A 0.33 0.51 G 0.0074 0.39 0.34 0.25 0.48 0.28 - 0.82 - 
22 rs23048917 Intergenic T 0.53 0.36 C 0.0095 0.50 0.39 0.25 2.04 1.19 - 3.51 - 
4 rs24114482 LRRTM3 T 0.51 0.35 C 0.0167 0.88 0.57 0.29 1.92 1.12 - 3.29  
8 rs8987872  Intergenic C 0.29 0.44 T 0.0250 1.00 0.76 0.32 0.53 0.30 - 0.93 - 
33 rs23828846 SEMA5B C 0.28 0.42 T 0.0305 1.00 0.82 0.32 0.54 0.31 - 0.95  
St
af
fo
rd
sh
ir
e 
B
u
ll 
Te
rr
ie
rs
  12 rs22184669 CYP39A1 T 0.25 0.00 G 0.0007 0.04* 0.05* 0.04* 0.00 0.00 - 0.00  
15 rs22380841 Intergenic A 0.40 0.13 G 0.0148 0.83 0.55 0.41 4.67 1.28 - 17.05 - 
1 rs21998646 Intergenic T 0.20 0.05 C 0.0276 1.00 0.78 0.49 0.25 0.07 - 0.90 - 
10 rs22030434 CCDC85A G 0.10 0.00 A 0.0419 1.00 0.93 0.49 0.00 0.00 - 0.00  
1 rs9094558 RNF152 A 0.17 0.44 G 0.0439 1.00 0.94 0.49 0.25 0.06 - 1.02  
KEY: A1 = base for allele 1, A2 = base for allele 2, F_A/U = frequency of allele in affected/unaffected animals, p(raw) = raw p-value. Three 
different tests for correction for multiple testing were performed: p (BONF) = Bonferroni p-value, p (FDR) = p-value for FDR, p(perm) = p-
value for 100,000 permutations. OR = Odds Ratio (≥1 implies A1 increases risk compared to A2, if ≤1 A2 increases risk compared to A1).  An 
asterix (*) means significance after correction for multiple testing,  ““/““= significant more than one breed. The row highlighted in yellow 
is of most significance. 
CONTINUED ON NEXT PAGE… 
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Function of the genes are colour coded: 
Purple - gene function involved in neuronal systems and development and maintenance of nervous system (LRRTM3, SEMA5B, SORCS2).  
Green - polyubiquination and apoptosis or were apoptosis enhancers (RNF152).  
Orange – miscellaneous functions - differentiation of keratinocytes; SERPINB13, bile-acid metabolism; CYP39A1 and no known function; 
CCDC85a 
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In the Labrador Retriever, four of the 53 SNPs that passed QA, replicated with a raw 
p-value ≤0.05 and were significantly associated with CCL rupture. The most 
associated SNP in this breed, rs24526391 on chromosome 8, showed significance 
after correcting for multiple testing in each of the three tests (p=0.02 in each of the 
three tests). 
 
In the Rottweiler breed, five of the 53 SNPs that passed QA reached significance 
with a raw p-value of ≤0.05. After correcting for multiple testing, no SNPs were 
significant. 
 
In the Staffordshire Bull Terrier breed, five of the 56 SNPs that passed QA were 
significantly associated with CCL rupture (raw p-value of ≤0.05), the most 
associated SNP (rs22184669) in this breed was on chromosome 12, in gene 
CYP39A1. This SNP was significant after correcting for multiple testing using all 
three methods (Bonferroni p-value = 0.04, permutation p-value = 0.05 and FDR p-
value = 0.04). 
 
SNPs that are common in more than one breed are shown in Table 4.7 for 
intragenic SNPs and Table 4.8 for intergenic SNPs.  
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Table 4.7. Intragenic SNPs shared by more than one breed  
Chr SNP Gene 
Newfoundland 
(stratified) 
EU NA 
Labrador 
Retriever 
Rottweilers 
Staffordshire 
Bull Terriers 
3 rs23569097 SORCS2 + + - + - - 
33 rs23801537 DIRC2 + - + - - - 
33 rs23835082 SEMA5B + + + - + - 
15 rs22346338 STAB2 + + - + + - 
33 rs8754330 ZDHHC23 + + + + - - 
15 rs22383474 ANO4 + + - - - - 
27 rs23333120 CLSTN3 + + - - + - 
33 rs23800347 KALRN + - + - + - 
4 rs24114482 LRRTM3 + + - - + + 
33 rs23795335 POPDC2 + - + - - + 
1 rs9094558 RNF152 + - + - - + 
33 rs23827731 SEMA5B + - + - + - 
33 rs8613571 STXBP5L + - + + - - 
33 rs8748659 STXBP5L + - + + - - 
33 rs23798518 STXBP5L + - + + - - 
10 rs22030434 CCDC85A - - - - - + 
12 rs22184669 CYP39A1 - - + - - + 
33 rs23799015 IGSF11 - - + + - + 
33 rs23828846 SEMA5B - - + + + - 
1 rs21895425 SERPINB13 - - - + + - 
33 rs23804256 TAGLN3 - - - + - + 
 
KEY: raw p-value is indicated by colour:  
Yellow =p≤0.001,  blue = p≤0.01,  green = p≤0.05,  red = non-significant. A minus  
(-) means that the SNP is not present in the analysis after QA.  
EU = European Newfoundlands, NA = North American Newfoundlands. 
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Table 4.8. Intergenic SNPs shared by more than one breed  
Chr SNP 
SNP 
position 
Newfoundland 
(stratified) 
EU NA 
Labrador 
Retriever 
Rottweilers 
Staffordshire 
Bull Terriers 
3 rs23566023 Intergenic + + - +  +  - 
15 rs22418471 Intergenic + + - +  - +  
1 rs21977372 Intergenic + + +  - +  - 
33 rs23806044 Intergenic + + - - - +  
33 rs23829198 Intergenic + + - - - - 
1 rs22014075 Intergenic + + - - - - 
36 rs23935034 Intergenic + - +  +  - +  
33 rs9122813 Intergenic + - - +  - +  
1 rs21956708 Intergenic + + - - +  - 
1 rs21882298 Intergenic + + - - +  - 
1 rs21998646 Intergenic + - + - - + 
33 rs23811087 Intergenic + - + - - - 
33 rs23835584 Intergenic + - + - - - 
1 rs21960910 Intergenic + - - - - - 
33 rs23801997 Intergenic + - - - - - 
1 rs21987554 Intergenic + - - - - - 
8 rs24496570 Intergenic + + - - - - 
8 rs24526391 Intergenic - + - + + +  
13 rs8712319 Intergenic - - - +  +  +  
8 rs8987872 Intergenic - + - + + - 
22 rs23048918 Intergenic - - - +  +  - 
33 rs23813763 Intergenic - - +  +  - +  
15 rs22380841 Intergenic - + - - - + 
KEY: raw p-value is indicated by colour 
Yellow =p≤0.001,  blue = p≤0.01,  green = p≤0.05,  red = non-significant. A minus  
(-) means that the SNP is not present in the analysis after QA.  
EU = European Newfoundlands, NA = North American Newfoundlands. 
SNPs shaded in grey are in each of the breed analyses (Labrador Retrievers, 
Rottweilers and Staffordshire Bull Terriers) apart from the Newfoundlands 
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A meta-analysis was run on the data to determine the SNPs that were significant in 
the whole cohort. The 20 most significant SNPs from the meta-analysis are shown in 
Table 4.9 
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Table 4.9. Meta-analysis of the 20 most CCL rupture-associated SNPs. The meta-
analysis was run using association data from the Stratified Newfoundlands, EU 
Newfoundlands, NA Newfoundlands, Labrador Retrievers, Rottweilers and 
Staffordshire Bull Terriers.  
Chr SNP Position 
Gene or 
intergenic 
A1 A2 
p 
(raw) 
Estimated 
p (BONF) 
OR Sig. 
Gene 
function 
3 rs23569097 59381030 SORCS2 T C 0.0003 0.02* 1.73 ***  
33 rs8748659 24536212 STXBP5L A T 0.0026 0.15 0.64 **  
33 rs23828846 25983710 SEMA5B T C 0.0037 0.21 1.46 **  
33 rs23827731 26001662 SEMA5B G A 0.0043 0.24 0.59 **  
33 rs23798518 24386039 STXBP5L T G 0.0043 0.24 0.65 **  
33 rs8754330 18223573 ZDHHC23 G A 0.0071 0.40 0.69 **  
33 rs8613571 24503510 STXBP5L T C 0.0119 0.67 0.68 *  
33 rs23835082 25987425 SEMA5B G A 0.0152 0.85 0.69 *  
33 rs23811087 26105553 Intergenic T C 0.0171 0.96 0.58 * - 
33 rs23806044 19502373 Intergenic T C 0.0337 1.00 0.74 * - 
33 rs23800347 27503643 KALRN G A 0.0366 1.00 1.39 *  
1 rs21956708 10822495 Intergenic G A 0.0376 1.00 1.53 * - 
1 rs21998646 13375903 Intergenic C T 0.0382 1.00 1.34 * - 
1 rs22014075 10756573 Intergenic C T 0.0422 1.00 1.40 * - 
33 rs23829198 19430035 Intergenic G A 0.0525 1.00 0.76 * - 
1 rs21977372 10792454 Intergenic A C 0.0526 1.00 1.33 * - 
8 rs24526391 11289491 Intergenic G A 0.0545 1.00 1.30 * - 
33 rs23795335 23291566 POPDC2 C T 0.0586 1.00 0.76 ns  
33 rs23801537 25923850 DIRC2 A G 0.0588 1.00 0.70 ns  
KEY: A1 = base for allele 1, A2 = base for allele 2, OR = odds ratio ( ≥1 implies A1 
increases risk compared to A2, if ≤1 A2 increases risk compared to A1). An estimated 
correction for multiple testing was performed, correcting for 56 tests (average 
number of SNPs in each of the breed analyses). * = Significant after correction for 
multiple testing.  Significance of raw p-value indicated by asterix (*) scale= p≤0.05, 
**=p≤0.01, ***=p≤0.001, ns = not significant. Function of the genes are colour coded: 
Purple - gene function involved in neuronal systems and development and 
maintenance of nervous system (KALRN, SEMA5B, SORCS2, STXBP5L).  
Blue - synaptic junctions and synaptic signalling (ZDHHC23).  
Orange – miscellaneous function (cancer and cellular transport; DIRC2) and (heart 
development; POPDC2) 
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Genes SORCS2, STXBP5L, SEMA5B, ZDHHC23 and KALRN showed significant CCL 
rupture-associations (p-value ≤0.05) with nine SNPs being found within these 
genes. The remaining eight of the 17 significant CCL rupture-associated SNPs in the 
meta-analysis were all intergenic SNPs. SNP rs23795335 within the gene POPDC2 
and SNP rs23801537 within DIRC2, neared statistical significance with a raw p-value 
of 0.058 for each of the two SNPs. The SNP with the lowest p-value rs23569097 
were significant after the applying the estimated correction for multiple testing. 
 
Discussion 
Many of the associated SNPs in the Newfoundland CMH analysis (18 out of 34) 
were intergenic. The functions of intergenic SNPs are largely unknown. They may 
alter the splicing pattern, transcription factor binding sites or affect non-coding RNA 
in some other way which has yet to be identified [163, 248]. The remaining SNPs 
were all within genes (except for rs9094558) and are all intronic. They probably do 
not have a direct effect on protein structure, synthesis or function, as they are 
spliced out when mature mRNA is formed [249]. They may be in LD with associated 
SNPs that are in exonic/protein coding regions that have not been screened in the 
study. SNP rs9094558 is downstream of the gene RNF152 and so its effect on 
protein function is also unknown; it may affect mRNA stability. 
 
Having confirmed the association of some SNPs in the Newfoundland breed, it was 
important to determine if the same associations were also present in other breeds. 
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Three other breeds with a high incidence of CCL rupture were available for 
comparison – Labrador Retrievers, Rottweilers and Staffordshire Bull Terriers. Only 
14 SNPs from the Newfoundland analysis were validated in the other breeds after 
QA (Table 4.6), seven are intergenic and seven were within genes. All SNPs were 
intronic except for rs9094558 (as mentioned above), rs21895425 which is in the 
3’UTR of SERPINB13 and rs21946171 which is upstream of SERPINB13. Table 4.7 
and Table 4.8 show the SNPs that are common to more than one breed analysis. 
None of the SNPs were common to all breeds studied. This could be indicative of 
different genetic components being involved in CCL rupture susceptibility in 
different dog breeds, however, it could be that the SNPs  have different levels of 
penetrance in the different breeds [177, 250]  
 
Certain genes identified in the analyses are of particular interest because of their 
potential relevance to CCL rupture susceptibility. SORCS2 had the highest 
associated SNP in the meta-analysis (after correction for multiple testing) and was 
identified in three of the six individual analyses (Stratified Newfoundlands, 
European Newfoundlands and Labrador Retrievers). It is strongly expressed in the 
nervous system [251-254]. SEMA5B (contains the two most significant GWAS SNPs 
in the Newfoundlands) is involved in axonal regulation and sends positive guidance 
cues to the axons during development [232]. This, coupled with the functions of 
several other genes of interest, involving synaptic membranes (ZDHHC23) [255], 
calcium-mediated postsynaptic signalling (CLSTN3 and ANO4) [256-258] and 
neuronal plasticity (KALRN) [259] indicate a possible role of neurological and/or 
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neuromuscular pathways in the susceptibility and incidence of CCL rupture. These 
could also impact on the severity of the disease. 
 
The neuromuscular system can control joint stability [38, 39]. The wiring of the 
nervous system is dependent on correct positioning of axons and dendrites, which 
is carried out by axonal guidance molecules - of which the Semaphorins (including 
SEMA5B) are a key group [232]. Axonal guidance involves activation of signal 
transduction cascades that can lead to re-organisation of the cytoskeleton [260]. 
The cytoskeleton plays an important role in distributing mechanotransduction 
signals to the extracellular matrix. Shultz et al. [261] were the first to document that 
cruciate ligaments contain mechanoreceptors which impact on knee 
proprioception.  
 
Rupture of the cruciate ligament causes mechanoreceptor impairment, which in 
turn leads to loss of proprioception (which can persist even after surgery to stabilise 
the knee). Joint instability, which is a defining feature of CCL rupture, may not only 
be caused by loss of restraint in the traditional sense (CCL being the primary 
stabiliser of the knee joint), but also due to the loss of proprioception and 
kinaesthesia [262, 263]. Loss of proprioception in human knees after ACL injury has 
been well documented [264-266] and has been linked with joint damage and knee 
function [263, 264, 267, 268]. Interestingly, in human research, it has been 
demonstrated that it is possible to significantly lower the incidence of ACL rupture 
during a sports season [269-271]. This was achieved by developing a training 
 
  
- 142 - 
 
programme for the neuromuscular system (proprioceptive training), focusing on 
factors such as proper landing techniques using wobble boards and balance mats. 
Clearly such training programs are not suitable for dogs, but it does add 
corroboration to the theory that neuromuscular responses, neurological system 
and proprioception are important factors when considering and preventing rupture 
of the CCL in dogs. Muscle imbalance, atrophy and changes in gait characteristics 
have also been documented as important predisposing factors for CCL rupture 
[272-275]. Mostafa et al. [275] have suggested that a preventative rehabilitation 
program may be implemented to help reduce the incidence of CCL rupture by 
strengthening the key muscles in the rear limbs of the dog, this too substantiates 
the neuromuscular argument. 
 
The SORCS2 gene has been shown to have a direct link to the neuropeptide activity 
pathway, as well as activating Substance P receptors (Neurokinin-1 receptors) [251, 
276]– see Figure 4.2. It is also associated within the neutrophin signalling pathway. 
This is important as neutrophins promote the survival of neurons and axonal 
growth – see Figure 4.3. Neuropeptides have been associated with joint conditions 
such as osteo- and rheumatoid arthritis [40, 277, 278]. High levels of neuropeptides 
(Substance P and Calcitonin Gene related peptide (CGRP)) have been found to be 
increased in inflamed joints and also in joints that have been injected with 
inflammatory mediators to mimic inflammatory disorders [279-283]. Substance P 
can induce synoviocytes (either directly or indirectly) to increase expression of 
noxious substances such as collagenase and free oxygen radicals that can damage 
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the synovium and cartilage [284]. Substance P also causes the release and 
activation of immune system inflammatory mediators such as histamine and 
cytokines [277, 281] and as such, the neural system appears to integrate with the 
immune system. Neuronal circuitry has also been implicated in immunological 
homeostasis [285] and may exacerbate inflammatory responses to CCL rupture.  
 
Bilviciute et al. [282] showed a bilateral increase in neuropeptides in the synovial 
fluid of rats that had one knee injected with pro-inflammatory substances and the 
other knee injected with saline for control purposes. Higher concentrations of 
neuropeptides in both stifle joints would mean that inflammatory changes and 
associated joint pain [279] in the contralateral knee would be instigated sooner, last 
longer and the rate of destruction sped up compared to normal. Brydges et al. [286] 
detailed an increase in pain and other sensory sensitivity in dogs with CCL rupture 
compared to dogs with no CCL rupture. They, and others [287] also detected 
alterations in the gait and weight distribution towards the contralateral side of the 
body and a shift in distribution of weight towards the fore limbs. This, one would 
presume, is a compensatory mechanism to help the dog cope with the pain and 
joint instability in the affected joint. It may also explain why there is a high 
incidence of dogs damaging the contralateral ligament at some stage after the 
initial injury [33, 107]. This is consistent with the reports that the neuromuscular 
system is important in CCL rupture susceptibility [275]. 
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Figure 4.2. Putative pathway linking SORCS2, Substance P and other neuropeptide receptors. Reproduced with permission from 
http://biograph.be/concept/graph/C1539804/C1155443 [288]. 
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Figure 4.3. Sortilin and the neutrophin pathway. Pathway reproduced with permission from KEGG pathways (http://www.genome.jp/kegg-
bin/show_pathway?map=hsa04722&show_description=show) PATHWAY: cfa04722. [289, 290] 
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Taken together all of the above evidence suggests that mechanotransduction, 
neurological and neuromuscular pathways could significantly alter the risk of CCL 
rupture and prolong the injury effect and associated pain. This has not previously 
been reported for canine CCL rupture investigations, although several human 
studies substantiate our findings. 
 
The low number of statistically significant SNPs found in the Labrador Retrievers, 
Rottweilers and Staffordshire Bull Terriers are most likely due to the relatively small 
sample size which resulted in low power. Associations that may be present in these 
breed could have been missed as a result (false negatives). We performed the 
stratified CMH Newfoundland analysis as it combines the numbers of 
Newfoundlands from both the European and North American analyses into one 
study increasing sample size and power. By further combining the results of each 
individual breed analysis into one meta-analysis, the low power issue is reduced 
again. The number of cases and controls are considered as one large group and the 
results should identify SNPs common to CCL rupture in all of the breeds studied. 
Given the fact that this study has yielded significant associations it shows that the 
study worked with the numbers of dogs used. Taking into account that the SORCS2 
SNP (rs23569097) was the most associated SNP in the stratified, European and the 
meta-analyses, as well as being significant in the Labrador Retriever breed analysis, 
it is highly plausible that this gene may have a role in CCL rupture susceptibility or 
resistance. 
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Additional validation of the associations found in this study should be conducted 
using larger cohorts (to increase statistical power) and also in more breeds (to 
determine if multiple breeds share associated SNPs).  A more refined, next 
generation, targeted re-sequencing approach could also be carried out on the 
significant regions to identify additional SNPs and determine precisely which 
SNPs/regions of interest are involved in CCL rupture susceptibility. To explore the 
genetic association to canine CCL rupture in more detail, a whole genome re-
sequence could also be carried out. A cheaper method that just sequences the 
coding regions of the genome (exons) - exome sequencing is also a valid method; 
transcriptome sequencing or RNA-sequencing (RNAseq) may identify new SNPs that 
alter the RNA or cause gene expression changes. SNPs in the coding regions of the 
genome are more likely to have a profound effect on a disease due to a direct effect 
on protein function/folding/structure.  
 
In conclusion, analysis of Sequenom genotyping confirmed genetic associations 
with CCL rupture on chromosomes 1, 3 and 33 that the GWAS study reported in 
Chapter 3. It indicated a potential role for neurological and neuromuscular 
pathways in the pathogenesis and susceptibility to CCL rupture, with genes such as 
SORCS2 and SEMA5B indicated as being highly associated with CCL rupture in 
multiple breeds. The data also indicated that there are likely to be breed-specific 
variations in the genetic factors involved in CCL rupture, as demonstrated by the 
association of different SNPs in different breeds of dog. However, there are also 
some similarities in the genes and SNPs among the different breeds indicating that 
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there is some degree of shared pathogenicity of CCL rupture between different dog 
breeds which may become more evident in subsequent validation studies.  
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Introduction  
In the previous chapters, GWAS (and Sequenom validation) identified novel 
chromosomal regions and SNPs of interest that may be associated with CCL 
rupture, using no prior knowledge of the disease or disease process to find them. In 
this chapter, genes were selected from the literature that may have a potential 
functional association with the disease initiation or progression. SNPs within these 
genes were tested for association with CCL rupture, for this reason this method is 
called the “Candidate Gene” approach. This is a purely hypothesis driven approach 
and relies on a prior knowledge and understanding of the disease, disease 
components and pathways to select genes that may be of potential interest in CCL 
rupture. This is a limiting factor and many disease associations within genes may be 
missed for not being present in obviously associated or functional genes. Before the 
advent of genome wide arrays, candidate gene analyses were the standard method 
for determining association of genes and SNPs for a variety of different diseases in 
humans and animals [235, 291-293].  
 
Although the GWAS whole SNP arrays have recently superseded traditional 
candidate gene studies, candidate gene analyses still remain a valid approach to 
investigate the genetic basis of diseases. Whole genome SNP chip arrays have gaps 
in the SNP distribution and some regions/genes do not necessarily have high 
coverage. By manually selecting SNPs within certain “key” genes of interest which 
may or may not be covered by the whole genome arrays, you improve the 
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opportunity of detecting an association in the specific gene. It is possible to then to 
confirm or eliminate it as a candidate in CCL rupture susceptibility or resistance. 
 
Candidate gene studies are based on selecting genes and SNPs that may be 
implicated in the disease process (or SNPs that are in linkage with the causative 
markers). As CCL rupture is a complex disorder, there are likely to be many genes 
implicated in initiation and progression of the disease. It is unlikely that all of the 
key genes have been characterised and selected for analyses. As each SNP may only 
have a small contribution to the disease risk, it is likely to be the additive effect of 
multiple variations from multiple genes that will impact on the overall risk for the 
condition. Thus, identifying individual variants that contribute more or less to the 
risk of CCL rupture will be difficult, especially with small sample sizes. Against that 
argument, the high LD present in individual dog breeds means smaller sample sizes 
are needed to identify significant SNP associations than if the study was being 
conducted in humans. Hence, any differences in allele frequency between canine 
cases and controls may indicate that the SNP is involved in the disease (or in linkage 
with another SNP that is functional). In this way, SNP associations may narrow 
down the gene/genomic area for further detailed investigation. This could then be 
further investigated by fine mapping, resequencing, as well as by using in-vivo and 
in-vitro functional association tests. 
 
In previous canine candidate gene studies, using a cohort of Newfoundlands, the 
researchers tested FBN1, COMP and COL9A1 for CCL rupture associations; they 
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found no significant associations [233]. Other work carried out within the Boxer 
breed also discounted Collagen type-IX (COL9A1, COL9A2, COL9A3) [235] and 
COL2A1 as potential candidates for association with CCL rupture [294]. Clements et 
al. [292] performed a candidate gene study for 20 genes that had been all found to 
be previously associated with osteo-arthritis (OA) in dogs. They found no significant 
associations between their 20 genes and CCL rupture and also no common genetic 
factors between the diseases either within the same breed or between the two 
breeds studied. 
 
Published candidate gene studies in human research have proven to be more 
productive. They have suggested that polymorphisms within COL5A1 are relevant 
to the risk of ACL rupture and in tendinopathy of the Achilles [234, 295]. COL1A1 
has also been linked with susceptibility to ACL rupture [296, 297]. In the latter work 
Khoschnau et al. performed a study evaluating association of the SP1 transcription 
factor binding site with ACL rupture and shoulder dislocations. The SP1 binding site 
is located on intron 1 of the COL1A1 gene and causes a G-T mutation [297]. The 
mutation causes an increase in binding of SP1 to the gene and an increase in 
COL1A1 transcription which leads to a greater tensile strength of the ligament. 
However, the imbalance between the COL1A1 and COL1A2 chains (normally in ratio 
of two units COL1A1: one unit COL1A2) can cause osteoporosis and other bone 
density problems. 
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This chapter will assess whether select candidate genes are associated with CCL 
rupture in a population of Newfoundland dogs and in three other breeds that are at 
increased risk for CCL rupture (Labrador Retrievers, Rottweilers and Staffordshire 
Bull Terriers). 
 
Methods 
Sample selection 
In addition to the Newfoundland dogs studied previously in this project, a further 
three breeds (Labrador Retrievers, Rottweilers and Staffordshire Bull Terriers) were 
studied; these were chosen because of the increased risk status of their breed for 
cruciate rupture [93]. They were included to determine whether the same 
candidate genes were associated with CCL rupture in the different breeds which 
would indicate a common pathogenesis to CCL rupture across susceptible breeds. 
 
The same 749 samples that were used in Chapter 4 (see Table 4.1, page 116) were 
also used in this study. 
 
Candidate gene and SNP selection 
Genes were selected for investigation into CCL rupture based on a potential 
involvement in disease initiation or progression, or functional association with 
ligament structure, function and tensile strength. Pubmed 
(http://www.ncbi.nlm.nih.gov), Scopus (http://www.scopus.com) and other 
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scientific library databases were used to compile the list of candidate genes. Search 
terms included cruciate ligaments, ligament structure, cruciate ligament injury and 
connective tissues. SNPs were selected from Ensembl and were chosen to be 
spread as evenly as possible throughout the genes of interest. Mutations that were 
non-synonymous or frameshift were given priority inclusion over intronic SNPs (the 
frequency of these types of mutations was lower than exonic synonymous 
mutations). An even coverage was selected so as to maximise likely associations 
within the genes. Given the high LD present in individual dog breeds (spanning MB 
regions in some cases) the likelihood of chosen SNPs being causative or being in 
linkage with a causative SNP was high. The genes chosen, reason for selection and 
the number of SNPs typed in each gene are shown in Table 5.1  
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Table 5.1. Selected candidate genes and reason for inclusion in the study. The 
number of SNPs chosen in each gene is also shown. 
Gene name 
Gene 
Symbol 
Number 
SNPs 
chosen 
Reason for choice 
Literature 
references 
Fibromodulin FMOD 1 
Part of ECM. Affects rate of 
fibril formation and 
fibrillogenesis 
[298, 299] 
Decorin DCN 9 Affects rate of fibril formation [300, 301] 
Elastin ELN 10 
Involved in elastic fibre 
formation which is key to CCL 
structure and stability 
[302-304] 
Opticin OPTC 13 
Part of ECM. Important in 
collagen fibril morphology, 
spacing and organisation 
[305, 306] 
Latent-transforming 
growth factor binding 
protein B2 
LTBP2 9 
Important in elastic-fibre 
architectural organisation 
and assembly within the 
ECM. Structural component 
of microfibrils 
[307, 308] 
Biglycan BGN 1 
Important in collagen fibre 
assembly and organisation of 
ECM 
[67, 72] 
Fibrillin 1 FBN-1 8 
Structural component of 
ECM. Important for calcium-
binding in microfibrils which 
provide the force bearing 
support to ligaments 
[309-311] 
Cartilage oligomeric 
matrix protein 
COMP 1 
Part of ECM. Role in 
structural integrity of 
cartilage via interaction with 
collagens and fibronectin. 
May have a role in 
pathogenesis of OA 
[233, 312, 
313] 
Serpin peptidase 
inhibitor, clade H 
member 1 
Serpin-H1 7 
Involved in biosynthetic 
pathway of collagen 
formation and helps bind 
collagens 
[149, 314] 
Procollagen-lysine, 2-
oxoglutarate 5-
dioxygenase 1 
PLOD-1 7 
Attachment site for 
carbohydrates in collagens 
essential for cross link 
stability in collagen fibres 
[315, 316] 
Lysyl oxidase LOX 6 
Important part of collagen 
formation and strength. 
Promotes crosslinking of 
fibres to fibrils 
[317, 318] 
Collagen type I 
COL1A1, 
COL1 A2 
3 
9 
Main component of ligament [319, 320] 
Collagen type III COL3A1 7 Component  of ligament [320] 
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Gene name 
Gene 
Symbol 
Number 
SNPs 
chosen 
Reason for choice 
Literature 
references 
Collagen type V 
COL5A1 
COL5A2 
COL5A3 
12 
7 
13 
Component of ligament. 
Important in fibril assembly 
and formation 
[234, 321-
324] 
Collagen type VI 
COL6A1 
COL6A3 
1 
9 
Component of ligament. Part 
of ECM 
[325] 
Collagen type XI 
COL11A1 
COL11A2 
11 
7 
Important in fibrillogenesis by 
controlling lateral growth of 
collagen fibrils. Component  
of ligament 
[326, 327] 
Collagen type XII COL12Al 11 
Interacts with COL type I. 
Component of ligament 
[328, 329] 
Collagen type XIV 
(also named Undulin) 
COL14A1 7 
Regulates fibrillogenesis by 
integrating collagen bundles 
Component of ligament 
[330] 
Collagen type XXIV COL24A1 9 
Regulation of fibrillogenesis. 
Mineralisation of bone 
[331] 
Matrix 
metalloproteinase - 1 
MMP-1 6 Cleaves collagen [332, 333] 
Cathepsin K CTSK 5 
Important in collagen 
fragmentation. Involved in 
osteoclastic bone resorption 
and bone remodelling, by 
causing ECM degradation 
[334, 335] 
Aggrecan ACAN 6 
Major component in ECM. 
Has a role in inflammatory 
joint diseases and OA 
[66, 336, 
337] 
SIX homeobox 1 SIX-1 1 
Involved in ligament, tendon 
and limb development 
[338, 339] 
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The candidate gene SNPs for this study were initially chosen from the CanFam2 
alignment of the canine genome. However, as a new build of the genome was 
released in May 2012 (CanFam3) the data were subsequently realigned to the new 
assembly. The majority of the SNPs retained their location within the same gene as 
the CanFam2 annotation, but one gene Elastin, was realigned from chromosome 9 
to chromosome 6. As a result of this realignment, the seven SNPs initially chosen 
because they located within the Elastin gene were no longer within that gene. Four 
of the SNPs (rs24535705, rs24568755, rs24535784 and rs24535768) are now 
intergenic and three of the SNPs (rs24553222, rs24566251 and rs24566255) located 
to other genes. These are a novel protein coding gene (rs24553222) and U6 
spliceosomal RNA (rs24566251 and rs24566255). One other SNP, rs22372241 had 
also been re-aligned to a novel protein coding gene instead of the COL1A1 gene.  
 
Once genes had been selected SNPs present within the gene or in regulatory 
regions (5’ or 3’ UTRs) were identified using the Ensembl database 
(http://www.ensembl.org). The SNPs of interest (and 100bp flanking sequence) 
were mined from Ensembl using Biomart and exported in FASTA format. They were 
converted to a format suitable to run through the Sequenom assay design software 
using a customised PERL script.  
 
In total, 196 SNPs from 28 genes were chosen for investigation in the candidate 
gene study. 
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The genotyping of the SNPs was performed using Sequenom iPlex MassARRAY® 
technology at the Wolfson Centre for Personalised Medicine in the Pharmacology 
Department at the University of Liverpool as in Chapter 4. 
 
Assay design 
The 196 SNPs chosen for the candidate gene study were pooled into seven plexes 
(reactions) by the assay design software – 5x29 plex, 1x28 plex and 1x13 plex; nine 
SNPs were excluded as suitable primers could not be designed (rs8817977, 
rs8907731, rs22913607, rs22913610, rs9113092, rs24584869, rs23655986, 
rs24044145 and rs8619084) and one SNP (rs8742180) formed a single plex that was 
not economically viable to be run and was excluded. This left 186 SNPs to be 
investigated. The primer and probe sequences for each SNP are shown in Appendix 
V. 
 
Quality assurance 
Following genotyping, the data were assessed for QA and data were excluded if the 
sample call rate was <75%, the genotype call rate <75%, the control population was 
not in Hardy-Weinberg equilibrium (p<0.001) and/or the minor allele frequency 
≤0.01. Following QA, the numbers of samples and SNPs that remained for analyses 
differed for each breed and are shown in Figure 5.1 
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Figure 5.1. The number of SNPs and cases/controls remaining for each breed after 
QA in the candidate gene study.  
 
The data were examined on a breed by breed case control basis and the 
Newfoundland group was analysed using a Cochran–Mantel–Haenszel (CMH) 2x2xK 
(stratified by country) analysis, as well separate analysis for the North American and 
European groups. A meta-analysis was also performed to determine associations 
across every breed. 
 
Correction for multiple testing was performed using three methods: 100,000 
permutations, Benjamini & Hochberg false discovery rate (FDR) and a modified 
“Bonferroni-style” correction where the p-value is divided by the number of genes 
in the analyses. When meta-analyses were run, multiple testing was not 
automatically carried out, therefore an estimated correction was applied after 
meta-analyses were run, using the modified “Bonferroni-style” correction. 
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The modified “Bonferroni-style” correction was used instead of the standard 
Bonferroni correction (dividing the p-value by number of tests i.e SNPs), as this was 
considered too severe for multiple correction given the LD structure of dogs. 
Correction for the number of genes was considered to be a suitable alternative 
because of the high LD with each other within each gene.  
 
Results 
The 20 most associated SNPs for the stratified CMH Newfoundland analysis are 
shown in Table 5.2. The SNPs that were associated with CCL rupture in the 
European and North American Newfoundlands, as well as in the other breeds 
(Labrador Retrievers, Rottweilers and Staffordshire Bull Terriers) analyses are 
shown in Table 5.3 
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Table 5.2. Twenty most CCL rupture associated SNPs in the Newfoundland CMH stratified candidate gene analysis 
CHR SNP Gene Consequenence A1 MAF A2 POSITION 
p 
(raw) 
p (BONF 
STYLE) 
p 
(perm) 
p 
(FDR) 
OR 95% CI 
36 rs8587007 COL 5A2 Intronic T 0.18 A 33604230 0.006 0.15 0.45 0.54 0.40 0.21 - 0.76 
9 rs24560587 COL 1A1 Intronic C 0.31 A 29515328 0.024 0.60 0.91 0.70 0.52 0.30 - 0.92 
17 rs22597612 Cathepsin K Downstream T 0.13 C 63008191 0.030 0.75 0.95 0.70 0.43 0.20 - 0.94 
9 rs24546447 COL 5A1 Intron splice variant T 0.13 G 54147364 0.035 0.88 0.97 0.70 2.31 1.09 - 4.91 
36 rs23942103 COL 3A1 Intronic G 0.06 C 33548721 0.043 1.00 0.98 0.70 2.87 1.02 - 8.11 
6 rs8652327 COL 11A1 Synonymous C 0.05 T 50628874 0.048 1.00 0.99 0.70 0.26 0.06 - 1.02 
11 rs22190862 LOX Intronic A 0.32 G 15041235 0.058 1.00 1.00 0.70 0.62 0.38 - 1.02 
38 rs24048794 OPTC 3’ UTR C 0.16 A 3222563 0.070 1.00 1.00 0.70 1.76 0.94 - 3.29 
9 rs24553222 Novel Intronic T 0.03 C 24898151 0.086 1.00 1.00 0.70 0.27 0.05 - 1.32 
11 rs8679272 LOX Intronic T 0.38 C 15038128 0.087 1.00 1.00 0.70 0.64 0.39 - 1.07 
3 rs23546710 ACAN Synonymous A 0.26 G 54860309 0.100 1.00 1.00 0.70 0.64 0.38 - 1.10 
9 rs24546410 COL 5A1 synonymous A 0.20 G 54141470 0.101 1.00 1.00 0.70 1.60 0.92 - 2.78 
9 rs8680884 COL 5A1 Intronic G 0.35 A 54093629 0.110 1.00 1.00 0.70 1.46 0.92 - 2.31 
9 rs24535705 N/A (Was Elastin) Intergenic A 0.03 G 24951335 0.111 1.00 1.00 0.70 0.34 0.09 - 1.34 
30 rs23648407 FBN1 Intronic T 0.20 C 17707531 0.112 1.00 1.00 0.70 1.61 0.90 - 2.89 
9 rs24566251 U6 Downstream A 0.03 C 24922431 0.114 1.00 1.00 0.70 0.29 0.06 - 1.47 
9 rs24578426 COL 5A1 Missense T 0.02 C 54169612 0.126 1.00 1.00 0.73 0.20 0.02 - 1.82 
9 rs8680883 COL 5A1 Intronic C 0.34 T 54093637 0.142 1.00 1.00 0.76 1.42 0.89 - 2.26 
17 rs22595730 Cathepsin K Intronic G 0.02 C 63012099 0.148 1.00 1.00 0.76 0.27 0.04 - 2.02 
9 rs24546719 COL 1A1 Synonymous A 0.01 G 29522007 0.175 1.00 1.00 0.80 0.00 0.00 - 0.00 
KEY: A1 = base for allele 1, A2 = base for allele 2, MAF = minor allele frequency, p(raw) = raw p-value. Three different tests for correction for 
multiple testing were performed: p (BONF STYLE) = modified “Bonferroni-style” corrected p-value (corrected for 25 tests, the number of 
genes used in this study), p (FDR) = p-value for FDR, p(perm) = p-value for 100,000 permutations.   OR = odds ratio, 95% CI = 95% confidence 
interval of the OR.  
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Six of the 98 SNPs that passed QA in the Newfoundland group as a whole (CMH 
analysis) had a raw p-value of ≤0.05. Five of these SNPs were located within 
collagen genes (COL5A2, COL1A1, COL5A1, COL3A1 and COL11A1) and one SNP (the 
third most associated) was found in Cathepsin K. After correction for multiple 
testing using all three methods, no SNPs were significant.  
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Table 5.3. SNPs significantly associated with CCL rupture in Newfoundlands from Europe North America, Labrador Retrievers, Rottweilers & 
Staffordshire Bull Terriers in the candidate gene analyses 
 
CHR SNP Gene Consequence of SNP A1 F_A F_U A2 p (raw) 
p (BONF 
STYLE) 
p (perm) p (FDR) OR 95% CI 
EU
 
9 rs24546447 COL 5A1 Intron splice site T 0.3 0.09 G 0.0023 0.06 0.20 0.24 4.23 1.59 - 11.23 
36 rs23942103 COL 3A1 Intronic G 0.2 0.07 C 0.0263 0.66 0.90 0.64 3.29 1.10 - 9.80 
9 rs24546410 COL 5A1 Synonymous A 0.31 0.17 G 0.0320 0.8 0.95 0.64 2.27 1.06 - 4.86 
3 rs23546710 ACAN Synonymous A 0.17 0.3 G 0.0417 1.00 0.98 0.64 0.46 0.22 - 0.98 
N
A
 36 rs8587007 COL5A2 Intronic T 0.06 0.25 A 0.00273 0.06 0.30 0.24 0.18 0.05 - 0.60 
38 rs24048794 OPTC 3’ UTR C 0.23 0.09 A 0.01696 0.39 0.80 0.75 3.08 1.20 - 7.86 
9 rs24560587 COL1A1 Intronic C 0.25 0.46 A 0.02576 0.59 0.90 0.76 0.39 0.18 - 0.85 
La
b
ra
d
o
r 
R
et
ri
ev
er
 6 rs24306291 COL 24A1 Intronic T 0.51 0.29 C 0.00002 <0.01* <0.01* <0.01* 2.56 1.66- 3.97 
6 rs24306964 COL 24A1 Synonymous A 0.57 0.41 G 0.00458 0.11 0.41 0.21 1.86 1.21- 2.85 
8 rs8721919 LTBP2 Intronic G 0.53 0.4 A 0.01443 0.36 0.79 0.37 1.74 1.12- 2.72 
12 rs22217603 COL 11A2 Synonymous T 0.05 0.12 G 0.01828 0.46 0.85 0.37 0.37 0.16- 0.87 
38 rs24048817 OPTC Splice region synonymous A 0.04 0.01 G 0.02313 0.58 0.90 0.37 7.91 0.96- 64.96 
3 rs23546710 ACAN Synonymous A 0.17 0.3 G 0.02435 0.61 0.91 0.37 0.46 0.22 - 0.98 
38 rs24038028 OPTC Downstream C 0.03 0.01 T 0.04115 1.00 0.98 0.48 6.82 0.81- 57.24 
38 rs24029015 OPTC 3’UTR  T 0.03 0.01 C 0.04148 1.00 0.98 0.48 6.80 0.81- 57.06 
R
o
tt
w
ei
le
rs
 9 rs24535768 N/A (Was Elastin) Intergenic C 0.01 0.14 A 0.00098 0.02* 0.08 0.09 0.07 0.01 - 0.53 
9 rs8680883 COL 5A1 Intronic C 0.53 0.34 T 0.00802 0.20 0.47 0.37 2.20 1.22 - 3.94 
30 rs23637297 FBN1 Intronic A 0.32 0.47 C 0.02980 0.75 0.92 0.5 0.52 0.29 - 0.94 
30 rs23651397 FBN1 Intronic T 0.33 0.47 A 0.04391 1.00 0.97 0.5 0.55 0.30 - 0.99 
15 rs22378757 Decorin Upstream T 0.11 0.03 C 0.04500 1.00 0.98 0.5 3.66 0.96 - 14.01 
SB
T 
6 rs24278005 COL 11A1 Intronic A 0.14 0.02 G 0.03693 0.96 0.95 1.00 8.37 0.82 - 85.42 
12 rs22255739 COL 11A2 Synonymous A 0.25 0.08 G 0.04670 1.00 0.97 1.00 4.00 0.95 - 16.83 
12 rs22184922 COL 12A1 Synonymous G 0.27 0.52 A 0.05014 1.00 0.98 1.00 0.35 0.12 - 1.02 
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KEY: A1 = base for allele 1, A2 = base for allele 2, EU = European Newfoundlands, NA = North American Newfoundlands, SBT = Staffordshire 
Bull Terriers, A1 = allele 1, A2 = allele 2 FA/U = frequency of allele in affected/unaffected dogs. p(raw) = raw p-value. Three different tests 
for correction for multiple testing were performed: p (BONF STYLE) = modified “Bonferroni-style” corrected p-value (EU, Labrador 
retrievers, Rottweilers corrected for 25 tests, NA corrected for 23 tests, Staffordshire Bull Terriers corrected for 26 tests), p (FDR) = p-value 
for FDR, p(perm) = p-value for 100,000 permutations.  OR = odds ratio, 95% CI = 95% confidence interval of the OR. Asterix (*) = significant 
after multiple correction, “” = significant in more than one breed. 
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Four of the 104 SNPs that passed QA in the European subgroup of Newfoundlands 
had a raw p-value of ≤0.05. The SNPs were found within collagen genes (COL5A1 
and COL3A1) and the fourth SNP was found in the ACAN gene. After correcting for 
multiple testing with all three methods, none were significant.  
 
Three of the 90 SNPs that passed QA in the North American subgroup of 
Newfoundlands had a raw p-value of ≤0.05. The SNPs were in collagen genes 
(COL5A2 and COL1A1) and in OPTC gene. After correcting for multiple testing using 
all three methods none were significant.  
 
Eight of the 92 SNPs in the Labrador Retrievers that that passed QA had a raw p-
value of ≤0.05. The most significant SNP in this breed (rs24306291) was significant 
after correcting for multiple correction in all three tests (“Bonferroni Style” 
p=0.001, permutation p=0.003, FDR p=0.002). This was an intronic SNP in COL24A1. 
The second most associated SNP was also present in COL24A1 and the SNP ranked 
fourth was in COL11A2, the remaining significant SNPs were within genes LTBP2, 
OPTC and ACAN.  
 
Five of the 92 SNPs that passed QA in the Rottweiler group had a raw p-value of 
≤0.05. The SNP that ranked number two was in a collagen gene - COL5A1. The other 
associated SNPs were in FBN1 and Decorin. The most associated SNP rs24535768 
(originally chosen for being in the Elastin gene in the CanFam2 annotation) is 
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intergenic in the new CanFam3 annotation. After correcting for multiple testing 
none were significant.  
 
Three of the 87 that passed QA in the Staffordshire Bull Terrier group had a raw p-
value of ≤0.05. All of the SNPs were within collagen genes (COL11A1, COL11A2 and 
COL12A1). After correcting for multiple testing using all three methods, none were 
significant. 
 
A meta-analysis was carried out on the data to compare the breeds in a case 
control study as a whole cohort. Table 5.4 shows SNPs that were associated with 
CCL rupture from this analysis. 
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Table 5.4. SNPs associated with CCL rupture from the meta-analysis of the 
candidate gene data of the stratified CMH Newfoundland data, the European 
Newfoundlands, North American Newfoundlands datasets and the Labrador 
Retriever, Rottweiler and Staffordshire Bull Terriers datasets.  
Gene CHR Position SNP 
Consequence of 
SNP 
A1 A2 P 
Estimated 
p (BONF 
STYLE) 
OR 
COL 5A1 9 50752492 rs8680883 Intronic C T 0.0011 0.03* 1.46 
COL 1A1 9 26190947 rs24560587 Intronic A C 0.0018 0.04* 1.52 
COL 5A1 9 50806219 rs24546447 Intron splice variant T G 0.0022 0.05* 2.45 
COL 3A1 36 30519543 rs23942103 Intronic G C 0.0036 0.08 3.06 
COL 5A1 9 50752484 rs8680884 Intronic G A 0.008 0.18 1.38 
COL 5A2 36 30575052 rs8587007 Intronic T A 0.0114 0.26 0.65 
N/A (Was 
Elastin) 
9 21631629 rs24535768 Intergenic C A 0.0177 0.41 0.15 
COL 5A1 9 50752527 rs8680882 Intronic T C 0.0195 0.45 1.38 
COL 11A1 6 47575177 rs8652327 Synonymous C T 0.0218 0.50 0.31 
FBN1 30 14717529 rs23648407 Intronic C T 0.0249 0.57 0.72 
LOX 11 12036988 rs22190862 Intronic A G 0.026 0.60 0.76 
COL 24A1 6 62282300 rs24306291 Intronic T C 0.0288 0.66 1.31 
Novel (Was 
Elastin) 
9 21569516 rs24553222 Intronic T C 0.0291 0.67 0.54 
COL 5A1 9 50800325 rs24546410 Synonymous A G 0.0357 0.82 1.33 
N/A (Was 
Elastin) 
9 21622700 rs24535705 Intergenic A G 0.0358 0.82 0.57 
COL 5A2 36 30548758 rs8867454 Intronic T C 0.0498 1.15 0.74 
LTBP2 8 47686777 rs24469329 Missense T C 0.0499 1.15 1.56 
KEY: A1 = base for allele 1, A2 = base for allele 2, Novel = novel protein coding 
gene, U6 = U6 spliceosomal RNA. OR = odds ratio. Estimated correction for 
multiple testing was run using the modified Bonferroni correction, correcting for 
23 tests (genes common to all breed analyses). 
 
Seventeen of the 107 SNPs which were common in two or more breed analyses 
were significant with a raw p-value of ≤0.05. Of the 17 SNPs that were associated 
with CCL rupture, 11 were within collagen genes – seven of which were collagen 
type-V (five in COL5A1 and two in COL5A2). The remaining collagens that contained 
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associated SNPs were COL1A1, COL3A1, COL11A1 and COL24A1. The other genes 
containing associated SNPs were FBN1, LOX, LTBP2, a novel gene and two SNPs 
were intergenic. The three SNPs with the lowest raw p-values were significant after 
estimated correction for multiple testing. They were in COL5A1 and COL1A1, 
indicating potential involvement of both the Collagen type I and type V genes with 
CCL rupture susceptibility. 
 
One mutation, rs24469329 (in gene LTBP2) is a missense mutation and causes a 
change in the codon from GAA-AAA. The altered codon causes an amino acid 
substitution E744-K, an acidic amino acid (Glutamic acid) being substituted with a 
basic one (Lysine). From the amino acid sequence the secondary structure was 
predicted for LTBP2 using the prediction software algorithm implemented by Chou 
& Fasman [340, 341]. The mutation is at amino acid residue 744 and is present in 
helix 721. There have been no NMR or X-ray crystallography structural models 
prepared for this protein that encompass the residue in question and so it is not 
possible to map on a  3D structure where the mutation lies (binding site, internal or 
external etc). Further functional analysis is required to determine the role of this 
mutation in CCL rupture susceptibility 
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Discussion 
The candidate gene data were analysed on a breed by breed case control basis to 
determine whether any SNPs associated with CCL rupture were in multiple 
susceptible breeds. It was hoped that this approach might identify risk (or 
protection) associated SNPs specific for each breed and common to all (or several) 
breeds. A meta-analysis was conducted to enable the data to be examined as a 
single cohort, this increased statistical power relative to the individual breed 
analyses. It considered genetic influences on CCL rupture susceptibility across all 
breeds studied. 
 
The most associated CCL rupture SNP in the Rottweilers (rs24535768) was an 
intergenic SNP (see Table 5.3) that was significant after correction for multiple 
testing with a “Bonferroni-style” p-value = 0.02. The SNP is ~50Kb upstream of the 
non-coding RNA for the U6 spliceosomal gene and is also ~50kb downstream of 
several Keratin-like associated genes. Keratin and keratin associated proteins are 
involved in the strength and structure of hair and skin and have functional roles in 
wound healing, epithelial repair and cytoskeletal protein synthesis [342, 343]. The 
homeostatic response to tissue damage in epithelial cells involves a complex 
response, including the upregulation of keratin filament genes. It has been 
suggested that a similar process to that which occurs during the epithelial 
regeneration, may also occur in other tissues (such as ligaments) in response to 
their injury [342]. Association of mutations in keratin genes with CCL rupture is 
therefore functionally feasible. 
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Two SNPs that were significant after correction for multiple testing in the meta-
analysis were in Collagen type-V gene. This suggests that this could be a particularly 
important gene in relation to CCL rupture susceptibility. Collagen type-V is an 
important candidate gene because it is involved in the formation and assembly of 
the collagen fibrils [234, 321, 323], which are key to the composition and strength 
of the ligaments. A third SNP which also significant after correction for multiple 
testing was in collagen type-I, the most abundant collagen type found in ligaments 
[43]. As collagen is a key component of ligament, a number of collagen genes were 
chosen for investigation. Mutations that directly (or are in linkage disequilibrium 
with one that do) alter the collagen protein sequence, formation, structure and/or 
organisation of collagen fibrils, such that they are unable to retain their normal 
organised structures and strength may cause weakness and loss of key stability in 
the CCL. This would mean that a ligament formed with the mutated collagen fibrils 
may be more susceptible to rupture under normal conditions – i.e. non-contact 
rupture.  
 
Other genes that had significant raw p-values (although significance was not seen 
after correction for multiple testing) include: Cathepsin K, Aggrecan, OPTC, LTBP2, 
FBN1, Decorin and LOX.  Cathepsin K is a matrix degradation protease that is 
involved in bone resorption and the degradation of cartilage and the ECM [344]. 
Levels are often found to be increased after injury [345] and defects in Cathepsin K 
have been linked to skeletal disorders such as osteoporosis [346] as well 
inflammatory conditions such as rheumatoid arthritis [347, 348]. There is an 
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emerging role for Cathepsins in the innate immune response [349], where they are 
believed to initiate apoptosis of inflammatory cells such as neutrophils [350]. 
Cathepsin K has been shown to be differentially expressed between ruptured and 
intact CCLs [351] and as such was seen as an important candidate gene to consider 
in this study. The associated SNPs in this gene may be in LD with SNPs that are in 
regulatory regions of the gene. It is possible that SNPs may cause an increase or 
decrease of proteolytic/collagenolytic activity of Cathepsin K within ligaments. 
Alternatively, a SNP may cause a change in localisation of the enzyme which may 
contribute to disease susceptibility. 
 
SNPs in several extracellular matrix (ECM) proteins were found to be associated 
(raw p-values) with CCL rupture in this study, although after correction for multiple 
testing they did not show significance. They were Fibrillin-1 (FBN1), Decorin, Lysyl 
oxidase (LOX),  Aggrecan (ACAN), Opticin (OPTC) and Latent transforming growth 
factor beta 2 (LTBP2). FBN1, Decorin, ACAN and OPTC are heavily glycosylated 
glycoproteins (proteoglycans), important in providing the structural support and 
integrity of the ECM and the ligaments [352, 353]. The integrity of the ECM is 
important in growth and repair [354], cell matrix communication [355] and is also 
important in withstanding load compression [356]. Altered ECM composition may 
lead to an increase in CCL rupture risk, as the ligaments are structurally altered such 
that they are unable to withstand normal load and compression.  
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Aggrecan (ACAN) is involved in cartilage formation which helps resist compression 
of cartilage and ligaments and is therefore critical in the structure and strength of a 
joint [66, 336, 357]. If ACAN is mutated such that the ability of the ligament and/or 
cartilage to resist compression and stretch becomes compromised, it may lead to 
premature rupturing of the ligament. This theory is supported by Pratta et al. [358] 
and many degenerative joint diseases such as osteoarthritis are characterised by 
proteolytic destruction of the matrix and loss of ACAN [336]. 
 
Latent transforming growth factor beta 2 (LTBP2), which has a high degree of 
homology with fibrillins [307], helps in the formation of elastin microfibrils [359]. 
This gene may have a key function in the ligament’s role as a connective tissue, 
providing recoil and resilience properties. It also has a role in cell adhesion [360, 
361], a key process in tissue repair [362].  
 
Fibrillin 1 (FBN1) is essential for the formation of the elastic fibres and is involved in 
structural support of connective tissues such as elastin [363]. Like LTBP2, it is 
essential in maintaining the elasticity of the ligaments.  
 
Lysyl Oxidase (LOX) is an extracellular enzyme that aids in the crosslinking of elastin 
and collagen fibres [51] by causing the catalysis of specific lysine and hydroxylysine 
residues in the collagen amino acid chain. The crosslinking determines the strength 
of the collagen fibres and the integrity of the ECM and the ligament. Mutations 
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within this gene may impact on the strength of the collagen and lead to a ligament 
that is unable to withstand daily stresses and is more susceptible to rupture than a 
ligament formed with normal crosslinks.  
 
Decorin is involved in matrix assembly and fibril formation and organisation [364] 
and can help bind growth factors such as epidermal growth factor (EGF) as well as 
collagens [365]. Disruptions in the decorin gene may lead to altered packing and/or 
assembly of the collagen fibrils, disrupting the normal strength of the fibres and 
may lead to a ligament that is more likely to rupture.  
 
Finally, Opticin (OPTC) helps to regulate collagen fibril assembly [305] and 
organisation. Mutations in this gene may have some impact on the ligament’s basic 
structure by compromising the ligament’s strength, leading to increased CCL 
rupture susceptibility. Although opticin has predominately been found localised in 
the ocular system [366], it has also been detected in several other canine tissues 
including shoulder, elbow, rib chondrocyte, ligament, skin, muscle and testes [305]; 
therefore association with CCL rupture can be tentatively inferred.   
 
All of the above genes, although they were not significant after correction for 
multiple testing, were chosen for analysis because they are key components in the 
ECM and are structural constituents of ligaments. A defect in any one of these 
genes may significantly affect the structural integrity of the ligament, resulting in its 
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failure during normal activity. Failure to retain significance after correction for 
multiple testing may be due to the small samples numbers. Further validation of 
these data in a larger cohort of dogs would verify the true significance of the 
results. 
 
Comparing the alleles that confer risk to the disease is important for development 
of genetic screening tests and for determining risk of each dog.  With the exception 
of SNP rs23546710 between the European Newfoundlands and Labrador Retrievers, 
the “risk” allele is the same in each breed. SNP rs23546710 has the same minor 
allele (A) in each breed, but the odds ratio shows the risk allele to be ‘G’ for 
European Newfoundlands and ‘A’ in the Labrador Retrievers. This ambiguity may be 
attributed to the SNP being in LD with the associated mutation rather than being 
associative itself. These mutations may be different and present with variable 
frequencies in the breeds studied, or there could have been a genetic cross-over 
during breed creation. Alternatively, the SNPs could be subject to genotyping error 
and may have been miss-called by the analysis software - this is unlikely however, 
as all SNPs were visually checked for correct clustering. Once the associated 
mutations have been identified and the risk alleles have been determined for each 
breed, a screening test can be developed. The genotype of each dog would be 
examined and those that have the risk alleles at each loci would be significantly 
more at risk compared to those dogs that have fewer or no risk alleles [367]. 
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To date, no candidate gene studies have shown significant results for canine CCL 
rupture. This study is the first of its kind to show potential associations of certain 
SNPs/genes with CCL rupture in dogs. The results need further validation in a larger 
number of dogs and breeds to confirm the associations and also to confirm (or 
refute) that different SNPs may be important in different breeds for susceptibility to 
CCL rupture. Fine mapping and next generation re-sequencing of the associated 
SNP regions should also be carried out to further examine regions of association. 
Expression work such as transcriptomics using Q-PCR should also be conducted for 
the significantly associated genes found in this study.  
 
In summary, this study confirms conclusions of several other studies investigating 
genetic components of cruciate rupture; collagens are important genes in CCL 
rupture susceptibility. Collagen type-V and type-I are the predominant genes that 
have statistically significant SNPs associated with CCL rupture in this study. 
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Introduction 
Previous chapters have considered genetic involvement in CCL rupture 
susceptibility, but have not focused their approach on any specific detailed genomic 
regions. As there may be an autoimmune component to CCL rupture [3, 31, 105] 
the main genes that control the immune system - the Major Histocompatibility 
complex (MHC) will be studied. MHC genes control the strength and nature of 
immunity and in dogs this is called the dog leucocyte antigen (DLA) system. 
Variations in the DLA region can control susceptibility of dogs to diseases. DLA 
associations have been found for several canine autoimmune diseases such as 
hypothyroidism, polyarthritis and diabetes [119, 120, 124]. 
 
There are two classes of MHC molecules, class I and class II. Class I have the role of 
presenting antigens from intracellular origin to CD8 cytotoxic T-cells [368]. Class II 
molecules can only present antigens from an extracellular origin, which have been 
taken up from vesicles of phagocytic cells such as macrophages, dendritic cells and 
B cells [369]. The DLA molecules then present the antigens to CD4 T-cells [368]. 
These are helper T-cells which activate other T cells and B lymphocytes to generate 
effective immune responses [369]. Destructive autoimmune responses may occur if 
self-antigens are recognised and targeted. 
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There are three genes that code for the MHC class II molecules in dogs and these 
are called DLA-DRB1, DLA-DQA1 and DLA-DQB1. It is the hypervariable region in the 
second exon of each of these genes that determines the efficiency of binding  to 
different antigens [370]. There are many different alleles for each gene >250 for 
DRB1 (206 with official names), >45 for DQA1 (37 with official names), >140 for 
DQB1 (100 with official names) and >280 haplotype combinations found in three or 
more dogs [personal communication from Dr LJ Kennedy]. Many of these are breed 
specific and each breed has only a limited diversity of DLA alleles [371-374]. The 
Centre for Integrated Genomic Medical Research (CIGMR) at Manchester University 
has considerable expertise in studying DLA alleles and their disease associations; 
because of the possible autoimmune nature of CCL rupture, DLA-typing our 
Newfoundland dog populations was considered to be a viable strategy. There is 
high linkage disequilibrium within DLA, especially between DLA-DQA1 and DLA-
DQB1 [375], because of this it is possible to determine haplotypes of the DLA group 
by typing just two of the three known genes (DLA-DRB1 and DLA-DQB1) to assess if 
there is an DLA association with susceptibility to CCL rupture. 
 
Methods 
Sample selection 
Ninety-five Newfoundland dogs (the same 95 that have previously been genotyped 
by Illumina GWAS and Sequenom) were characterised for the two main loci of DLA 
class II (DLA-DRB1 and DLA-DQB1) by sequence based typing of DNA using locus 
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specific, intronic primers. A negative control containing no DNA was also included 
to identify any contamination or crossover of reagents.  
 
Primer design  
The primers were produced by Metabion (Martinried, Germany) as previously 
described [372, 376], and are detailed in Table 6.1 
Table 6.1. DLA primers used for genotyping the DLA  
Primer SEQUENCE 
DRB1 forward DRBIn1 CCGTCCCCACAGCACATTTC 
DRB1 reverse DRBIn2-T7 TAATACGACTCACTATAGGGTGTGTCACACACCTCAGCACCA 
DQB1 forward DQB1BT7 TAATACGACTCACTATAGGGCTCACTGGCCCGGCTGTCTC 
DQB1 reverse DQBR2 CACCTCGCCGCTGCAACGTG 
 
The product sizes are 303bp for DRB1 and 300bp for DQB1. 
 
PCR 
DNA was normalised to 5ng/µl. The PCR reaction was carried out in 96 well plate 
format, with 25ng DNA in a 25µl reaction volume, containing 20µl of master mix 
and 5µl of DNA (5ng/µl). For each well the master mix included: 2.5µl 10x PCR 
buffer (20mM, Roche, Hertfordshire, UK), 0.5µl dNTP mix (10mM, Roche, 
Hertfordshire, UK), 0.13µl of fast start Taq (5U/µl, Roche, Hertfordshire, UK), 0.5µl 
of forward primer (50µM), 0.5µl of reverse primer (50µM) and 15.87µl of dH20.  The 
PCR was run on a tetrad gradient cycler in a touch-down PCR cycle with the 
following conditions:  
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DQB      DRB   
95˚C – 5 minutes    95˚C – 5 minutes 
95˚C – 30 seconds    95˚C – 30 seconds 
73˚C – 1 minute  ‐1°C each cycle  62˚C – 1 minute ‐1°C each cycle 
72˚C – 1 minute    72˚C – 1 minute 
 
95˚C – 30 seconds    95˚C – 30 seconds 
66˚C – 1 minute    55˚C – 1 minute 
72˚C – 1 minute    72˚C – 1 minute 
72˚C – 10 minutes    72˚C – 10 minute 
 
To confirm successful amplification, 5µl of each resulting PCR product was run on a 
2% agarose gel. The PCR products were purified using shrimp alkaline phosphatase 
(SAP) to remove any unincorporated dNTPs. A 1:8 dilution of SAP (USB® ExoSAP-IT®, 
Affymetrix, UK) was made and 4µl was mixed with 1µl of PCR product. This was 
then left for one hour at 37˚C and then heated for 15 minutes at 80˚C. 
 
DLA sequencing 
The samples were sequenced at SourceBioscience (Nottingham, UK). The sequence 
analysis and allele/haplotype designation was carried in conjunction with Dr LJ 
Kennedy, CIGMR2. 
 
Allele designation of sequence peaks was conducted using the SBTengine software 
(http://www.gendx.com) – see Figure 6.1.  
 
                                                     
2
 Dr Lorna Kennedy, CIGMR (Centre for Integrated genomic research), Faculty of Medical and Human 
Sciences Manchester University, Manchester, M13 9PT, UK 
X20 
X14 
X20 
X14 
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Figure 6.1. An example chromatogram showing sequencing of DLA haplotypes. 
Allele designation was carried out in standard way: colour of peaks – allele: Green 
= A, Red = T, Blue = C, Black = G. Double peak in one position = heterozygous (C+G 
= S, C+T = Y, C+A = M, G+T = K, G+A = R, T+A = W). 
 
The software aligned the generated sequences to a consensus sequence and each 
polymorphic locus was analysed by the software and checked manually. The 
annotated sequence was matched to a library reference sequence (taken from 
http://www.ebi.ac.uk/ipd/mhc/dla/index.html). 
 
Analysis of haplotypes 
Haplotype frequencies were determined for each analysis (Case control, European 
case control, North American case control and European versus North America) and 
the statistical analyses was performed using STATCALC [377]. Contingency tables 
(2 × 2) were used to determine a Yates corrected chi-squared value and 
corresponding p-value which are tabulated in each results table. Correction for 
multiple testing is not currently carried out when analysing DLA data [121, 173]. 
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Results 
Ninety-five Newfoundlands were characterised for their DLA loci and nine different 
DLA haplotypes were found in the cohort as a whole; DRB*00601/DQB*00701, 
DRB*00201/DQB*00101, DRB*00601/DQB*02001, DRB*00901/DQB*008011, 
DRB*01201/DQB*013017, DRB*01301/DQB*00201, DRB*01501/DQB*02301, 
DRB*02001/DQB*01303 and DRB*03001/DQB*00301.  
 
Analysis was split into standard case control analyses (Table 6.2) and case control 
analyses were carried out on the European (Table 6.3) and North American (Table 
6.4) samples separately.  A comparison between the European and North American 
dogs was also carried out irrespective of cruciate rupture status (Table 6.5).  
Significant haplotypes (p≤0.05) are highlighted in yellow in following the tables. 
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Table 6.2. DLA haplotype frequencies, full cohort case control.  
DLA Haplotype 
Number 
haplotypes: 
Cases 
Number 
haplotypes: 
Controls 
p-value OR 95% CI 
DRB*00201 / DQB*00101 16 16 0.953 0.95 0.41 - 2.17 
DRB*00601 / DQB*00701 7 5 0.825 1.37 0.37 - 5.20 
DRB*00601 / DQB*02001 4 5 0.947 0.76 0.16 - 3.38 
DRB*00901 / DQB*008011 0 5 0.062 0.00 0.00 - 1.09 
DRB*01201 / DQB*013017 16 22 0.288 0.63 0.29 - 1.38 
DRB*01301 / DQB*00201 25 10 0.013 2.90 1.22 - 6.99 
DRB*01501 / DQB*02301 8 6 0.847 1.30 0.39 - 4.45 
DRB*02001 / DQB*01303 13 12 0.907 1.04 0.42 - 2.62 
DRB*03001 / DQB*00301 5 9 0.358 0.51 0.14 - 1.74 
KEY: Yellow = significant (p-value ≤0.05), OR = Odds ratio 
 
Table 6.3. DLA haplotype frequencies, European case control study.  
DLA Haplotype 
Number 
Haplotypes: 
EU case 
Number 
Haplotypes: 
EU control 
p-value OR 95% CI 
DRB*00201 / DQB*00101 12 13 1.000 0.90 0.33-2.46 
DRB*00601 / DQB*00701 5 5 0.738 1.00 0.23-4.37 
DRB*00601 / DQB*02001 3 5 0.712 0.57 0.10-3.00 
DRB*00901 / DQB*008011 0 0 - - - 
DRB*01201 / DQB*013017 11 14 0.642 0.72 0.26-1.98 
DRB*01301 / DQB*00201 11 5 0.171 2.56 0.73-9.41 
DRB*01501 / DQB*02301 1 2 1.000 0.49 0.02-7.24 
DRB*02001 / DQB*01303 3 0 0.241 - - 
DRB*03001 / DQB*00301 2 4 0.673 0.48 0.06-3.27 
KEY: EU = European, OR = Odds ratio 
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Table 6.4. DLA haplotype frequencies, North American case control study.  
DLA Haplotype 
Number 
Haplotypes
: NA case 
Number 
Haplotypes: 
NA control 
p-value OR 95% CI 
DRB*00201 / DQB*00101 4 3 0.900 1.24 0.21-7.55 
DRB*00601 / DQB*00701 2 0 0.515 - - 
DRB*00601 / DQB*02001 1 0 0.963 - - 
DRB*00901 / DQB*008011 0 5 0.051 0.00 0.00-1.01 
DRB*01201 / DQB*013017 5 8 0.436 0.52 0.13-1.97 
DRB*01301 / DQB*00201 14 5 0.064 3.24 0.94-11.69 
DRB*01501 / DQB*02301 7 4 0.628 1.71 0.40-7.65 
DRB*02001 / DQB*01303 10 12 0.622 0.69 0.24-2.03 
DRB*03001 / DQB*00301 3 5 0.613 0.52 0.09-2.72 
KEY: NA = North American, OR = Odds ratio 
 
Table 6.5. DLA haplotype frequencies, European versus North America 
(irrespective of cruciate status).  
DLA Haplotype 
Number 
haplotypes: 
EU 
Number 
haplotypes: 
NA 
p-value OR 95% CI 
DRB*00201 / DQB*00101 25 7 0.00238 4.07 1.56 - 11.08 
DRB*00601 / DQB*00701 10 2 0.05290 5.00 0.99 - 34.10 
DRB*00601 / DQB*02001 8 1 0.05500 7.91 0.97 - 172.13 
DRB*00901 / DQB*008011 0 5 0.05560 0.00 0.00 - 1.04 
DRB*01201 / DQB*013017 25 13 0.08840 2.03 0.91 - 4.58 
DRB*01301 / DQB*00201 16 19 0.50800 0.73 0.33 - 1.62 
DRB*01501 / DQB*02301 3 11 0.03420 0.23 0.05 - 0.92 
DRB*02001 / DQB*01303 3 22 0.00004 0.10 0.02 - 0.36 
DRB*03001 / DQB*00301 6 8 0.65400 0.67 0.20 - 2.23 
KEY: EU = European, NA = North American, Yellow = significant (p-value ≤0.05), OR 
= Odds ratio 
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A visual representation of the haplotype data for each analysis (using pie-charts) is 
shown in Figure 6.2. 
 
Figure 6.2. Pie charts showing the DLA haplotype frequencies in the different 
analyses. A star (☆) indicates significantly different haplotype (p≤0.05) EU = 
European, NA = North American.  A – Case control analysis, B – EU case control 
analysis, C – NA case control analysis, D – EU/NA analysis 
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Discussion 
DLA associations have been found for many canine auto-immune diseases including 
SLE and autoimmune haemolytic anaemia [122, 378]. However, it has previously 
been reported, in a cohort of Labrador Retrievers and Golden Retrievers, that there 
is no association between DLA haplotypes and CCL rupture [379]. At the time of this 
study, there had been no investigation into DLA haplotype association with CCL 
rupture in Newfoundlands, nor had there been a study investigating DLA 
haplotypes across geographical groups within the same breed of dog.  
 
Comparing DLA haplotypes in a case control study using Newfoundlands with 
cruciate rupture compared to healthy controls (using the whole, unstratified, 
cohort of 95 Newfoundlands), there was only one haplotype that was significant, 
haplotype DRB*01301/DQB*00201 (p=0.013). However, having demonstrated in 
previous chapters that it is inappropriate to analyse North American and European 
Newfoundlands in the same analysis without first accounting for population sub-
structure, this would need to be validated in the separate European and North 
American cohorts before the haplotype can be classed as being truly associated 
with cruciate rupture susceptibility in Newfoundland dogs.   
 
When the data was split into separate European and North American cohorts and 
the DLA haplotypes then assessed for association with cruciate rupture on a case 
control basis, there were no significant haplotypes associated in the European 
cohort, but there was one haplotype significant in the North American cohort. This 
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haplotype, DRB*00901/DQB*008011, was only found in the North American 
Newfoundlands. 
 
Haplotype DRB*01301/DQB*00201 had the lowest p-value in the European and the 
second lowest p-value in the North American haplotypes (p-value  0.17 and 0.06 
respectively). It failed to reach significance in either analysis, which may in part be 
due to the small individual sample group sizes i.e. 47 dogs from the European group 
and 48 from the North American group. To confirm whether this haplotype is 
definitely significantly associated with CCL rupture in the Newfoundland breed the 
analysis should be repeated with a much larger cohort of Newfoundlands from each 
country. 
 
When comparing the European Newfoundlands with those from North America 
(irrespective of the cruciate status), there were eight DLA haplotypes common to 
both subgroups of Newfoundlands, four of which exhibited significant differences 
between the two populations. These were DRB*02001/DQB*013030 (p=0.00004), 
DRB*00201/DQB*00101 (p=0.002), DRB*01501/DQB*02301 (p=0.03) and 
DRB*00601/DQB*00701 (p=0.053). There were also two haplotypes that were 
nearing statistical significance in the dataset DRB*00601/DQB*02001 (p=0.055) and 
DRB*00901/DQB*008011 (p=0.056). The four significant haplotypes and two that 
were nearing significance showed that there are clear DLA differences between 
European and North American Newfoundlands. It also confirmed the genetic 
population stratification within the Newfoundland breed from different 
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geographical origins that was found in the other datasets in this project. The 
stratification is probably due to limited intercontinental breeding. This effectively 
acts as if the populations are isolated from each other and will lead to different 
allele frequencies between the two groups. The stratification within the 
Newfoundland breed will have an impact on any future genetic investigations into 
canine immune-related conditions using the breed. It would suggest that any 
genetic studies (small or large) have a PCA (or similar population stratification test) 
conducted on the data (even from dogs within the same breed) to determine if 
stratification exists before performing any genetic and statistical phenotype 
association analyses. If there are differences within the populations, then the 
stratification must be accounted for or the results analysed separately. 
 
Previous research has shown that there are differences in the DLA haplotype 
frequencies found between different breeds of dog [371, 373, 380]. This is due to 
breed isolation, breed creations and other bottlenecks. There has been limited 
research has been conducted into different haplotypes within the same breed of 
dog but from different populations – such as geographical location. Isolated 
populations of feral dogs, such as those found on islands like Bali, Australia and 
New Guinea have large genetic diversity of DLA [381]. There are no selective 
breeding pressures or physical barriers to prevent cross breeding, populations are 
large, outbred and heterozygosity is high.  Pedigree dogs however, are isolated by 
breed rules and strict breeding standards, hence in these circumstances 
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heterozygosity and genetic diversity is low and resistance to certain diseases, 
including auto-immune diseases is reduced.  
 
In conclusion, this chapter supports the work of Clements et al. (2011) that there is 
no DLA association involved in CCL rupture susceptibility whether this be in the 
Labrador Retriever, Golden Retriever or Newfoundland breeds of dog. There may 
still be autoimmune components to cruciate ligament rupture, but the SNPs and 
genes involved are not part of the DLA region. This chapter confirms that there is 
genetic stratification within the Newfoundland breed, which can be attributed to 
the geographical origin of the dog.  
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Introduction 
In previous chapters, candidate genes and genomic regions associated with CCL 
rupture were identified either by whole genome approaches (GWAS) or by 
selection as potential candidates using the existing knowledge of the disease 
process. These genetic approaches considered the inheritance of CCL rupture, but 
did not take into account potential downstream effects of these genetic changes. 
The first important step after genomic changes is the actual expression of a gene 
under different circumstances such as growth, repair or disease. It is possible that 
many genomic differences could be detected between the different phenotypes but 
only a few would be relevant to the development of a phenotype. It is for this 
reason, so much attention has been given to gene expression in the last 20 years, 
particularly in relation to health and disease [382-387]. 
 
By investigating gene expression patterns, one may identify particular processes 
which are functioning to either cause a condition or attempting to prevent the 
repair of disease processes. Another reason that the science of transcriptomics has 
become so well used in comparative biology is because it is now relatively easy to 
do and is cheap to generate quantitative data with fairly inexpensive laboratory kit. 
Indeed, it is far easier, because of the genome annotations now available, to assess 
gene expression for almost any molecule in almost any species and this would be 
virtually impossible to achieve at the level of proteins, even with the recent 
advances in proteomics.  
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Gene expression changes have been described for many diseases [386, 388-391]. 
Genetic variations that influence gene expression, such as changes in the DNA 
sequence in the promoter or enhancer regions of a gene, can impact on disease 
phenotype. Previously, gene expression would have been assessed by RNA 
microarrays [392, 393], but these have largely been superseded by Q-PCR. [385, 
394] and more recently, global transcriptomics (RNAseq) [395]. Quantitative-PCR 
(Q-PCR) can be used to examine changes in gene expression over time in a disease, 
or during treatments regimens and as such is a useful diagnostic aid, as well as a 
tool for research. 
 
Q-PCR is an innovative version of a standard PCR reaction that evaluates gene 
expression changes in real time. It measures the kinetics of the reaction in the early 
stages of the cDNA amplification (exponential phase). Assuming 100% reaction 
efficiency, the amount of product doubles with each cycle of PCR that is carried out. 
There is a quantitative relationship between amount of starting product and 
amount of target product at any given cycle.  
 
The aim of this study was to evaluate gene expression changes between ruptured 
CCL tissues compared to normal healthy CCL tissue samples in a standard case 
control experiment. 
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Methods 
Sample collection and storage 
Five clinical CCL rupture cases (ruptured ligament tissue) were collected during 
reconstructive CCL surgery. The breeds were varied and included a Border Terrier, a 
Jack Russell Terrier, an English Springer Spaniel, a Bulldog and Labrador Retrievers. 
These were compared with healthy control CCL tissue collected from five cadavers 
that had been euthanased for reasons other than degenerative joint diseases (as 
described previously in Chapter 2). The control breeds comprised of Beagles and 
Staffordshire Bull Terrier type breeds. 
 
Once collected, the tissue was immediately placed into RNAlater solution 
(Invitrogen California, US) to quickly and efficiently stabilise the RNA in the sample. 
This alleviates the necessity to process it immediately or snap freeze the samples in 
liquid nitrogen. When required for analysis, the sample was removed from RNAlater 
and processed as if it were normal fresh tissue just collected. 
 
RNA Extraction 
Tissue samples were removed from the RNAlater solution and homogenised with 
1ml of trizol reagent (Invitrogen, California, US) before RNA extraction. The RNA was 
extracted from samples using the PureLink RNA mini kits (Ambion, UK) according to 
the standard manufacturer’s instructions, for more detail see materials and 
methods (Chapter 2). 
 
  
- 194 - 
 
The RNA quality and quantity was assessed as detailed in Chapter 2 using the 
Agilent 2100 Bioanalyser (Agilent, California, US). 
 
cDNA synthesis 
Reverse transcription was performed using oligo dT primers and Superscript II 
reverse transcriptase (Invitrogen, California, US) according to the manufacturer’s 
instructions; for a more detailed method see materials and methods (Chapter 2). 
 
Design of primers and probes 
Target sequences were chosen for Q-PCR by predicted functional association with 
CCL rupture: MMP-2 (matrix metalloproteinase-2), BGN (Biglycan), TRAP (tartrate 
resistant acid phosphatase), CTSK (Cathepsin-K), MMP-1 (matrix metalloproteinase-
1), COL1A1 (collagen type I alpha 1), COL1A2 (collagen type I alpha 2), IL-6 
(interleukin 6), TNFα (tumour necrosis factor alpha). In addition, the nine most 
associated genes from the GWAS were also selected; SEMA5b (semaphorin type 5), 
CDH19 (cadherin 19), GAP43 (Growth Associated Protein 43), DIRC2 (disrupted in 
renal carcinoma 2), CDH7 (cadherin 7), PARP-14 (poly ADP ribose polymerase 14), 
PARP-9 (poly ADP ribose polymerase 9), PARP-15 (poly ADP ribose polymerase 15) 
and PDIA5 (protein disulfide isomerase family A member 5).  
 
Transcript sequences of the cDNA were obtained from Ensembl 
(http://www.ensembl.org, CanFam2) and primer and probe reactions were 
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designed for each gene of interest using the Universal Probe Library Assay Design 
Centre [396] (Roche, Hertfordshire, UK). GAP43 was excluded from the study 
because assay design failed, leaving a total of 17 genes to design and validate 
primers and probes for. 
 
Each primer and probe sequence was compared against the canine genome using 
BLAST (http://blast.ncbi.nlm.nih.gov/) to ensure specificity for chosen target only. 
Primers were designed with the following constraints; a G-C content within the 
range of 30-80%, identical runs of bases (especially guanine) were avoided and the 
Tm was in the range of 58-60˚C. The primers were designed to cross intron/exon 
boundaries so that any contamination with genomic DNA could not be detected – 
only cDNA from mRNA gene transcripts would be amplified, not genomic copies of 
the gene. Chosen genes and the associated primer/probe sequences and details are 
shown in Table 7.1. The probe for the PARP-14 assay was not found in our library 
and was excluded from the experiments, this left 16 genes for experimental 
detection. 
 
Lyophilised primers were resuspended to a stock concentration of 100μM. The 
primer mix was created for each assay; 10μl of forward primer plus 10μl reverse 
primer and 180μl of molecular grade water – each primer in the mix was at a 
concentration of 5μM. 
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Table 7.1. Genes (including 3 reference genes) used for expression analysis in CCL 
tissue 
Gene 
symbol 
CHR Transcript ID 
Roche 
Probe 
# 
Probe 
sequence 
Amplicon 
length 
(nt) 
Primers TM 
% 
GC 
CDH19 1 ENSCAFT00000000075 5 cagccaca 75 
Left - tgatcgagagattagtgcttgg  
Right - gcagaaatttgttgcacattg 
59  
59 
45  
38 
CDH7 1 ENSCAFT00000000076 89 ggatgctg 114 
Left - aattcttggatggtccgtacac  
Right - gggcactgttgccatatgta 
60  
59 
45  
50 
MMP2 2 ENSCAFT00000014986 14 ctgggaga 95 
Left - gggggagactctcactttga  
Right - cagtactctccgtcggcatt 
59  
60 
55  
55 
MMP-1 5 ENSCAFT00000023900 48 actgggaa 94 
Left - tcgatgctgctgtttctgac    
Right - tccatggattgcttatattcatca 
60  
60 
50  
33 
COL1A1 9 ENSCAFT00000026953 65 ctggagga 94 
Left - ctttgctccccaaatgtctta  
Right - gagaccacgaggaccagaag 
59  
59 
43  
60 
TNF 12 ENSCAFT00000000804 29 cttctgcc 119 
Left – cctcagcctcttctccttcc 
Right - tgattagttggaggccatttg 
60  
59 
60  
43 
COL1A2 14 ENSCAFT00000031580 81 ggccctgg 66 
Left - gcccagtatgatggaaaagg  
Right - acctctaggtcccatcaaacc 
59  
59 
50  
52 
IL6 14 ENSCAFT00000004340 65 tcctccag 114 
Left - ccaatctgggttcaatcagg   
Right - acattttccttatcaccctcatagtt 
60  
59 
50   
35 
CTSK 17 ENSCAFT00000019202 38 ggaagcag 78 
Left – caatgggacctttggaagaa   
Right - ccaaattaaacgccgagaga 
59  
60 
45  
45 
TRAP 20 ENSCAFT00000027439 20 ctggctgg 111 
Left - ccaacgacaagaggtttcg     
Right - agacgttccccaggtggt 
59  
60 
53  
61 
DIRC2 33 ENSCAFT00000019042 5 tgtggctg 113 
Left – tctccagctgggacatcg       
Right - cagaagcacagttatccgaaga 
60  
59 
61  
45 
PARP-9 33 ENSCAFT00000018954 39 aggtggag 60 
Left - tgaaaactgtggtttgcaggt  
Right - gccatgagaacggaattgtc 
60  
60 
43  
50 
PDIA5 33 ENSCAFT00000019138 20 ctggctgg 85 
Left - aatgccacatttccagaagg  
Right - ttcaaattccgaggggtaga 
59  
59 
45  
45 
SEMA5B 33 ENSCAFT00000019107 14 tctcccag 109 
Left - gggtcttcaccaccaacgta  
Right - gggttctcctggtatcgaaat 
60  
59 
55  
48 
PARP-14 33 ENSCAFT00000019011 35 agaagagga 91 
Left - aaagaacatgtcaaagagccaga  
Right - cacattcttctgaggtatcttcca 
60  
59 
39  
42 
PARP-15 33 ENSCAFT00000018979 19 ggctggag 64 
Left – tcccaatgaggacaagaatctc 
Right - gctggagaccatcgtgaac 
60  
59 
45  
58 
BGN X ENSCAFT00000030457 22 ctccacca 84 
Left – tgcagaacaacgacatctcag 
Right - tgttgttcaccaggacgaga 
60  
60 
48  
50 
C7orf28B 
Ref Gene 
6 ENSCAFT00000036998 72 gccaggaa 89 
Left – gcaggaagggattctccagt 
Right  -tcattaaggttcaagggtcca 
60  
59 
55  
43 
ATIC 
Ref Gene 
37 ENSCAFT00000022733 62 cagcaggt 79 
Left - cgctgcctctttcaaacat       
Right - gcagactttggcctcatctt 
59  
59 
47  
50 
HIRP5 
Ref Gene 
10 ENSCAFT00000005296 39 aggtggag 77 
Left – aattcagaacatgctgcaatttta 
Right - tttcatctgattcatcatccataac 
60  
59 
29  
32 
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Reference gene selection 
To account for variations in RNA extraction, the amount of initial sample or RT-
variability, it was necessary to include reference genes, to which each unknown 
sample was normalised [397]. Reference genes (often referred to in the literature 
as housekeeping genes) need to be stably expressed in the tissue of interest and 
the expression levels of such genes should not alter with disease state or 
environmental factors [398].  
 
Historically, the same reference genes were used universally for all experiments 
across all tissue types and experiments. However, more recently, it has been found 
that there is huge variability in the expression of commonly used reference genes 
such as GADPH and beta-actin in different tissues and under different experimental 
conditions [399, 400]. It has been necessary therefore, to use statistical algorithms 
such as geNORM [401], BestKeeper [397] and NormFinder [402] to determine 
which genes are stably expressed in the specific tissue being studied. This is done by 
testing a panel of SNPs in the chosen tissue on either microarray or Q-PCR 
platforms. Reference genes that have already been proven as stably expressed in 
CCL tissue via these methods were used in this study; ATIC, HIRP5, C7orf28B, 
MRPS7 and ORMLD2 [13]. These five genes were further reduced in number by 
selecting the three most stably expressed genes (ATIC, HIRP5 and C7orf28B) which 
were then taken forward as reference genes for the normalisation of the Q-PCR 
data within this project. Sequences and probe information for the selected 
reference genes are included on the end of Table 7.1.  
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Q-PCR 
Each Q-PCR reaction was carried out using the Applied Biosystems 7900HT PCR 
machine in 384 well formats.  There were three negative (no template) controls for 
each assay. Each reaction was in 10µl volume - containing 5µl of master mix 
(Taqman 2X PCR master mix, Applied Biosystems, California, US), 0.2μl of primer mix 
(each forward and reverse primer in mix at 5μM, Roche, Hertfordshire, UK), 0.1μl of 
10μM probe (Roche, Hertfordshire, UK), 0.1μl distilled water and 4.6μl of sample 
cDNA (or water for the negative controls). The PCR reaction was carried out using 
the following thermal cycling conditions: 
50˚C – 2 minutes 
95˚C – 10 minutes 
95˚C – 15 seconds 
60˚C – 1 minute 
 
The Q-PCR was carried out using TaqMan style probes, from the Universal Probe 
Library (Roche, Hertfordshire, UK). The probes were dual-labelled with a reporter 
fluorophore (FAM) on the 5’ end and a quencher dye on the 3’ end. When Taq 
polymerase extends through the probe it is hydrolysed and the fluorophore is 
released from the inhibitory effect of the quencher. A fluorescent signal is produced 
that is then detected by the camera in real time. This process is illustrated in Figure 
7.1. 
  
X40 
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Figure 7.1. Diagrammatic representation of TaqMan probe chemistry (adapted 
from www.Invitrogen.com).  
1. The probe anneals to the cDNA sequence downstream of the primer. 
2. Taq DNA polymerase extends the primer and synthesises a new DNA strand. 
3. Taq DNA polymerase extends into the probe causing hydrolysis of the probe 
and release of the fluorophore. This emits a fluorescence signal that is 
proportional to the amount of amplicon product. 
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Primer probe validation 
The primers and probes needed to be validated to check they worked effectively 
and to check the efficiency of the reactions. A serial dilution of the template was 
made with six dilutions from 1:10 to 1:1,000,000. A negative control was included 
to form a standard curve. Each dilution was run in triplicate with the standard Q-
PCR mix, for the standard cycling conditions (see above). 
 
The efficiency of a Q-PCR reaction is the rate at which the amplicon is generated. In 
the geometric phase of amplification, the product rate should double with each PCR 
cycle, so a reaction should have an efficiency of 100%. The slope of the reaction can 
be used to determine the efficiency (E), using the following equation E = 10(-1/slope)-1. 
The ideal slope should have a value of -3.32 which correlates with an efficiency of 
100% i.e. 100% of the target is amplified. A slope of between -3.1 and -3.7 is 
considered to be the acceptable with upper and lower values for an efficiency of 
between 110% and 86%. A reaction that has an efficiency of greater than or less 
than this range indicates a a non-linear reaction. This may occur when too much 
target is added (causes inhibition and saturation of the PCR reaction), too little 
target is added (too low a concentration of sample to detect a CT), pipetting errors 
when creating the standard curve, detection of a PCR inhibitor, primer-dimer 
formation or bad design of primers/probes. Any primer/probe sets that were out of 
the efficiency range in this project were excluded from the study. 
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A 1:10 dilution of sample was chosen for use in experiments in this project. This 
concentration of sample universally produced the best amplification curves during 
primer testing and showed no inhibition of reaction due to too much template or 
too little amplification due to small amounts of target. 
 
Data analysis 
Determination of CT values 
A threshold value is decided in the exponential phase of the amplification reaction 
and the cycle threshold (CT) is defined as the number of cycles required for the 
fluorescent signal to cross the threshold. CT levels are inversely proportional to the 
amount of target in the sample – the larger the amount of target sample the lower 
the number of PCR cycles required for the fluorescence to exceed the threshold, 
hence the smaller the CT value. CT values are used to calculate fold change. 
 
Fold Change  
The fold change between experimental condition and controls was calculated using 
relative quantification using the delta-delta CT method in the following manner: 
  
First, the mean and standard deviations of the CT data were determined. Any 
values falling outside ±2 SD of the mean were excluded as outliers. Technical 
replicates were averaged before analysis and biological replicates averaged after 
delta-delta CT calculation. 
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The delta CT (ΔCT) was calculated using the geometric mean of the reference genes 
(ATIC and HIRIP5) using the formula: 
ΔCT = CT target gene of interest (GOI) – CT geometric mean reference genes (REF) 
The SD of the ΔCT was calculated by using the SD of GOI and SD of REF in the 
following formula: 
SD ΔCT = √                 
The delta-delta CT (ΔΔCT) was calculated using the ΔCT of experimental condition 
and the control condition in the following formula: 
ΔΔCT = ΔCT experiment – ΔCT control 
The SD of the ΔΔCT is the same value as the SD for the ΔCT of the experimental 
condition 
The fold change is calculated using the following formula 
Fold Change = 2–ΔΔCT 
 
Statistics 
An unpaired t-test was used to compare the fold change values between the 
ruptured/healthy samples to determine whether or not the difference in expression 
was significant. The data was non parametric in its distribution (Shapiro-Wilk test 
for normality was applied to the data – see Appendix VI.) and subsequently non 
parametric versions of a t-test were run; the Mann Whitney test was performed as 
the samples are independent of each other.  
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The fold change was deemed to be significantly different in the experimental 
samples compared to control/normal if the resulting raw p-value was ≤0.05. 
 
Results 
Efficiency of primer/probe sets 
The efficiency of the primers was evaluated after running standard curves. The 
efficiency of the reaction for the primers/probes used was on average 105%, with 
an R2 value of ≥0.9. Primers and probes with low efficiency and/or poor 
amplification were removed from subsequent experiments – these were CDH7, 
SEMA5b, CDH19, PARP-15 and TNFα. For a full table of all primer efficiencies, R2 
values and the threshold values see Appendix VII. 
 
Fold change  
Any samples that had failed to amplify, or had a CT value that deviated ±2SD from 
the mean were excluded from analyses. The spread of variation of the remaining 
samples is plotted in Figure 7.2 
 
There was sometimes large variation between each replicate sample, as indicated 
by the standard error of the mean (SEM) - values ranged from 4.89 - 8.02. This was 
due to no biological replicates because of the small amount of ligament available 
from each dog, particularly in the ruptured tissue group. The amount of RNA 
obtained from the extraction was also low in many cases.  
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Fold change and consequent p-values are shown in Table 7.2. They are graphically 
represented in Figure 7.3. Significant results (p≤0.05) are indicated by an asterix (*). 
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Figure 7.2 Gene expression changes in CCL rupture tissues. Clustering of the individual ruptured (n=10, five samples with two technical replicates) and 
healthy samples (n=10, five samples with two technical replicates) for each gene (minus samples ±2SD from mean). Error bars (standard error of the 
mean) are shown in red. CT = Cycle threshold 
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Table 7.2. Fold change values for ruptured vs. healthy experiment.  
 
Fold 
Change 
Ruptured 
± SEM 
p value (Mann 
Whitney) 
MMP 2 9.19 6.85 0.1153 
Biglycan 0.28 7.89 0.9677 
Trap 3.67 5.11 0.0172* 
Cathepsin K 1.47 8.02 0.4427 
COL 1A1 36.58 5.40 0.0001* 
COL 1A2 72.87 7.77 0.0172* 
IL6 0.31 4.89 0.6547 
DIRC2 12.14 5.29 0.0028* 
PDIA5 2.86 6.74 0.1153 
PARP 9 3.01 6.60 0.4429 
MMP 1 1.71 6.19 0.4429 
KEY: * - significant result (p ≤0.05). SEM = standard error of the mean.  
 
 
Figure 7.3. Gene expression in ruptured CCL. Fold change differences between 
healthy and ruptured CCL tissue. Asterix (*) = significant result (p ≤0.05). Data is 
shown on a log10 scale. 
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There were four genes that have significant differential expression levels between 
the ruptured and healthy tissues, TRAP (p=0.0172), COL1A1 (p=≤0.0001), COL1A2 
(p=0.0172) and DIRC2 (p=0.0028). They all showed increased expression in the 
ruptured ligament tissues compared to the control tissue. 
 
Discussion 
Analysis of gene expression data is a very powerful way to study the pathogenesis 
of disease. It can help elucidate the underlying mechanisms of disease initiation and 
progression by investigating differential gene expression between disease or 
experimental conditions and controls [391]. This chapter aimed to determine the 
expression levels of select candidate genes identified as potentially having a role in 
the susceptibility or resistance to CCL rupture.  
 
Q-PCR evaluates changes in expression at the time of tissue collection. Although the 
cases have ruptured their CCL, it may have been days/weeks/months or years after 
the initiation, diagnosis and subsequent surgery to collect the sample. Gene 
changes important for CCL rupture may have already occurred and may not have 
been present at the time of sampling and analysis. Indeed, changes in expression of 
genes that promote repair may have been prominent instead. Despite this 
significant reservation, it is still valid to investigate gene dysregulation in CCL 
rupture, as long as the above provisos are considered when data interpretation is 
concerned. 
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The data showed two potentially important genes which have significantly 
upregulated expression in the ruptured tissues. These are COL1A1 and COL1A2 with 
p-values of 0.0001 and 0.0172 respectively. Type-I collagen is the predominant 
collagen protein type found within ligaments [43] and its production is crucial in the 
ligament repair processes and during healing/scar formation [403, 404]. 
Upregulated expression of these genes in the ruptured ligaments compared to 
healthy ligaments denotes that a reparative process may be being attempted by the 
cells. The process of ligament healing after injury is thought to involve four phases; 
the inflammatory phase, an epiligamentous repair phase, a proliferative phase and 
then a remodelling phase [405]. Collagen is involved primarily in the proliferative 
and remodelling phases of this process [406, 407]. These results and conclusions 
are confirmed in other independent studies [408, 409] [50]; the authors proposed 
that the differential gene regulation was thought to be due to a reparative process 
within the ligament after the injury/rupture.  
 
A study by Clements et al. (2008) investigated the expression profile of CCL in dogs, 
using normal and ruptured ligaments from Labrador Retrievers. They also 
compared normal Labrador Retriever CCLs to normal Greyhound CCLs (a breed that 
is less susceptible to CCL rupture) [13]. There were no differences between the high 
and low risk breeds, but 16 genes were differentially expressed between the 
Labrador Retrievers with CCL rupture and healthy Labrador Retrievers. COL1A2 was 
one of several matrix associated proteins (including COL5A1, COL3A1, lumican, 
aggrecan, tenascin-c) that were upregulated in the ruptured tissues. Our study not 
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only confirms the work of Clements et al., that COL1A1 and COL1A2 are 
upregulated in CCL ruptured tissue compared to normal CCL tissue samples, but 
also confirms their hypothesis that this is due to a remodelling and repair of the 
matrix of the after ligament injury.  We did not wish to repeat every gene that 
Clements et al. studied (this thesis is an original piece of work), so were not able to 
confirm similar trends with any other genes. This section of the project was 
performed concurrently to the Sequenom candidate gene study which had not 
been analysed at the time of choosing genes. This is also why certain key candidate 
genes such as Collagen type V were not studied in this project, but they should be 
included in any subsequent expression studies. 
 
We have showed that collagen mRNA levels are increased in ruptured compared to 
healthy CCLs (indicative of an attempted reparative process being carried out), but 
Young et al. 2011 [410] found that the actual collagen levels in CCL tissue were 
reduced. There are several flaws to directly comparing the two studies. Firstly, the 
collagen produced within the cells may be rapidly degraded before secretion to the 
ECM and therefore not able to be detected by the hydroxyproline assays used. 
Secondly, levels of mRNA do not necessarily correlate to protein synthesis and 
expression because of complex stages between transcription and translation [411]. 
It is feasible that both hypotheses are correct. Indeed lower levels of ECM proteins 
are consistent with a structurally altered ligament that is unable to withstand 
normal loading and therefore more susceptible to rupture. 
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Two other genes showed significant differences in gene expression between 
healthy and ruptured CCLs. These were tartrate resistant acid phosphatase (TRAP) 
and disrupted in renal carcinoma-2 (DIRC2), with p-values of 0.0172 and 0.0028 
respectively. TRAP is of interest, as it has been found, along with Cathepsin-k and 
some other matrix-metalloproteinases, to be expressed during chronic 
inflammation and it induces leucocyte mediated collagenolysis [412-414]. TRAP is 
secreted by osteoclasts and macrophages [415, 416] and can initiate collagenolysis 
by forming free-radicals and reactive oxygen species (ROS).  These are highly toxic 
to cells and can cause degradation and loss of structure/strength of the collagens 
(and therefore ligaments) [414]. Over expression of TRAP has been shown to 
increase amounts of ROS, which may subsequently increase the amount of collagen 
destruction [413, 417].  
 
DIRC2 does not have such an obvious role in the pathology or susceptibility to CCL 
rupture. DIRC2 is a member of the major facilitator superfamily (MFS) transporters 
[418]. They are a group of single polypeptides which act as secondary carriers and 
are capable of transporting small solutes across membranes in response to 
chemiosmotic ion gradients [419]. DIRC2 has been found localised in many 
organelles including lysosomal membranes. Lysosomal enzymes can degrade 
collagen fibres in periodontal ligaments [420], so it is feasible that if DIRC2 is 
upregulated then the enzymes within the lysosome are released more abundantly 
and cause degradation and loss of structure/strength of the collagens and 
subsequently the ligaments. 
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The upregulation of TRAP and DIRC2 seen in ruptured CCLs compared to healthy 
CCLs indicates that degradation is occurring within the ligament simultaneously 
with the attempted reparative process. This is conclusive with the limited healing 
potential seen in a CCL after rupture [421, 422]. Although the limited healing is in 
part attributable to reduced vascular response [423], it may also be due to this 
protease degradation. 
 
The weakness of this Q-PCR experiment was that the breed, age, sex, neutering 
status or weight of the dogs was not collected. Also, more importantly, the history 
of trauma pre-initiating the rupture was unknown. This part of the project was 
focussed on investigating the disease process and was not concerned with any 
inherited genetic components of the condition; hence, the breed of dog was less 
important. CCL rupture-associated changes in expression are likely to be the same 
regardless of breed and so this should not impact the biological significance of the 
results.  
 
Only very small amounts of RNA are extractable from CCL tissue and given the high 
sample consumption of Q-PCR experiments this limited the number of genes that 
could be studied by this approach. For this reason, the number of reference genes 
used, was reduced from three to two (C7orf28B was dropped from the list because 
it was reported as being the least stably expressed [13]) and only the most efficient 
Q-PCR reactions were selected for inclusion in the experiments. The small amount 
of RNA also meant that only a small number of replicate samples could be used in 
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the experiment (two per sample). The standard errors were large due to only 
having duplicate samples (rather than triplicates, which is the standard for Q-PCR 
experiments) the error bars represent this on the fold change chart (Figure 7.3). 
 
Alternative methods of studying gene expression involve the use of microarray 
chips to examine a wide selection of mRNA sequences that have been hybridised to 
a chip [393]. Differential labelling of the case and control RNA samples can identify 
genes that haven been up or down regulated by measuring the intensity of the 
colour on the microarray [424]. This method uses an unbiased approach to identify 
novel genes that may be up or down regulated in a disease process. Data analysis is 
lengthy and requires validation by Q-PCR to avoid false positive data. Due to 
budgetary and time constraints, this approach was impractical and is why gene 
expression was evaluated by Q-PCR instead. 
 
Innovative, next generation sequencing approaches have recently been developed. 
These sequence the entire RNA library (transcriptome) of individual tissue samples 
to generate information pertaining to the differential gene expression between 
cases and controls [425, 426]. This technology was extremely new when conducting 
this project and as such the cost implication for running this would have been 
prohibitively expensive. This would be a good way to follow up the results of this 
experiment, to confirm and replicate the gene expression changes seen. In addition 
this approach may identify novel genes that may not have been identified in the 
current literature as candidate genes. 
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In conclusion, this study revealed that collagen type I genes (COL1A1 and COL1A2), 
as well as TRAP and DIRC2 were significantly upregulated in ruptured versus healthy 
CCL tissue samples. This indicates that repair and proliferation is being attempted 
by the ligaments after the initial injury, but that a degradative process is also still 
occurring. The data shown here most likely represents gene changes that have 
occurred after the injury and not initiating factors in ligament rupture. It is 
impossible to predict when a dog will rupture its ligament (or the stage of rupture), 
so investigating pathological changes in expression before rupture occurs is not 
feasible. Our approach is best viewed as a way to help elucidate changes that occur 
after injury. Treatments can be targeted to the effects, thereby hopefully limiting 
the damage caused to the contra-lateral ligament. 
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Introduction 
In previous chapters, the CCL rupture disease process and genetic susceptibility 
factors were investigated using case control association studies. Such studies 
require large numbers of both case and control samples to provide sufficient 
statistical power. For gene expression work, there is a finite amount of ligament 
tissue available, which hampers that approach to disease investigations. A 
laboratory model of CCL rupture which could be simulated in a controlled 
laboratory situation may facilitate investigations into the causes and treatments of 
diseases and would reduce the need for laborious collection of samples. Various 
methods of disease modelling are available from the more traditional in-vitro 
primary cell cultures [427, 428], isogenic/immortalised cell line models [429, 430] 
and in-vivo animal and transgenic models [431, 432], to the more recently 
developed 3D-cell culture technologies [433].  
 
Cell culture models (primary or secondary/isogenic cell lines) have been used as in-
vitro models to map disease and tumour progression in many cancers such as 
cervical cancer (HeLa cells [430]), breast cancer (MCF-7 cells [429]), colorectal 
cancer (HCT-116 cells [430]) and in other diseases such as cystic fibrosis (ΔF508 cells 
[434]) and Alzheimer’s disease (IMR-32 neuroblastoma cells [435]). The advantages 
of using cell lines as models for disease are that they are cost effective, relatively 
easy to maintain and are reproducible under the defined conditions. Furthermore 
they reduce the number of animals that are needed in research. Disadvantages are 
that the cells may not behave like they would in-situ because the morphological 
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and spatial development may be different in-vitro relative to the disease process 
being modelled [436]. Such variation can be minimised by using primary cultures 
that have been taken directly from the tissue of interest in preference to secondary 
(immortal) cell lines. Cultures should be monitored for senescence and/or 
transformation due to genetic drift and should be discarded before this happens  
[437]. Alternatively, animals models can be developed (in-vivo research), but this 
can be costly [438]. 
 
In-vivo transection of the CCL in animals has been used to as an experimental 
laboratory model to study the developmental process of osteoarthritis associated 
with CCL rupture [432, 439, 440]. This model is considered to be suitable for 
studying downstream effects after the initial CCL rupture, but not the early disease 
changes which occur before the rupture. There are few verifiable models for early 
stage ligament degeneration. Lopez et al. [441] developed a model that simulates 
partial rupture/damage of the CCL, which will then progress to complete CCL 
rupture.  
 
Surrogate platforms may only have limited clinical relevance, as cell lines and 
surgically induced animal models do not always fully represent the normal disease 
process that is seen in the human or dog [442]. A surgically induced transection (or 
otherwise tampered with) ligament may not behave in the same way as a naturally 
stretched ligament and subsequent degeneration and rupturing may be altered as a 
result. Despite their drawbacks, these laboratory models of disease can enable 
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proof or denial of physiological processes that may increase disease susceptibility, 
initiation and progression or can be useful for testing therapeutic agents to treat or 
prevent a disease.  
 
Models that effectively model a disease process and enable a reduction or 
replacement of animals used for research are very useful [443]. They will allow 
more general laboratory work to be carried out within a more ethical framework, 
without the restrictions of home office licences and animal husbandry etc.  
Currently, there are no in-vitro models for CCL rupture and it is for this reason we 
aimed to try and develop an in-vitro model for the condition. 
 
Tissue culture modelling can be accomplished by three main methods: cell culture, 
explant culture or organ/biopsy culture [444-446]. Primary cell culturing is 
conducted via enzymatic or mechanical disruption of a tissue, to disperse the cells 
into a suspension and cells are then grown as a monolayer culture [447]. Explant 
culture involves a fragment of tissue being placed directly onto a culture plate. 
During culture with appropriate media, the cells slowly migrate and outgrow from 
the tissue to form a monolayer culture [444, 448]. This method is time consuming 
and carries a high risk of bacterial contamination from the original tissue sample. 
This method was attempted but was not taken forward in the project as no cell 
migration was seen within a week of culturing and after two weeks only a small 
number of cells had migrated out. It was not seen as a viable option for monolayer 
culturing within the project’s time frame. An organ biopsy is similar to an explant 
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culture but the experiment is carried out on the piece of tissue itself [446]. The 
histological and cell architecture is retained, but the reproducibility is low and 
intersample variation is high, making this method redundant in most studies. 
Microscopic monitoring of the cells daily to check for signs of contamination is 
important for all of the methods. 
 
TNFα is a pro-inflammatory cytokine which is commonly used in a laboratory 
environment to model chronic inflammatory and autoimmune disorders such as 
osteo- and rheumatoid arthritis, Crohn’s disease and inflammatory bowel diseases 
[428, 449-452]. Levels of the TNFα have been shown to be elevated in ruptured 
ACLs in man [453, 454].  The aim of this chapter was to compare and evaluate gene 
expression in cultured ligamentocytes in the presence or absence of TNFα, to 
determine whether TNFα induced ligamentocyte fibroblasts were valid as an in-
vitro model for CCL rupture.  
 
Methods 
Sample collection  
Samples were collected by sharp dissection of CCL ligament from five cadaveric 
dogs that had been recently euthanased for reasons other than degenerative joint 
diseases and which had been donated to the University for teaching purposes. The 
tissue was placed directly into sterile culture medium (as described in the Chapter 
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2), to obtain primary ligamentocyte cell lines. The breed could not be pre-selected, 
but the majority of cadavers were of the Staffordshire Bull Terrier type.  
 
Sample preparation 
Once collected, the tissue was immediately processed for tissue culturing via 
enzymatic disruption as described previously, to generate ligamentocyte monolayer 
cultures (see tissue culture of ligament cells in materials and methods – Chapter 2). 
Once confluent, the cells were cultured for 24 hours with or without recombinant 
canine TNFα (10ng/ml), as described below. 
 
Ligamentocyte stimulation with TNFα 
Recombinant canine TNFα (R&D systems, Minneapolis, US) was used. This was 
reconstituted to a stock volume of 100ug/ml in sterile PBS with 0.1% bovine serum 
albumin. When used in stimulation experiments it was used at a working 
concentration of 10ng/ml. The cells were exposed to TNFα for 24 hours (as 
described in the monolayer section detailed in materials and methods - Chapter 2) 
prior to assessment of changes in gene expression. 
 
Experiments were carried out in triplicate on three independent days to allow for 
technical and biological replicates – see Figure 8.1. Cells in this project were never 
taken beyond passage 8 to avoid cellular transformation or senescence. 
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Figure 8.1. Plate setup for the tissue culture induced/control expression 
experiment, shown for two dogs. Colours indicate the biological (red circles) and 
technical replicates (blue circles) which were used in each experiment.  
CCL ligamentocytes were cultured in 6-well plates, either with or without TNFα 
(10ng/ml) as shown above. Each experiment was executed in triplicate on three 
separate days, for five dogs. 
For each dog there are nine induced samples (numbered) and nine control 
samples. For the five dogs used, there were a total of 45 TNFα induced samples 
and 45 control samples to be analysed by Q-PCR. Technical replicates from each 
day (1-3, 4-6, 7-9) were averaged before delta-delta CT calculations were 
performed (15 induced values - three from each of the five dogs, and 15 control 
values - three from each of the five dogs) to determine gene expression changes 
between normal and TNFα induced ligamentocytes. 
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RNA Extraction 
Post culture, the adherent cells were lysed directly on the plate with Trizol before 
continuing with RNA extraction. The RNA extraction protocol was as described in 
Chapter 7.  
 
cDNA synthesis 
Reverse transcription of RNA was performed using oligo dT primers and Superscript 
II reverse transcriptase (Invitrogen, California, US) according to the manufacturer’s 
instructions. Further details are in Chapter 7. 
 
Design of primes and probes 
Target sequence and reference gene selection was performed as in Chapter 7, using 
the same genes and primer sets.  
 
Primer probe validation 
The primers had been found to be efficient from the experiments reported in 
Chapter 7. 
 
Q-PCR 
Each Q-PCR reaction was carried out in triplicate using the Applied Biosystems 
7900HT PCR machine in 384 well formats, as detailed in Chapter 7.  A 1:10 dilution 
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of each cDNA was used for experiments in this project, as this concentration of 
sample produced the best amplification curves during primer testing and showed 
no inhibition of reaction. 
 
Data analysis 
Fold Change  
The fold change between experimental condition and controls was calculated using 
the delta-delta CT method as detailed previously in Chapter 7. 
 
Statistics 
A paired t-test was used to compare the fold change values between 
induced/control samples to determine whether or not the difference in expression 
was significant. The data was non parametric in its distribution (Shapiro-Wilk test 
for normality was applied to the data – see Appendix VI.) so non-parametric 
versions of the t-test were used; The Wilcoxon test was performed as the samples 
were paired. The fold change was deemed to be significantly different between the 
experimental cultures compared to control cultures if the resulting raw p-value was 
≤0.05. 
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Results 
Fold Change  
The variation between each individual replicate of induced/control samples was 
minimal; once samples which varied ±2 SD from the mean were removed, the 
clustering of the 45 individual replicate samples for each gene was evaluated and 
the results presented in Figure 8.2 
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Figure 8.2. Gene expression in canine ligamentocytes induced by TNFα. Clustering of the induced (n=45) and control (n=45) samples for each 
gene (minus samples ±2SD from mean). Error bars (Standard error of the mean) are shown in red. 
 
  
- 225 - 
 
The fold changes and the p-values for each gene are shown in Table 8.1 and are 
graphically represented in a grouped bar chart (Figure 8.3). Significant results (p-
value ≤0.05) are indicated by an asterix (*). 
 
 
Table 8.1. Fold change values for CCL cells that had been cultured with 10ng/ml 
TNFα for 24hrs versus normal, control cells.  
Gene 
Fold 
change 
Induced 
± SEM p-value (Wilcoxon) 
MMP 2 1.33 1.69 0.0640 
Biglycan 0.56 1.40 0.0180* 
Trap 0.70 2.61 0.3780 
Cathepsin K 0.85 2.16 0.7610 
COL 1A1 0.33 1.80 0.0130* 
COL 1A2 0.28 1.81 0.0160* 
IL6 45.78 2.59 0.0001* 
DIRC2 1.12 1.70 0.2010 
PDIA5 1.09 1.64 0.2080 
PARP 9 5.81 2.99 0.0001* 
MMP 1 6.57 2.90 0.0009* 
KEY: * - significant result (p-value ≤0.05), SEM = standard error of the mean 
 
 
 
  
- 226 - 
 
 
Figure 8.3. Gene expression in cultured CCL cells: Fold Change between normal 
cultured CCL cells and CCL cells that had been cultured with 10ng/ml TNFα. * = 
significant result (p-value ≤0.05) 
 
Six genes showed significant differential expression between the induced 
ligamentocytes and the normal cells, these were Biglycan (p=0.0180), COL1A1 
(p=0.0130), COL1A2 (p=0.0160) which had reduced expression with TNFα 
stimulation and IL6 (p=0.0001), PARP 9 (p=0.0001) and MMP-1 (p=0.0009) which 
were upregulated by TNFα stimulation.  The expression of IL-6 after TNFα induction 
was 45 times that of control cultures. 
 
 
  
- 227 - 
 
Discussion 
We evaluated gene expression changes in cultured ligamentocytes in the presence 
or absence of TNFα. This method was used not only to determine the gene 
up/downregulation in response to TNFα, but also to determine if this system was a 
valid in-vitro model for CCL rupture. Readily identifiable downstream inflammatory 
or degradative molecules are induced when cell cultures (in a variety of tissues) are 
stimulated with TNFα [449, 455]. This is seen here with the ligamentocyte cultures 
that are induced to over express PARP 9, MMP-1 and most strongly, IL-6. Similarly, 
the ligamentocytes cultured with TNFα had reduced expression of extracellular 
matrix molecules Biglycan, COL1A1 and COL1A2. 
 
Upregulation of IL-6 is highly relevant as it confirms that the TNFα used in this 
project was viable and that the experiment induced a pro-inflammatory response. 
When cells are challenged with TNFα it causes the release of further inflammatory 
cytokines such as IL-6 [456] and as such the significant upregulation seen here, is a 
direct result of the TNFα induction.  
 
MMP-1 was also upregulated significantly in the TNFα-treated ligamentous 
fibroblasts. Matrix metalloproteinases are commonly involved in many diseases 
where inflammation is present [457, 458] and have a key role in tissue remodelling 
and degradation [332]. Given that the cells have been challenged with TNFα (an 
inflammatory mediator), it indicates that the cells are responding to TNFα 
stimulation in both an inflammatory and degradative manner. 
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PARP-9 (poly ADP ribose-9) catalyses the post-translational modification of proteins 
by the addition of multiple ADP-ribose moieties (ADP ribosylation) and may be 
induced by cellular processes involving inflammatory mediators, such as TNFα, 
macrophages, IL-1, IL-6 and nitrite molecules (NO2) [459]. PARP can also interact 
with other pro-inflammatory mediators such as NF-κB. As such it will have an 
inflammatory effect on cells [460] via these other pathways, which are also likely to 
be activated/induced under inflammatory conditions. Upregulation of this gene is 
therefore also consistent with the inflammation caused by the TNFα stimulation.  
 
Biglycan, a small leucine-rich proteoglycan, is functional in the formation of 
connective tissue and mineralised tissue (bone) matrices, due to its mineralisation 
deposition properties [461]. It also has a role in elastic fibre formation (during the 
elastogenic phase) in fibres such as tropoelastin and fibrillin-containing microfibrils 
[462] as well as in tissue remodelling [463]. As the TNFα-treated cells are 
undergoing an inflammatory response, the ability of the cells to form matrices is 
hindered – hence the downregulation of this gene. This downregulation is 
consistent with other research (in man) that has found that stimulation of 
fibroblasts with TNFα, decreases expression of Biglycan [464-466].  
 
The downregulation of the COL1A1 and COL1A2 gene expression is also consistent 
with the degradative response from the TNFα stimulation, which hinders repair and 
proliferation of the matrix. 
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We aimed to determine whether TNFα was a suitable model for studying CCL 
rupture in the laboratory. Expression data from the induced ligamentocytes 
compared to normal ligamentocytes varied considerably from the expression of 
ruptured CCL tissue versus healthy tissue (as detailed in Chapter 7). No genes were 
simultaneously up or downregulated to the same extent in both studies. Ruptured 
CCL tissue is considered to be abnormal, and changes relating to CCL rupture may 
have already occurred, therefore comparative investigations into the disease 
process using this method may not be suitable. The TNFα model (using healthy CCL 
tissue) may instead be used as a successful model to investigate the CCL rupture 
disease process.  
 
TNFα can be used legitimately to study inflammation in ligamentocytes (and other 
cells), and the early stages of CCL rupture may be modelled using this cytokine via 
this model. However, as factors other than inflammatory process are considered to 
be involved in the initiation and progression of CCL rupture it may also be deemed 
unsuitable. CCL rupture is considered a complex disease with many environmental 
and genetic factors playing a role in the initiation and progression of the disease 
[36], as a result It is very difficult to study early stage CCL rupture in animals. 
Furthermore, it is important to consider the nature of the cells in the test system. It 
is difficult to know in any meaningful way how much they can represent the 
function of ligamentocytes and whole ligament in-vivo, as the morphological and 
spatial characteristics will be different in-vitro compared to in-vivo situations.  
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As the factors involved in early stages of CCL rupture are still largely unknown, 
studying this process in-vitro will be difficult and in-vivo models (using rabbits etc) 
are still primarily the best model to investigate changes that occur after CCL 
transection in a laboratory environment.  
 
In conclusion, we showed that TNFα may be suitable as a laboratory model to study 
CCL failure as an in-vitro model, and will be useful to identify individual pathways 
that may be important after CCL failure in dogs.   
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Chapter 9.        
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Discussion & 
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Introduction 
This thesis aimed to investigate the genetic basis of cranial cruciate ligament (CCL) 
rupture in Newfoundland dogs, but also considered other susceptible breeds and 
investigated downstream events from genomic variations. By using a whole 
genome genotyping approach (GWAS) to look for SNP associations, a large amount 
of data was generated that was useful for identifying a list of key genes, considered 
likely to have some involvement in CCL rupture susceptibility. Subsequent studies 
were able to concentrate on specific candidate genes and their potential role and 
expression in both diseased tissues and in a potential laboratory model for CCL 
rupture.  
 
Stratification 
A primary confounder in our association studies was that the genetic structure of 
the two main Newfoundland groups, Europe and North America were significantly 
different. Stratification of genetic data between different ethnicities in humans 
[467] as well as in different breeds of dog [170, 231] is well recognised and is 
expected given the wide variation in shape, size and colour between different 
breeds of dog but is not necessarily expected between dogs of the same breed. 
Stratification within the Newfoundland breed has not been documented before. To 
avoid spurious associations within datasets it is essential to use cases and controls 
from the same breeds and location. However, to increase the power to detect 
disease associations in studies, researchers have often included dogs from the same 
breed but other locations with little regard to how this potential sub-structure 
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would affect underlying stratification in the datasets i.e. assuming same breed, 
same genetics approach [231]. Stratification within the same breed of dog from 
different geographical locations has been reported in recent years [177, 230] and as 
such, it is now commonplace to assess stratification before carrying out analyses to 
ensure no underlying bias will be present in the data. 
 
GWAS results 
Analysis of the GWAS data accounting for the stratification using a CMH stratified 
by country analysis, identified three main chromosomal regions associated with CCL 
rupture on chromosomes 1, 3 and 33. The two most associated SNPs from the 
analysis (BICF2S23133650 and BICF2P1311062) reached genome wide significance 
and were significant after testing for multiple correction. These two SNPs were both 
on chromosome 33 in the gene SEMA5B and were found in a statistically significant 
haplotype block with each other. 
 
The key SNPs identified by the GWAS in the Newfoundlands were subsequently 
considered in a validation study using Sequenom iPlex technology in a larger cohort 
of Newfoundlands and in three other highly susceptible breeds (Labrador 
Retrievers, Rottweilers and Staffordshire Bull Terriers). The regions of association 
on chromosomes 1, 3 and 33 were confirmed in the Newfoundlands but did not 
validate significantly in the other breeds. Interesting associations with CCL rupture 
were found in genes involved in neurological pathways such as SORCS2 (Chr 3) and 
SEMA5B (Chr 33) indicating that mechanotransduction, neurological and 
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neuromuscular pathways may play an important role in the pathogenesis and 
susceptibility to CCL rupture; a novel process that hasn’t previously been 
documented with regards to CCL rupture susceptibility in dogs. 
 
Candidate gene results 
The “traditional” candidate gene studies investigate genes that may have a 
potential functional involvement in CCL rupture initiation or progression. Across all 
of the CCL rupture-susceptible breeds studied, the data suggests that mutations in 
the collagen genes have the most significant role in CCL rupture susceptibility, with 
11 of the 17 most significant associations from the meta-analysis being within this 
gene family. This was expected as collagen is the main component of ligament 
structure [37]. The collagen and collagen-associated genes have a prime function in 
assembly and formation of collagen fibrils that are important in the integrity of the 
ligament extracellular matrix and the ligaments strength and stability [72, 301, 311, 
318, 329, 359]. Other CCL rupture associated mutations within the different breeds 
were also found in Aggrecan (ACAN), Opticin (OPTC) and Latent transforming 
growth factor beta 2 (LTBP2); key proteins involved in the ECM formation and 
maintenance [66, 305, 359]. Mutations within these genes may compromise the 
ligament’s strength and composition leading to an increased risk of CCL rupture for 
dogs with the associated mutations.  It is clear therefore, that mutations affecting 
the strength and structure of the ligament and its composition may be important in 
CCL rupture susceptibility. 
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Changes in gene expression  
Having investigated gene expression changes between diseased and healthy tissue 
samples, we found that there were significant differential expressions seen in 
certain genes. Collagen type I genes (COL1A1 and COL1A2) as well as TRAP and 
DIRC2 were found to be significantly up-regulated in CCL rupture tissues. This 
suggests that the ligament is undergoing proliferation as part of a repair process 
following the initial rupture, but that a degradative process is still in progress which 
hinders the actual repair of the ligament. These changes, although unlikely to be 
indicative of pre-rupture changes, are important for understanding changes that 
occur after injury and may be useful for developing treatment regimens to minimise 
further damage to joint and/or contralateral ligament. 
 
We also showed that a TNFα induced cell line model may be a suitable system to 
study CCL rupture in-vitro, although it is more useful to mimic the inflammatory 
changes seen after the injury and hence be useful in studying the mechanisms of 
new treatment regimens rather than the early changes that precede CCL rupture. 
 
DLA association 
Having assessed the main loci of the DLA region, for association with CCL rupture, 
we showed no association of the DLA region with the condition. We did identify 
differences in haplotype frequencies between the Newfoundlands from North 
America and those from Europe. This confirms the genetic stratification within the 
Newfoundland breed that was seen within the GWAS data. Without further 
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replication in a larger cohort of Newfoundlands from both North America and 
Europe this DLA result cannot be confirmed, but it does support other studies 
indicating that there is no association of DLA regions with CCL rupture [379]. 
 
Conclusions 
These data have shown that there are complex multigenic interactions involved in 
CCL rupture in Newfoundland dogs. There are likely to be different variations 
involved in susceptibility between different breeds of dog. Furthermore, the 
involvement of environmental factors is highly likely, making the determination of 
risk for CCL rupture even more complicated.  
 
This research has made a small but significant understanding in CCL research. It is 
gratifying that newly developed technology has potentially enabled the 
identification of key genes that may be important in CCL rupture susceptibility. 
These associations obviously require further investigation and analysis in 
Newfoundlands and in other dog breeds with CCL rupture, as well as in humans 
where this is also a major clinical problem. These findings are only a small part of a 
much bigger picture, but they may be used to help develop advances in treatment 
and/or prevention of CCL rupture and limit damage to contralateral ligaments.  
 
In summary, to take this work forward, the associated regions and genes associated 
with CCL rupture need to be further investigated in larger numbers of dogs 
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(samples and breeds) using more up-to-date technologies such as targeted next 
generation sequencing or transcriptomic approaches such as RNAseq. These 
technologies would allow the regions/genes to be examined in greater detail and 
could potentially identify the exact causative mutations that are involved in CCL 
rupture. Further work involving functional analysis, for example knock-out or 
transgenic models, could also be considered to determine the effect of the 
mutations in a mouse model. Once the causative mutations have been determined 
in each breed, a screening test can be developed and used, to allow an informed 
breeding program to be instigated that should reduce the incidence of the disease 
in dogs. This would be of great benefit to dog owners, breeders and of course, to 
the dogs themselves! 
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I. Sample dog data 
 
Appendix 1. Summary of age and sex data for each dog breed: including age (minimum and maximum), sex of dogs (number of males, 
females, unknown sex and the number of dogs spayed/neutered) and the total number of dogs in each category. 
 Age of dogs Sex of dogs 
Breed 
Minimum 
age 
Maximum 
age 
Mean 
age 
Total 
females 
Female 
(entire) 
Female 
(spayed) 
Total 
males 
Male 
(entire) 
Male 
(neutered) 
Unknown 
sex 
Total 
number 
of dogs 
Newfoundland Case 4 m 12 yr 3 yr 3 m 53 27 26 45 24 21 1 99 
Newfoundland Control 5 yr 13 yr 7 yr 6 m 93 40 53 45 30 15 34 172 
Labrador Case 1 yr 12 yr 1 m 5 yr 3 m 68 23 45 51 25 26 5 124 
Labrador Control 5 yr 13 yr 7 yr 3 m 76 43 33 87 62 25 2 165 
Rottweilers Case 1 yr 10 yr 3 yr 4 m 30 17 13 22 19 3 5 57 
Rottweilers Control 5 yr 14 yr 7 yr 2 m 26 20 6 24 21 3 31 81 
Staffordshire Bull Terriers Case 1 yr 10 yr 4 yr 2 m 6 1 5 5 3 2 2 13 
Staffordshire Bull Terriers Control 5 yr 8 yr 3m 6 yr 4 m 19 11 8 19 15 4 0 38 
           749 
Key: yr = years, m = months 
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II. Sample submission form which accompanied each sample submitted 
Appendix 2. Sample submission form which accompanied each sample submitted 
  
Client Name..................................... ..............................   
Age.............y..............m                        Gender:     M         F   
Neutered/Spayed:  YES     NO   
Referring Clinician...............................................................   
Address....................... ............................................   
..................................................................................   
Tel...............................................................................   
Canine cruciate disease in  
Newfoundlands 
  
  
  
  
  
  
  
  
  
  
Kennel club number      .....................................................................................................   
Age of onset       .....................................................................................................   
Family history       .....................................................................................................   
Bodyweight       .....................................................................................................   
History of trauma     ................. ...................................................................................   
Owner Name       .....................................................................................................   
Dog Name       ............................................. ......................................................   
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Cruciate information 
Age of onset (index joint)  ..............................................days/weeks/months/years 
Age of onset (contra lateral joint) ..............................................days/weeks/months/years Joints 
affected:        LEFT  RIGHT          BOTH 
 
Radiographic findings (if available) 
Index joint  Effusion  Osteophyte  0       1       2       3      
Contra lateral joint Effusion  Osteophyte  0       1       2       3      
 
Synovial fluid analysis (if available) 
Index joint    WBC ............. x109/L      PMN’s ............... % 
Contra lateral joint  WBC ............. x109/L      PMN’s ............... % 
 
Surgical findings 
Partial tear     Complete tear 
Med. Meniscal injury    lat. Meniscal injury Lat. Meniscal inj r  
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Information sheet for owner 
Great advances in veterinary medicine have been made recently and many of these have 
centred on new developments in body imaging, new treatments and surgical procedures, 
and the identification of genes which cause disease. Major developments in molecular 
biology have taken place in the last few years, making it possible to quickly analyse the DNA 
of both humans and animals. This is helping scientists work out what the underlying causes 
are for diseases and why some individuals become ill, whereas others remain well. Many of 
the diseases seen in companion animals including dogs, cats and horses are caused by a 
combination of genes from their parents (this is often referred to as “nature”) and the 
external or environmental factors they have experienced during their lives (this is called 
“nurture”). 
Most scientists now accept that for the majority of features about ourselves and our animals 
are the result of a mixture of nature and nurture. For example, body weight, and height are 
in part caused by which genes are inherited and in part caused by our nutritional intake. In 
the same way, diseases such as diabetes in dogs, sarcoid in horses, and renal failure in cats 
are likely to be caused by a combination of both nature and nurture. The analogy often given 
to explain why such diseases develop is that of requiring both seed (nature) and the soil 
(nurture) before a plant can grow.  
If researchers can determine which environmental factors (for example vaccination, diet, or 
drugs) and which genes interact together to cause disease, we may be able to make huge 
strides in improving animal welfare by, for example, advising owners which food their pets 
should have or avoid in order to reduce risk of developing a particular disease. 
Researchers from all six UK Veterinary schools are now beginning to investigate the genetic 
and environmental factors underlying a wide range of diseases in companion animals. To do 
this it is important to collect large numbers of DNA samples from animals where the clinical 
features of the disease are clearly defined. The Vet Schools in the UK have agreed to work 
together in assembling one national UK DNA archive to avoid many small or duplicated 
sample collections. 
The information collected will be kept strictly confidential. The samples and clinical data may 
be made available, through application to a review committee, to bona fide research groups 
working on projects that are ethically sound. It is also possible that samples will be made 
available to research groups working in partnership with non-academic industrial partners. 
The DNA samples being submitted to the archive will be usually derived from blood leftover 
from routine pathology tests being performed. Samples will only be included if the owners 
give their written consent. The sample will be anonymous once it is entered in the archive. 
The owner retains the right to remove the sample from the archive in the future if so wished. 
No information regarding tests performed on the DNA sample will be given back to the 
owner. This is because it will only be possible to find out which genes and environmental 
factors are important by identifying patterns in large numbers of affected and unaffected 
animals.  
Should you require further clarification of any issues raised please contact Wendy Hallows 
Archive coordinator Tel: 01517947208 whallows@liv.ac.uk  
 
 
  
- 274 - 
 
 
Owner Informed consent 
 
1. I have read and understood the accompanying leaflet explaining the UK DNA archive for 
Companion Animals 
 
2. I appreciate that in order to advance our understanding of veterinary diseases there is a 
need to determine how a particular condition relates to the genetic profile of the 
animal 
 
3. I understand that any genetic tests relating to my animal will not provide specific 
information about its condition but will contribute to the general body of knowledge 
about the disease in the species. I realise that no specific information regarding genetic 
tests on my animal will be reported back to me.  
 
4. I agree to DNA being extracted from blood that may be taken from my animal for the 
agreed clinical investigations and that is surplus to requirements for clinical tests. I 
agree that this will be used entirely for research purposes. I give consent for the 
material to be stored and made available to bona fide scientists in the field of animal 
disease and genetics.  
 
5. I understand that all information I give will be held in strict confidence and the source of 
the archived DNA will not be divulged  
 
6. I understand that this research will not benefit my animal directly, but in the future may 
be of benefit to other animals.  
 
7. I understand that the custodianship of the DNA resides with the University of Liverpool 
but I retain the right to remove my animal’s sample from the archive in the future if so 
wished.  
 
 
Signed.....................................................    Date.................................... 
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III. Table detailing full gene name and abbreviation 
Full gene name Abbreviation 
Aggrecan ACAN 
Anoctamin 4  ANO4 
Biglycan BGN 
Calsytenin 3  CLSTN3 
Cartilage oligomeric matrix protein COMP 
Cathepsin K CTSK 
Coiled-coil domain containing 85a  CCDC85a 
Collagen type I COL1A1, COL1 A2 
Collagen type III COL3A1 
Collagen type V 
COL5A1, COL5A2, 
COL5A3 
Collagen type VI COL6A1 COL6A3 
Collagen type XI 
COL11A1, 
COL11A2 
Collagen type XII COL12Al 
Collagen type XIV (also named Undulin) COL14A1 
Collagen type XXIV COL24A1 
Cytochrome P450, family 39, subfamily A, polypeptide 1  CYP39a1 
Decorin DCN 
Disrupted in Renal Carcinoma 2  DIRC2 
Elastin ELN 
Fibrillin 1 FBN-1 
Fibromodulin FMOD 
KALRN Kalirin 
Latent-transforming growth factor binding protein B2 LTBP2 
Leucine rich repeat transmembrane neuronal 3  LRRTM3 
Lysyl oxidase LOX 
Matrix metalloproteinase - 1 MMP-1 
Opticin OPTC 
Popeye domain containing 2  POPDC2 
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 PLOD-1 
Ring finger protein 152 RNF152 
Semaphorin 5b  SEMA5B 
Serpin peptidase inhibitor clade B (ovalbumin) member 13  SERPINB13 
Serpin peptidase inhibitor, clade H member 1 Serpin-H1 
SIX homeobox 1 SIX-1 
Sortilin-related VPS10 domain containing receptor 2  SORCS2 
Stabilin 2  STAB2 
Syntaxin binding protein 5 like  STXBP5L 
Zinc finger DHHC-type containing 23  ZDHHC23 
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IV. Primer and probe sequences for the replication study detailed in 
Chapter 4 
Appendix 3. Primer and probe sequences for the replication study 
Plex 
# 
SNP_ID 
Forward Primer  
(5' - 3') 
Reverse Primer 
 (5' - 3') 
Probe 
(5' - 3') 
1 rs22051140 
ACGTTGGATGGACAG
GTATAGGTTCTAAAC 
ACGTTGGATGCTTCTC
AGATCATCCTCTCC 
CATCCTCTCCTCACCAA 
1 rs24496570 
ACGTTGGATGAGTAC
AGCCAGAGAACACAC 
ACGTTGGATGGGCCC
CAGAACACCAATATC 
TTAGCTGTGCCACAGAC 
1 rs23827731 
ACGTTGGATGCTTAG
GGAATTATGCTTGGG 
ACGTTGGATGTGATCC
CATCCTAACTCAGC 
CCTAACTCAGCATTTCCA 
1 rs9063975 
ACGTTGGATGCCAGT
GGCCTATTATGTTCC 
ACGTTGGATGGTGGG
ACTGTGATTAGGAAG 
CAAGTGCTGTAGGTGATT 
1 rs21971362 
ACGTTGGATGTTCCCT
TCCCACTTACGTAG 
ACGTTGGATGTCTTCG
TGTGTTGTTCTCCC 
TGTTCTCCCCAAGGGTACA 
1 rs23801997 
ACGTTGGATGCCCTGT
GTAAATCAAAGCTG 
ACGTTGGATGCGGTT
GGGATCGCTTTTAAC 
TATACAGGGACGGAAGAAG 
1 rs23048918 
ACGTTGGATGCTTGA
GGCTGTAGGATTTGG 
ACGTTGGATGGAAAA
TGTGGTAAACTTCCAG 
GTAAACTTCCAGAAATGGTC 
1 rs23935034 
ACGTTGGATGAAGGA
GTCTGCTCAGATGTG 
ACGTTGGATGAACCAC
CTTCTAATGCCAGC 
CTTTCTAATGCCAGCCTCATA 
1 rs9094558 
ACGTTGGATGATGTCC
TCGAGTTCTGTGTG 
ACGTTGGATGTTGCAC
TAAGAAACACAGGG 
CCAAGAAACACAGGGCTCTAC 
1 rs8568925 
ACGTTGGATGGGTGT
TCTTTGAATGCCGTG 
ACGTTGGATGGGAAC
ACCATGCACATGAAG 
CAGGGGATAAGGATCCCGTGA 
1 rs23813763 
ACGTTGGATGAATGCT
TGGTTGGACCACAG 
ACGTTGGATGAAATCC
TGCAATTTCGTGGG 
CTCGCGGGGTTTAACGGCCAAC 
1 rs23795335 
ACGTTGGATGTTGACA
GACAGTGGGAACAG 
ACGTTGGATGCCCAG
GGATTTCCTTCCAAA 
GGTAAAAGTGCAAGGGACTAAG 
1 rs23566023 
ACGTTGGATGACCAAT
GATGTGTGTGTCTG 
ACGTTGGATGTTTTGA
GGATGTGGCTCTGG 
GCAGTGTGCACGCCTTCCATTTG 
1 rs22074260 
ACGTTGGATGGGAAC
AAAAATAATGAGCTG 
ACGTTGGATGAGCTG
GTAGATAACTGTGTC 
AACAGAAAAGTTGCATTTGATTT 
1 rs23812432 
ACGTTGGATGATTAAT
GGATCACAACCTGC 
ACGTTGGATGGACATC
TCTTTTTCTTCAG 
CATCTCTTTTTCTTCAGATATTTT 
1 rs23835082 
ACGTTGGATGTGGGT
AGACTGAAAGCAAAC 
ACGTTGGATGAATGTA
GGGAGCTGAGAGCG 
ATAAAAGCTGTTTGGCCAGAATTG 
1 rs23333120 
ACGTTGGATGGGGAT
ATGGGTATACAAGGG 
ACGTTGGATGACACTC
CCTTCCTCATAGAC 
CTACCATGACGGTGAGTCTATCTC
C 
1 rs23829198 
ACGTTGGATGTATCAC
CAAGTGGTTGCCTC 
ACGTTGGATGGAGGA
ACAGAAAGGAGGAAC 
CTGAACAGAAAGGAGGAACTAAT
GT 
1 rs9253138 
ACGTTGGATGTACTTC
TTGACATTCCGGAG 
ACGTTGGATGGGGCC
ACTGGTTTATAACAC 
CGCCACTGGTTTATAACACATACTT
C 
1 rs22418471 
ACGTTGGATGACATCC
TCACCAAACTCAGC 
ACGTTGGATGCGCAC
ACATCATAGAGAAAC 
TGAACAAAATTATGGGCAATCCTG
TC 
1 rs22017302 ACGTTGGATGAGTAG ACGTTGGATGCCCACC GAAAAGTTAGAAGATGCCAGGGA
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Plex 
# 
SNP_ID 
Forward Primer  
(5' - 3') 
Reverse Primer 
 (5' - 3') 
Probe 
(5' - 3') 
GTTCTTTGTAGAGGC GTATGATTACTCTG CAC 
1 rs21960910 
ACGTTGGATGGAAAT
AAAAAGGTCTACGGG 
ACGTTGGATGTAGAAT
CCTGCTTCCAGCAC 
CTCTCCCAGCACTCTGTAAAAGCA
AAA 
2 rs8748659 
ACGTTGGATGGGCCT
CAGTATTACAAAGAC 
ACGTTGGATGGATTTG
ACATCAGAGATCAC 
CACTTTCATGCTTCGTC 
2 rs23804256 
ACGTTGGATGCCAGTA
GCTACCATTTGTGC 
ACGTTGGATGAGCCA
ATAATGGTTGCAGGG 
TGCAGGGATGGCTTTTA 
2 rs23835584 
ACGTTGGATGTATTCA
GGACTGCGTCCTTG 
ACGTTGGATGACGCTA
GACTCATACACCTC 
CTCATACACCTCAAGAGA 
2 rs21956708 
ACGTTGGATGCAGCC
ATGATACCTGAACTC 
ACGTTGGATGTCCTCA
AATGACATCACCCC 
TCATTCTCCCCACAGCAGG 
2 rs23569097 
ACGTTGGATGGTATG
CAAGGCTGGGAAAAG 
ACGTTGGATGAACCA
AACACAGAAGTCCCC 
TGCCCCACTGTAAAGGTGA 
2 rs21976781 
ACGTTGGATGTCCCAC
TCCCTCTGCTCCT 
ACGTTGGATGCTGTG
GACTGCTTTATGAATC 
TTTTTGAGAGAGTGTGAAC 
2 rs22035867 
ACGTTGGATGAAAGA
ATCTCGTGAGTGAGG 
ACGTTGGATGTCAAAA
CAGGCTCCCCATAC 
CCCCATACTCTACATGGAAA 
2 rs8987872 
ACGTTGGATGTGCGT
GGTTAACAAAACTGG 
ACGTTGGATGGATGC
TTCTGCAAGAAAGGG 
CCTTGGCCTCAACGTATCCCA 
2 rs8498499 
ACGTTGGATGCCTGAA
GCTGAGTGAGGTTG 
ACGTTGGATGAAAAT
AGCCGGTCTGGCTTC 
AGCCGGTCTGGCTTCTATTCT 
2 rs24526391 
ACGTTGGATGAGTGA
GATACTAACCTGGAG 
ACGTTGGATGCACTCA
AGTAGTGACATCATC 
GAGTTTGTGACAATCAAGTTA 
2 rs22030434 
ACGTTGGATGTGGAA
AGCAAAGTGAGGCTG 
ACGTTGGATGAGTAA
CTGTGAAAACTTGG 
CTTGGATCTAATTGAAGCTCCT 
2 rs21882305 
ACGTTGGATGATTTTG
CATTTCCTCTTCC 
ACGTTGGATGCATCTC
TCCATGGACCAAAG 
TTCCAGAGATAGAGAAATAGAT 
2 rs21880947 
ACGTTGGATGGCTGA
CTTTCTCCTTGAGAC 
ACGTTGGATGGGCTT
GGAACATTCCTTCAG 
TTTCCTTGTTTACTAGAGTACTG 
2 rs24114482 
ACGTTGGATGGTATCA
ATCCAGGCAGCCAC 
ACGTTGGATGCATACT
TCCAAATCTTCGGTG 
CATCTTCGGTGATAATGGAGACA 
2 rs9122813 
ACGTTGGATGGGCTTT
CACCTGCACAGTTA 
ACGTTGGATGCAGCAT
TCAGAAGACTGAGC 
GGAATGTTGCAGCCTAAAGTACCC 
2 rs23828846 
ACGTTGGATGACTGCA
GACTTCCTATCTGG 
ACGTTGGATGAGGTC
AATCAGACAGTGGTG 
GGCAATCAGACAGTGGTGAGCAG
C 
2 rs21946491 
ACGTTGGATGGCCCTT
ATAAAAGGTCATTGC 
ACGTTGGATGTTCCTT
CTAGAGGAATATCG 
GGAAGAGATAAAGAGAAAGAAAC
A 
2 rs21895425 
ACGTTGGATGCACCAA
TTAGTGCACAAAGC 
ACGTTGGATGCGAGG
CTCATTAGTAATCTC 
TTGATTTCTTCTGAAAGTAAGTCAA 
2 rs23800347 
ACGTTGGATGTGGAG
TTTGAAACCCAAGCC 
ACGTTGGATGAAACT
GGGAAATTCTGAGAC 
GGAACTTCTGAGACTAGAATTCAT
CG 
2 rs23798518 
ACGTTGGATGTCATAG
ACGCAGTACATGCC 
ACGTTGGATGTGAGA
TGTGGAGTGTGGTTC 
CATTCCTGGGGAAGATGCTTGATG
GT 
2 rs21882298 
ACGTTGGATGCTCGAT
AATAAGATAGCCAC 
ACGTTGGATGCACTAA
CACTCAAGGACTTTG 
CCCCATAAATCCATTCTGAGCTTAG
TT 
3 rs23799015 
ACGTTGGATGTGAGA
AAAGCGATGAAGCTG 
ACGTTGGATGTCACAA
TGTGGACCTGAACC 
TGAACCTTCCAACCTCC 
3 rs23048917 ACGTTGGATGGCACA ACGTTGGATGAAACCC GGTGTGAGCACTGTCCC 
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Plex 
# 
SNP_ID 
Forward Primer  
(5' - 3') 
Reverse Primer 
 (5' - 3') 
Probe 
(5' - 3') 
GGCGATAAAGCTTTC ATGATGCCTCACTG 
3 rs23811087 
ACGTTGGATGCCCAG
GCATCCCAGTTAAAG 
ACGTTGGATGAGCCCT
TTCCTACTTTTACC 
CCATTTAGTTGTCACTCC 
3 rs21973355 
ACGTTGGATGAGTACC
ACACGTGTTCTCTG 
ACGTTGGATGATCAGT
GCTCTCACACCTAC 
GCAGTGTACGTTAGAGTT 
3 rs22184669 
ACGTTGGATGACCTGT
AAGTTACCTCTTTC 
ACGTTGGATGCTATGA
ATTCATACTCCTGGC 
TCATACTCCTGGCATAAAA 
3 rs8959368 
ACGTTGGATGAGTGC
TCCTGACTTCCTCTC 
ACGTTGGATGGGTATT
TTAGTGAGTGCCTG 
GTAGTGCCTGAGAGTGAGA 
3 rs23605299 
ACGTTGGATGAACAA
AAAGGAGGAGAAGCG 
ACGTTGGATGTTCCTG
AGACGTAGGAGGAG 
ATTCTGAGGCGATCGGATTC 
3 rs23806044 
ACGTTGGATGCCAAA
GACAAGCAGGTCTTC 
ACGTTGGATGTGCTGC
TCAGCAATTCTCTC 
CGCAATTCTCTCTTCCTTTTG 
3 rs22014075 
ACGTTGGATGGCTTGT
CAAATAAAACACTG 
ACGTTGGATGACCCAT
TCCTCTATTGCCTC 
CCTCTGAATTGATGTCTTGCC 
3 rs8712319 
ACGTTGGATGCCCTTC
TTGAGAAGTTTCCG 
ACGTTGGATGGTCAA
ACTCCCCTGAAACAC 
CCCCACCCTGAAACACCCCACC 
3 rs8647709 
ACGTTGGATGGGATC
AGATTTAAAAAGGC 
ACGTTGGATGGGGCA
GTGAGTTCTGGTTTC 
ATAAAATGTCTTCCTGAACTTA 
3 rs22346338 
ACGTTGGATGTTGGA
CAGGGGTCCTCAAGT 
ACGTTGGATGTGCAG
TGTGCTGGCTTTGAG 
GGCGCGTGCCAGTGTTCATGGT 
3 rs8754330 
ACGTTGGATGAACCCT
CCTGATGCAAACTC 
ACGTTGGATGTGTGG
ATTGCTAGTGCACAG 
CCTGTTAGAAGCAATGCCCATCC 
3 rs21946171 
ACGTTGGATGAACATC
CTTAGTGTCTCTAC 
ACGTTGGATGTGCCCC
TTCAAATCACTATG 
GAGGAGCAAGCAGTGTTTCTTTA 
3 rs8613571 
ACGTTGGATGGAGAG
AGGGAGCAATATCTA 
ACGTTGGATGTGAATC
ATGAGGAAAGAAGG 
GGACTGAGGAAAGAAGGCCCTAG 
3 rs21987554 
ACGTTGGATGGGGAA
TTGCATGAAGGAGTG 
ACGTTGGATGTTCCAG
TTGCAGACTCTTTC 
TGCAGACTCTTTCTATGTATTTTG 
3 rs22383474 
ACGTTGGATGCTATAC
TCCTCCATGGAACC 
ACGTTGGATGCTGCA
GAATCTTGGTTCTGG 
CCTTCCTGGCCGTCCCTTCTTTGTT 
3 rs21998646 
ACGTTGGATGTCTCGC
TTATCTGCAAGGAC 
ACGTTGGATGGGGCA
CATTCATGAGTAAAG 
CCTACTTCTTAGAATAAGTCTCTGA 
3 rs23801537 
ACGTTGGATGCGGGA
AAAAGATTGGATACTC 
ACGTTGGATGCTAGAC
CTTTAGACTGATA 
CCGACTGATATTTAAAGCAAGAAA
T 
3 rs21977372 
ACGTTGGATGTCAGA
GCAGGACTCACTTAG 
ACGTTGGATGGGAGT
ATTGTAACCTTTCTAC 
CTTCACCTTTCTACTAATAAAAACC
T 
3 rs22380841 
ACGTTGGATGACAGT
AGCCCTAGATCTAAC 
ACGTTGGATGGTGATT
CTGGATACATTGCC 
GGTTTAATGACTGTCAAATTCTTG
AA 
3 rs21880470 
ACGTTGGATGCTCATT
GCCATTCATTCTGC 
ACGTTGGATGTCCATG
TCAGGACAGAACAC 
CCCAAAACAGCCATTTATACATATA
AT 
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V. Primer and probe sequences for the candidate gene study detailed in 
Chapter 5 
Appendix 4. Primer and Probe sequences for candidate gene study 
Plex 
# 
SNP_ID 
Forward Primer 
(5' - 3') 
Reverse Primer 
(5' - 3') 
Probe 
(5' - 3') 
1 rs23942105 
ACGTTGGATGAAACGA
TGGCAGGTGGTTC 
ACGTTGGATGTGAGTTT
CCTGTGCTTCCCC 
TCCTCTGAGAGCCCA 
1 rs24048819 
ACGTTGGATGCTGAGC
ACCCAGTACCAAG 
ACGTTGGATGCGCCTG
GTGTGACTCTATTC 
CACTGAGGGGTTTCC 
1 rs22868921 
ACGTTGGATGTACAGA
AGACCCTGTGGATG 
ACGTTGGATGACAGAG
GCCAGGCCCGTCAA 
CGCCCCCTCGCACGCC 
1 rs24260515 
ACGTTGGATGGAACTT
AGTCCCCTATACAC 
ACGTTGGATGACCCAAT
GGACATCTAAGAG 
GCGTGCGTGCGTGCAT 
1 rs24469329 
ACGTTGGATGTACTCG
AGCTCACATATCCG 
ACGTTGGATGTAGCTCT
TCTGTGCTTGCTC 
GGCCAGTTCCTCCTCTT 
1 rs22255739 
ACGTTGGATGCTTTTCC
AGCTGTTCCAGTC 
ACGTTGGATGAGGGAG
CAGCAGGAGAGAC 
CCAGGGCCCCCAGGACC 
1 rs24535768 
ACGTTGGATGCCTGGT
GAATAATAAGAGGG 
ACGTTGGATGTTAGGG
AAGGGTCATCAGAG 
CTTGGAGAATTGCATGG 
1 rs24730359 
ACGTTGGATGTCTCTG
GCTTCAGGTTGTTG 
ACGTTGGATGAGCTACT
GGAGATGATGAGG 
GCCAGCGTCAAGTACCAG 
1 rs22957764 
ACGTTGGATGTATCCC
CTGCTCAGCTTTTG 
ACGTTGGATGCTGTGTC
CTAGCAGGGACAT 
CTGCCTGCCCAGCAGTCCC 
1 rs9049305 
ACGTTGGATGCCTTGG
AGATCTCTTGACTG 
ACGTTGGATGACTTACA
TTGGCTCCAACAG 
GTTGCTCCAACAGGGCCCA 
1 rs8721918 
ACGTTGGATGAGCTTT
CTGAAGCCAGAGTC 
ACGTTGGATGTGGCCCT
GACACCTTCTTG 
GACGTCTTGCCAGGAGGGT 
1 rs8652327 
ACGTTGGATGGTGAAG
TAATGGTCTGCTGG 
ACGTTGGATGGACCTT
GGACTCCATCTCTC 
CCCTCATCTCTCCCTGCGGG 
1 rs22229903 
ACGTTGGATGCTTCCA
CGGTGTTGAAAAGC 
ACGTTGGATGAGCCGT
GTGAGCGTATATTG 
TGAGATTGCGAAGACTGCTA 
1 rs8867454 
ACGTTGGATGTGATCA
CCTTTGTCACCTCG 
ACGTTGGATGAATTATA
GTCTCACCAAGC 
TGTATCACCAAGCAATATCCA 
1 rs23527990 
ACGTTGGATGTATGAC
GCCATCTGCTACAC 
ACGTTGGATGTTCTAAG
CTCCCCTCCTCTG 
GCACCAATTTCCGTGGTGCTA 
1 rs22876135 
ACGTTGGATGTCACGT
AATGTCACTTTGGC 
ACGTTGGATGCTTTCCT
GTGTTGAGAGGTG 
TGTGTTGAGAGGTGAGATCTA 
1 rs24048798 
ACGTTGGATGGGCCAC
TGCTGCTAGCTCA 
ACGTTGGATGAGTCTGT
GCCTTTGGCAGGT 
GCAAGGTGGTGAGGCCCCTTGC 
1 rs8706610 
ACGTTGGATGAGACGG
GAATGCATGGAATG 
ACGTTGGATGACAACG
TTTTGCAAGAGCAG 
ACAAAACAGTTCCCTTGTTTAAT 
1 rs24546719 
ACGTTGGATGGGGTCC
GGGAAGTCCAGG 
ACGTTGGATGTGCCCTC
TCCCCTCCGCTG 
GGTTTTGGCCGAGATGGCATCCC 
1 rs22578989 
ACGTTGGATGTTTGCA
TGGATAACTGTGCC 
ACGTTGGATGGTGAGT
ACTCTGCTTCACA 
GGGGTTGCTTCACAGCAGCTAAT 
1 rs8957513 ACGTTGGATGCTCAAG ACGTTGGATGTTGAGC GGACAAGGTTATGATGTCAGGGT 
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Plex 
# 
SNP_ID 
Forward Primer 
(5' - 3') 
Reverse Primer 
(5' - 3') 
Probe 
(5' - 3') 
CAAACTCTGTGCTG ATCAGACTCAAGGG 
1 rs22270010 
ACGTTGGATGGTCATG
TCTGACTAATGGAG 
ACGTTGGATGGAGCTG
AGGCTAAAGTAGAG 
TTTGAAAGTGAACCTCTTTCCCAA 
1 rs22402697 
ACGTTGGATGGTCCTT
TGTCAGTTTTTTTT 
ACGTTGGATGTCTCCCT
CTTTCTGTGTCTCTGC 
TTGCATCTCTCTCTCTCTATCTCTG 
1 rs8907726 
ACGTTGGATGCCAAGT
CCCGTTATTCTCTC 
ACGTTGGATGTGATCG
CATCCAACTTGCAG 
GGGATCAACCCAGTACTCTCCTGAA 
1 rs22214751 
ACGTTGGATGAAATCC
TTGGGTGAACCACG 
ACGTTGGATGTGGATG
TCCACCTGTTGAAG 
ATCTAGTTGACATTAAAAAATGATT
C 
1 rs23269193 
ACGTTGGATGTTCCTG
GTCCTCATCTCATC 
ACGTTGGATGGCAACA
CCAAACTGCTTGAG 
CCCTTCTGCAGAATCATCTACTTCA
TC 
1 rs24324848 
ACGTTGGATGTTTGGC
ACCAGATGAACCAG 
ACGTTGGATGGTTAGG
GAATTATTACTCAG 
AATGATTATATTCTTACTTTTTCTCT
A 
1 rs24535784 
ACGTTGGATGGTATTT
ATTGTGAGGGATTGG 
ACGTTGGATGCTGCCTT
TAGACTTCACTGC 
GGGTTGGACTTCTCAGGCTCCATAT
CT 
1 rs8615753 
ACGTTGGATGCTCTCTC
TCTGTGACTATC 
ACGTTGGATGAGCAGC
CTATCTCCATTTTG 
CCCATTTTGGTTTTTTTTTTAACTTTT
T 
2 rs22197326 
ACGTTGGATGTGGGTG
TCGGTAGGAGACAG 
ACGTTGGATGAAGCAA
GGCTCAGAGCAAAC 
CACAGTCCCCCACAC 
2 rs23644868 
ACGTTGGATGATGCTA
GGCCACAAAATAAG 
ACGTTGGATGTCAGGG
TCAAGTGTTTGAGC 
GCCTCATGTCGAGTG 
2 rs22816235 
ACGTTGGATGGTTAGG
AAAGCCCGTGTGTG 
ACGTTGGATGAAGGGA
ACACAGGTCCCAC 
ACTCCCCTTCATGCCC 
2 rs22330976 
ACGTTGGATGGTATGC
AGAAAGTTATGAG 
ACGTTGGATGGCTAATT
ACCATCTCCCTCG 
CTCTCCCTCGGCATTG 
2 rs24048807 
ACGTTGGATGTAGAGA
CCATGCAGACAGAC 
ACGTTGGATGTTGATG
GGATTGCCATCCAG 
GGGATGTCTTCCAGCC 
2 rs24048794 
ACGTTGGATGAGCCAA
CTGCAAAACTCACC 
ACGTTGGATGCTGTGT
GTATATGTGTGTGC 
TGCTCGGGTGTAGCAG 
2 rs22378757 
ACGTTGGATGCCCCTC
TATACCACATAAGC 
ACGTTGGATGGCAGCC
AGAAAGTTTATCGG 
ATCGGCCTTTTTTCTCC 
2 rs24448073 
ACGTTGGATGTTTCCA
CTGCTTCTGCAGCC 
ACGTTGGATGACCATTC
CAGGCCTACTGAC 
CGGCCTACTGACCTGTGC 
2 rs24754119 
ACGTTGGATGTGGACC
CTACAACAGGTAAG 
ACGTTGGATGATGAAA
TGGGAGGAGAGAAC 
TGAGGAGAGAACACTGAG 
2 rs24306291 
ACGTTGGATGGGTCCC
TACAAGAAAATGAG 
ACGTTGGATGTTTCTGT
GTGTAGCCTCAAC 
TTGTAGCCTCAACTACATT 
2 rs24770733 
ACGTTGGATGAGCACC
AAGAAACAAAATG 
ACGTTGGATGCCCGTA
AGTTGTGATCATGC 
ATGACTGTATAGCTGAACT 
2 rs23624676 
ACGTTGGATGCATCTTT
GTGGTCTCAGAAC 
ACGTTGGATGCCTTTTC
TGTAACTTTTCTC 
AACTTTTCTCTTGACATCAT 
2 rs8686504 
ACGTTGGATGCAGAGA
TTTAGATGCCCTGC 
ACGTTGGATGATATCTG
GACCACCCGTCAC 
ACCGCCACCCCCCTGGGGTA 
2 rs24278934 
ACGTTGGATGCTAGCC
AAGGCAGTATGAAG 
ACGTTGGATGGTGCAC
CATCTCTTTCTACC 
CCTAGAGAGAACATTCTAGAT 
2 rs24602445 
ACGTTGGATGAAAAGG
GAGAACCTGCCATC 
ACGTTGGATGACGACC
CACATGTCTTGCAG 
TGGGATAAGAAAATGCCTTAC 
2 rs24306964 ACGTTGGATGGTTTTT ACGTTGGATGAGGCCT CATCTCCAGAGAGACCTCTTCC 
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Plex 
# 
SNP_ID 
Forward Primer 
(5' - 3') 
Reverse Primer 
(5' - 3') 
Probe 
(5' - 3') 
ACTGGGTTACAGGG GTCTCTCCTTTTTC 
2 rs22919040 
ACGTTGGATGTAAAAA
TGGCCTCCTGGTCC 
ACGTTGGATGCTTGGCC
TCTAGCAACTCAC 
GGCGCTAGCAACTCACCTTCTT 
2 rs8946670 
ACGTTGGATGAAATGA
GCAGTGGATCCGAG 
ACGTTGGATGAGGTTC
AGTACCTGGTCTCC 
GTAACTGGTCTCCCGTCGCTGTA 
2 rs23906411 
ACGTTGGATGTGCTGT
GTCTATATACTCTG 
ACGTTGGATGCGGTAG
GACCCTGAAGAAAA 
AATTTTAGAGGTAAAAAAGCATC 
2 rs24560587 
ACGTTGGATGGATTCC
AGGTGAGGCCTCAT 
ACGTTGGATGGAGAGC
AGGATTAGAATCAG 
AACAAGGACAAAGGGGACCCCATA 
2 rs24575600 
ACGTTGGATGATATCC
ACGATGGGCACTTG 
ACGTTGGATGTGCTTCC
CAGACGAAGAAAG 
GCATACGAAGAAAGGGTATCAGAA 
2 rs8697617 
ACGTTGGATGGCTCTC
AGAATTCAGCAACC 
ACGTTGGATGGGTGAA
CAAAACCATTAACCC 
TAAAAAAACCATTAACCCCAAACAC 
2 rs22842378 
ACGTTGGATGCTTATCT
CCATCTCAGGGTC 
ACGTTGGATGTATCACG
TACCTTCACACCC 
CCCACCCCGAGGTCCAGGATAGCC
C 
2 rs24748955 
ACGTTGGATGGAGTAT
ATCTGGGAATTTC 
ACGTTGGATGGGGCCC
ATCTGGAAATATAG 
TGCAATAAAATATCTTTCACATATA
A 
2 rs8946915 
ACGTTGGATGGACAGA
TGGTATATAAGACAC 
ACGTTGGATGGAGCTC
TTGTCCACTTAAAC 
CTTCAACATTTAGCAATAGTGCAAT
T 
2 rs8879536 
ACGTTGGATGAATATT
CCACCACTGGTCTC 
ACGTTGGATGCCGTGG
AATTAGTGGTGTTC 
GCCGTTGAGTGTAAGTTACTCGATT
T 
2 rs22929544 
ACGTTGGATGAAGACA
AAAGGAGGAGGCAG 
ACGTTGGATGAATCCTC
CTTTGTTCCCCTC 
CTGTCCCCTCCCCAGACTAGGCATT
C 
2 rs9222557 
ACGTTGGATGGTTTTTT
TTGGTTTTGTTTG 
ACGTTGGATGCAGGTA
ACATATTTTCTCC 
TTCTCCATGTCTTTTTATTTTTCATAT
A 
2 rs22786371 
ACGTTGGATGAGAGG
AGGTCCCTGTCCCCA 
ACGTTGGATGGAAGAA
ACAAGTCTGCCCTG 
TGGACGAAACAAGTCTGCCCTGGG
ACGA 
3 rs23627318 
ACGTTGGATGGCACAT
ACTGCTTCTCTTCC 
ACGTTGGATGAGCACC
TTTATGCCTCACAC 
CCTCACACTCAGGCT 
3 rs24654871 
ACGTTGGATGCTTAGG
GAGGGGAGCTGGG 
ACGTTGGATGAGGCAC
TGCGGACAGAGAGA 
AGAGGGGCGGCCTCC 
3 rs24299845 
ACGTTGGATGACCCCG
TATGGACAATAAGC 
ACGTTGGATGAACCTG
GAGAAGCAGGGAAC 
AGCAGGCACAGGCGT 
3 rs23942103 
ACGTTGGATGAAACGA
TGGCAGGTGGTTC 
ACGTTGGATGTGAGTTT
CCTGTGCTTCCCC 
TGCTTCCCCGGCTCCT 
3 rs8721919 
ACGTTGGATGAAGCAG
CACAAAGCAGTGAC 
ACGTTGGATGATGGAG
AGGGATGAGAGGAG 
TTGGCCCTGACACCTTC 
3 rs8861243 
ACGTTGGATGGGGAG
GTATGAGATCAGAGC 
ACGTTGGATGGAATGA
ACAGAAACCAGGGC 
CATAAGAGTCCTCGGTT 
3 rs22930994 
ACGTTGGATGTTCCTTC
CTTTGGGTCCTTC 
ACGTTGGATGCAGGGG
ATACTTACCTTGGC 
ACTTACCTTGGCTCCTTT 
3 rs22597612 
ACGTTGGATGAACTCC
TCCAACTAAGCCAG 
ACGTTGGATGTCAGAT
ACTGTGCTAGGTGC 
GCTAGGTGCTAGAGACAG 
3 rs22217603 
ACGTTGGATGAACAGT
GACTTACAGGCTCC 
ACGTTGGATGCATGTGT
GTCTCCTTCAGGC 
CTCCCCTTCAGGCTGCCCG 
3 rs9222556 
ACGTTGGATGATGGCA
CCCATTGGACCAGT 
ACGTTGGATGGTTGTA
GGTTTCTCATACTG 
ACCTCATTTTTGCTTTAGG 
3 rs24029016 ACGTTGGATGGCATGT ACGTTGGATGTCAGGA GGAAAGAGGATGAGAAATG 
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Plex 
# 
SNP_ID 
Forward Primer 
(5' - 3') 
Reverse Primer 
(5' - 3') 
Probe 
(5' - 3') 
GCAGAATGTCCTTC GCCGTAAGGTTTTC 
3 rs22861513 
ACGTTGGATGGCCATC
ACAGACACAGTTTC 
ACGTTGGATGTCTCTGC
CATCCTCTATACC 
TTAGCACACACACAACCCAA 
3 rs22738485 
ACGTTGGATGAACTTC
TTCAGGAGCTCTCG 
ACGTTGGATGTCTGTG
GCTGCAGTTATGAC 
TGCAGTTATGACGTGGTGTT 
3 rs22190862 
ACGTTGGATGCATCTG
CCCTGTATGCTGAG 
ACGTTGGATGAATGGA
AAGGGTTTTGCTTG 
TGAAAGTACTAATGTTTCCTT 
3 rs24566255 
ACGTTGGATGCAGTGC
TATTGACAGTAGCC 
ACGTTGGATGATACCAC
ATCTGCTTTATCC 
CCAATCTGCTTTATCCGTTCAT 
3 rs8824603 
ACGTTGGATGACTATG
GCTCCAAGGAGAAG 
ACGTTGGATGTGTATTC
AATGGCACTGCCC 
CCCTATGTGTCATTCTTCTGCT 
3 rs24278947 
ACGTTGGATGATTGGA
AGTGTCAGAAGGTG 
ACGTTGGATGCTTATAA
GAGTTCTGCTGCC 
GTCTGCCAAATCTTCTGTAATG 
3 rs22239815 
ACGTTGGATGATTGCA
TCAAAGTTGGCCAC 
ACGTTGGATGCTGCAG
ATGCAAAAGAACTC 
GGGCAAAAGAACTCAAACAAAT 
3 rs22184922 
ACGTTGGATGCGCCTT
CATCCTTGAGTTTC 
ACGTTGGATGGGTGTT
CTCATCACTGATGG 
CGGATGGAAAATCACAAGATGA 
3 rs8680883 
ACGTTGGATGAACAGG
ACGTCTTGGTCCC 
ACGTTGGATGGTGGGA
CCTTTGTATGCATC 
GTACCTTTGTATGCATCTCCCTCC 
3 rs8945015 
ACGTTGGATGGAAGCT
CTTGCAGTGTTGTC 
ACGTTGGATGTCACCTT
CTGTGTGCTAGAC 
CTTTGGCACTTCGAACCACTGCTT 
3 rs24736591 
ACGTTGGATGTGTTTA
CATGTTGGAACAC 
ACGTTGGATGATCTTGA
GGCTGATGAAGTC 
TGTTGACTTCAGTTTAACTAATGG 
3 rs9095802 
ACGTTGGATGACACTC
ACCTTGTCCCCATC 
ACGTTGGATGAGGGAA
AGATGGGATCCCAG 
GGGGTCCCAGGGCCCCTGGGGCTT 
3 rs24522316 
ACGTTGGATGGAACTT
TTGCAGCAGTGCCG 
ACGTTGGATGTTCTCGC
CCCCGCTGGCAC 
GATGGCACCCGCCACCGCGTCCTC
CC 
3 rs24535705 
ACGTTGGATGAAACGC
GGGTCTAACTTAGG 
ACGTTGGATGTTTCTCT
GAGCATGCACCTG 
ATGACCCATCCCCACACATGTGAAA
A 
3 rs8621422 
ACGTTGGATGTGGATG
TCATCTGTGTCTGG 
ACGTTGGATGACACTG
ACTTTGGGCACAAC 
AACTTCAAAATGAGATTTTAAGAGT
T 
3 rs24029017 
ACGTTGGATGAGGACA
TTCTGCACATGCAC 
ACGTTGGATGTGTACAC
AGACACACCGATG 
CCACACAGACACACCGATGCACAG
ATA 
3 rs22378728 
ACGTTGGATGGGGCAC
GTGACTACAGAATC 
ACGTTGGATGCACTGG
TAAAACTTTCATTGC 
ATTGCAATATCAATTTCTTTGTAAA
CA 
3 rs22309803 
ACGTTGGATGGAGCGT
GGAGAAAGAGTAAG 
ACGTTGGATGCCTTTGT
CAGGCTAATGCAG 
ACCGTTGTCAGGCTAATGCAGTGA
TAG 
4 rs23269200 
ACGTTGGATGTCCCCA
TGGCAGCGATGAC 
ACGTTGGATGACCCTGC
ACTTCTCTCTCAC 
CTCTCTCACCCCCCC 
4 rs8686503 
ACGTTGGATGGTTGAT
TGGCTGAGAGGTTG 
ACGTTGGATGCTCATCC
TCACCTTTGCTTC 
TTGCTTCCCCTCCTC 
4 rs22863806 
ACGTTGGATGAGGGAT
GACAGGCCCAGTG 
ACGTTGGATGATCCCTC
GAAGACCCTCAG 
AGGCCCCATACGTCC 
4 rs8891835 
ACGTTGGATGTTCCTG
GTCAACCTGGTGC 
ACGTTGGATGAGTAAT
GCCCAGAACTCACC 
GGATGGATGTCCGGG 
4 rs23639382 
ACGTTGGATGTGCCCA
GAAACTGCACATAG 
ACGTTGGATGTCAGGC
ACTTAGTGAGTAGG 
AGGGTCACTTCACTGT 
4 rs23589114 ACGTTGGATGTGACCC ACGTTGGATGTAGAGT GTTGTCCTGCACCCCAC 
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(5' - 3') 
Reverse Primer 
(5' - 3') 
Probe 
(5' - 3') 
TCTTGCCAAAGCAG GACCAACTGGTCTC 
4 rs24466233 
ACGTTGGATGACAGAG
GCAGAGGAAGGAG 
ACGTTGGATGGTGAAC
GAGTGCGAGCTCAT 
CGCATGCTGGCGGTGTG 
4 rs23242714 
ACGTTGGATGGGGATT
TTCCACCCAGAAAC 
ACGTTGGATGCTCTTTG
TCAAGTCTGCTGG 
CGGAGCCGGATAGAAGA 
4 rs24288752 
ACGTTGGATGGGCTTC
AGAATAAATCAGAG 
ACGTTGGATGGGGAGA
AAACATTGGTAGAG 
TCTACTGCTCTGACACTG 
4 rs24448071 
ACGTTGGATGTTTCCA
CTGCTTCTGCAGCC 
ACGTTGGATGACCATTC
CAGGCCTACTGAC 
CCCTCTACTGACCTGTGCC 
4 rs22823788 
ACGTTGGATGATCTAA
AGGCCTCTCCTTCC 
ACGTTGGATGCCAGCG
CCAGAGAACCTG 
CCCAGAGAACCTGAGAGAC 
4 rs22378703 
ACGTTGGATGATTGGG
CATGCTGAGGTTTG 
ACGTTGGATGGCCTAC
ATGCTCAGGATTAG 
CATACAATGGGTGGTTTTT 
4 rs24607603 
ACGTTGGATGAATACC
CGCCATTTGCTTCG 
ACGTTGGATGTGTTTGT
CCTTCTCCGATTG 
TTTCACTCAGCATAATACCCT 
4 rs8680882 
ACGTTGGATGTGGAGA
GGTTTAGCAAAGGG 
ACGTTGGATGATGCAT
ACAAAGGTCCCACG 
GGCCAAGGTCCCACGGGCCTC 
4 rs22308173 
ACGTTGGATGGCCTAT
ATGGATGAGGAGAC 
ACGTTGGATGTCGGCA
ACCAGTTCAACATC 
CATGGGAACCTTGCAGAATGA 
4 rs24546410 
ACGTTGGATGTAATGC
CCACCTTCTCTCTC 
ACGTTGGATGTCATTCC
CTCCTGAACCCAC 
CCCTCTGGCCGCCCTTCTCTCC 
4 rs24052183 
ACGTTGGATGTCTGTT
ATGTTCCCAGGCAC 
ACGTTGGATGCACTCTC
ATTAGATGTGCCC 
TGCCCTATTTATTTCTGCATAC 
4 rs24278933 
ACGTTGGATGCCTTCT
GGAACTCTAACAAG 
ACGTTGGATGGAGTCA
AAGATGTTTGTCCC 
CTCTGTTTGTCCCATTCAATTCA 
4 rs22372241 
ACGTTGGATGAACCAG
GATCTGGTTTTTTG 
ACGTTGGATGATTTGG
ATCCTGTCTCACTC 
CTCGCTGATGAGTCTGGCTAAAG 
4 rs22803160 
ACGTTGGATGCTGGCA
CTTAGGAGTCTAGG 
ACGTTGGATGCTGGAA
ACCTAGCAACTGAG 
GGGTACCCCCGCTCCATCCCATCG 
4 rs24221465 
ACGTTGGATGTTCCTT
GACCAGCAGAACAC 
ACGTTGGATGTGGCAG
TCCATCACCTTAAC 
TAAGTCCATCACCTTAACTAAGAA 
4 rs22320220 
ACGTTGGATGAGAGG
ACCACGTGGAGAAAG 
ACGTTGGATGCTGTCA
GTTTTCTGTAGTTTC 
TAACATGTAGTGTTTAAATATGGT 
4 rs8898239 
ACGTTGGATGTAAGTA
ACCTACCACAGGAC 
ACGTTGGATGGATTGCT
TTGAGAGGTCCAC 
CCCAACCTGGCCCAATGGGTCTAAC 
4 rs22957760 
ACGTTGGATGGAAATC
CCCAGGACAAAAGC 
ACGTTGGATGTCCTTTG
AGCTGCCACTTAC 
CATTATCCTTCCTCTCAGGAAACCT
A 
4 rs24278005 
ACGTTGGATGTGATAA
GCTCTGTGAAAGGG 
ACGTTGGATGGCTCGCT
CTTTTACTTTTGG 
ATCTTTTACTTTTGGTAAGGATAAC
A 
4 rs8679272 
ACGTTGGATGGGAAGT
ATAGATATAAGGAAG 
ACGTTGGATGAAGCCC
CAGTGTTGACTTAG 
TGACTTAGATTAGTTGTATTACAAT
G 
4 rs22555948 
ACGTTGGATGGTGGTC
CATTCTAGTGGAAG 
ACGTTGGATGCCTTAAA
CACAAGTTGGACC 
GCCAGATTACATTCCCAATCTGAAA
CT 
4 rs23537789 
ACGTTGGATGGGTGCT
GGGTAGATTTCTTC 
ACGTTGGATGCCTACAA
AGTGAAGAATGGC 
GATTAATTTTAAGTTCATGACTTTCT
AA 
4 rs24568755 
ACGTTGGATGAGCTGC
TCTGATCTCTGAAG 
ACGTTGGATGGAGGGG
CCTGATTAAGATTC 
GGACTGATTAAGATTCATTATTTCT
GAT 
5 rs24048809 ACGTTGGATGTTGATG ACGTTGGATGTAGAGA CCCGAGGAGCACAAA 
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SNP_ID 
Forward Primer 
(5' - 3') 
Reverse Primer 
(5' - 3') 
Probe 
(5' - 3') 
GGATTGCCATCCAG CCATGCAGACAGAC 
5 rs9117174 
ACGTTGGATGATCCTG
CATGAGGTAGGAAG 
ACGTTGGATGCCTTAGC
TCATAAAGCAATC 
TCTTTGCCTCAACACT 
5 rs22881468 
ACGTTGGATGTTACCC
GATCTCCTTTAGGC 
ACGTTGGATGCTCTACA
CTCTCTCTTACCC 
CCCTGGCTTCAAGGGC 
5 rs23637297 
ACGTTGGATGGCTTTT
GTTCTGGAGATTGG 
ACGTTGGATGCACAGA
ACACAGCAGAAAAC 
ACAAGGTTCATAGCGAA 
5 rs22738509 
ACGTTGGATGATTTCTC
TACCCAGAAGCCC 
ACGTTGGATGAGAAAG
CTCTGGAGAAGCAC 
AACGCGGACAAGGAGGA 
5 rs23648407 
ACGTTGGATGGTGTGA
GTGAAGAGTACCAG 
ACGTTGGATGGTTGGC
ATGAAGAATCCCAC 
CAAGAATCCCACCATGAT 
5 rs9008179 
ACGTTGGATGCTTTTG
CAGACTTTTTGTGAG 
ACGTTGGATGCTTGATA
ACTGAGGACCTGC 
TGATGGCAGGAGATTATT 
5 rs8950487 
ACGTTGGATGCAAGGT
TATCGATGAGCTGG 
ACGTTGGATGCTGACAT
CATCGCTGTACTG 
CCCTGCTGTACTGAGCCAC 
5 rs24767776 
ACGTTGGATGAGAATC
ATCTCAGCCATGCC 
ACGTTGGATGGTGGAT
TCTTGGAGCCTTTC 
AGGAGCCTTTCTTAGGGAG 
5 rs23625894 
ACGTTGGATGAGGCAG
AGACATAGGCAGAG 
ACGTTGGATGATCCTG
GAGACCTGGGATCG 
CCCCCGGGATCGAATCCCAC 
5 rs22214750 
ACGTTGGATGGACTGG
AGAGAAAAGTCTTC 
ACGTTGGATGCCTTATA
TTTGGTCTCTGGC 
TTCTATCACGGTATGAATTG 
5 rs23651397 
ACGTTGGATGTTCCTCT
GCGTGATGGTTCC 
ACGTTGGATGTAAAAC
ATGGGCCTGTCCTG 
GGAGAAGAATTCCATGAAGG 
5 rs22106265 
ACGTTGGATGTTGTAG
GGACTGAGTTACCG 
ACGTTGGATGATCGGA
GAAGAGAGAAACGG 
CCCGGGGAGAAATCTTCAACC 
5 rs24546447 
ACGTTGGATGTTGGCC
CCCTACATCCTTC 
ACGTTGGATGAAGGAG
ACATGGGCATCAAG 
AGAAAGGGTGATCGGGTAAGT 
5 rs22919923 
ACGTTGGATGAACCCC
CCCTAGTTTGATTC 
ACGTTGGATGTTAAGCC
TGCCTCAGTGTTC 
GGTATAGCCAAATGCTTTCTCA 
5 rs8703991 
ACGTTGGATGCCAGCT
TCAGGTAAAAACAG 
ACGTTGGATGAGCAAC
ACTCAGTACTTCAC 
GAGTTACCAATGTGTAAGAAGT 
5 rs22413365 
ACGTTGGATGACACTC
TGTGTGTGTATGGG 
ACGTTGGATGGCAATTT
TGTAGATTTCTCTG 
GTAGATTTCTCTGTTAATCTCAT 
5 rs23989232 
ACGTTGGATGGGAGTC
GCTAACCAATTCTC 
ACGTTGGATGATCTGGT
TCACCTGGAGTTC 
GGGTGAGGCAAGGTAAGTATTTC 
5 rs8587007 
ACGTTGGATGCTCCAT
GGGAGAAAGGGTAA 
ACGTTGGATGCTATCAT
TCCTTACTATCCC 
TTACGATCCCAAAATCTACCCATA 
5 rs8907730 
ACGTTGGATGCGAGAG
GAACACATATGGAG 
ACGTTGGATGAATTTG
GTGTGGACGTTGGC 
GGATGTTTGCTTTTTATAAACCAA 
5 rs24346522 
ACGTTGGATGAGAGA
GACGCTGTACAAATG 
ACGTTGGATGAGGAAA
ATTTCTCCTGGGAC 
CTCATGGGACATGGTATTAAAAAT 
5 rs22255738 
ACGTTGGATGCTGTTC
CCTTTAGCAACGTC 
ACGTTGGATGAAGGTG
AGTAAAGGGTCAGG 
GAATGGAACTTGTGAGGACTAGAG
T 
5 rs8893358 
ACGTTGGATGTGGCGC
TCCTGTAAGTATTG 
ACGTTGGATGTGTCATA
CTCCACACCTTTC 
CTTTAATTCTGTTTTTTTTTTCTTTT 
5 rs8785162 
ACGTTGGATGCCCGTG
TGAGTAGAATTTTG 
ACGTTGGATGTTTGGA
AAGCTGCTCAACTC 
AAGATGCTCAACTCAAATCAAGTA
AA 
5 rs23209310 ACGTTGGATGGGATAA ACGTTGGATGAACTAG GTTCCTCTTTCTGTTTTAGGGTATTC
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# 
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(5' - 3') 
Reverse Primer 
(5' - 3') 
Probe 
(5' - 3') 
CCTCGATAGCCATC AGGCTTTCACCGAG C 
5 rs8780512 
ACGTTGGATGCCCAGC
ATGACAAGTATTTC 
ACGTTGGATGACCCTTT
TTCATTCTTTTC 
TCATGAAAAACTAAGTGTATAATTC
AG 
5 rs22165230 
ACGTTGGATGCCGGCG
CTCAGTAACCTG 
ACGTTGGATGTGTCGTC
GGAGTACTTGTAG 
CCCCCCACCATGCCATCCACGCGGC
TGG 
5 rs24737225 
ACGTTGGATGGCAGTT
CAGTCATTCAGAGG 
ACGTTGGATGGAGGTT
TCAACCTAAACCAG 
ACAAGAATTTCCTATTTAGAATCCC
AAC 
5 rs22195359 
ACGTTGGATGTACAGA
CATCCCCAGAGTTG 
ACGTTGGATGTGTGGT
GTCACTGTGTGATG 
ATAGCTGACATGATTCCACATGTGT
ATG 
6 rs24619748 
ACGTTGGATGAGACTT
TAGTGCTTCCTCAG 
ACGTTGGATGTCCAGG
ATGCCTTCCTTGAC 
CCTTGACAACCACCC 
6 rs24732865 
ACGTTGGATGATACGC
CTTATCTGTGACGG 
ACGTTGGATGTTACCTT
CGAGGGTCATTCC 
GGCATCTCCAGCCCC 
6 rs24011145 
ACGTTGGATGAGGTAA
GTGGTTGTCTTGGG 
ACGTTGGATGTCTCATC
TGCGTGTGCCTTG 
TGGCTCCTCTGTGTA 
6 rs9024664 
ACGTTGGATGGAATGC
ACATCACACAGACC 
ACGTTGGATGACTGAG
AGCTCTGTGGGTTC 
GGGTTCTCAGCGGGA 
6 rs24038028 
ACGTTGGATGTGTCAC
CGAGAGTGTCATTG 
ACGTTGGATGACTAGT
AACCATGTTCTTG 
ACAATGACATCGCTCA 
6 rs22106266 
ACGTTGGATGGGTCTG
GGTCGGCCGGCG 
ACGTTGGATGGCACGC
CGATCCTGCTGC 
TGTCCTGCTGCTCCGCA 
6 rs24615406 
ACGTTGGATGTTCATA
TTCGGGCTCTCTGG 
ACGTTGGATGAGCGTG
GTGCTCTCCAAAGA 
TCTCCAAAGACGCTTTA 
6 rs24278945 
ACGTTGGATGTTGGCT
AGCTGCCATTTCTG 
ACGTTGGATGTGTGTTG
CACGATGATCACC 
CGATGGACTTAGATGCT 
6 rs8830091 
ACGTTGGATGGCCTCC
TTTTTTCCAGGATG 
ACGTTGGATGTCTGTAC
CCTCTGCACTTAG 
GAGGCCTTGCCTGTTGGG 
6 rs24278946 
ACGTTGGATGAGGACG
TTGGGTATTAGGAG 
ACGTTGGATGTTTACAA
TGTGCGGCACCTC 
CCGAGGCACCTCCTGAACA 
6 rs24380667 
ACGTTGGATGCTCTAT
ATGAATATTTTACAAG 
ACGTTGGATGTCCATTT
TTTAAGAGCCGAC 
GAGCCGACTCTTAATAGAT 
6 rs8950488 
ACGTTGGATGCTGACA
TCATCGCTGTACTG 
ACGTTGGATGCAAGGT
TATCGATGAGCTGG 
TGGATGTGAAACCAGAGGG 
6 rs8561539 
ACGTTGGATGCTGAAG
TTCTTGGAGTTGCC 
ACGTTGGATGGGAATA
TTGGCTTTGGCAAC 
CCTGGATTAAATACTGACCC 
6 rs8927359 
ACGTTGGATGTATGGC
AATTAAAATCACC 
ACGTTGGATGTTCCATA
GGGAGCAGATGGC 
GGCTTCAGAGGCCTCAAGGG 
6 rs24566251 
ACGTTGGATGGAGCGT
TAATTGCTTGCAGG 
ACGTTGGATGGCAGTC
TCTTGAGTTCTTAG 
TCCTCTTGGGAATCCACATAT 
6 rs9095803 
ACGTTGGATGAGAAG
GCCCAACAGCTCCAG 
ACGTTGGATGTTCCCAT
CAGGGTGAACGTG 
GGCATGGCCCCACAGGGAAAA 
6 rs24261266 
ACGTTGGATGGCAACA
ACCATAAAAGATG 
ACGTTGGATGAGGAAT
TGTGGGAAGTCCAG 
GAGTCCAGGGAAAAAGGTAAT 
6 rs23232135 
ACGTTGGATGCCATAG
AGTCATCTTGCAGG 
ACGTTGGATGTACACCT
CCTTGACGTTCAC 
CCAGAATCACGAAGAAATAACC 
6 rs8926268 
ACGTTGGATGTTTCCTA
AAAGGGACCTGCC 
ACGTTGGATGCATTACT
CTTGTTACTCTGC 
CACGCTTGTTACTCTGCACTTAC 
6 rs8898240 ACGTTGGATGGGTCTT ACGTTGGATGCTTGCCT TCGCTTGCTTTGAGAGGTCCACC 
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Probe 
(5' - 3') 
CCAGTTAGACCCAT GAGTTTGGTCTAC 
6 rs8861242 
ACGTTGGATGTAGAAA
GTCACCACCTCCAC 
ACGTTGGATGTTAGGG
ATGGAGAGAAACGC 
TATAGAGAGAAACGCATAATGAA 
6 rs24553222 
ACGTTGGATGACAGTA
AAGACACGAGTGCG 
ACGTTGGATGATAAAG
AGCCATTCCCCCTG 
CCCTGATATTAAAATCTCCTGATT 
6 rs24048817 
ACGTTGGATGACAACC
TTCTGGACTCCATC 
ACGTTGGATGTCTACTC
AGTGGTCTTGCTC 
AAGGATCCTGGGGAGGCTGCTTAC 
6 rs24029015 
ACGTTGGATGCTGGCT
AAAGCATGCCACTG 
ACGTTGGATGCCACAC
AGAATGTCAGGAAG 
GGAGAGGAGAAGAAAAGGAGGAA
G 
6 rs22595730 
ACGTTGGATGGGCAAG
CCACAGTTATGAAG 
ACGTTGGATGGGGTAG
TCTGTAGGAAAATG 
GGGAGTCTGTAGGAAAATGAATTG
C 
6 rs22165232 
ACGTTGGATGGCCCGG
CGCTCAGTAACCT 
ACGTTGGATGTGTCGTC
GGAGTACTTGTAG 
ACAACCATGCCATCCACGCGGCTG
GG 
6 rs8523506 
ACGTTGGATGCCCAAG
TGATTTAGGAGAAA 
ACGTTGGATGCACAAT
ACTAACAAGTTAGA 
ACAAAATGAGAAAACAAATAAACA
AA 
6 rs22378754 
ACGTTGGATGACACCG
TCTCAAATCTGACC 
ACGTTGGATGGGGATT
CCCTTACGAAAAG 
GAAAAGAAATTTGAATGTAATTTA
AATC 
7 rs24528134 
ACGTTGGATGTCGGCG
TCCACGTAGGAGA 
ACGTTGGATGACCAAG
GTTGCAAAGGCTGG 
GAGCACCCCCCTTGT 
7 rs24048796 
ACGTTGGATGCTGTGT
GTATATGTGTGTGC 
ACGTTGGATGAGCCAA
CTGCAAAACTCACC 
CCACCCCCACTCCCTT 
7 rs22356416 
ACGTTGGATGATGGAA
GCACTCACAGCTGG 
ACGTTGGATGTTCTGCT
TCTAGGGAGCCCG 
TGAGAGAGGACGTGT 
7 rs22217604 
ACGTTGGATGAGGAGC
TCCTTTCACTTACG 
ACGTTGGATGATTATCG
TGAGGAGACGGAG 
ACCCTGCCTTGTCTGC 
7 rs24864610 
ACGTTGGATGCTATCG
CTGTGAGGTTATGC 
ACGTTGGATGACGTTCT
CACCTTTCACCAC 
GGGTAGCCTCACTGTC 
7 rs8680884 
ACGTTGGATGGTGGGA
CCTTTGTATGCATC 
ACGTTGGATGAACAGG
ACGTCTTGGTCCC 
GGTCCCTCCGGAAGCCA 
7 rs24758506 
ACGTTGGATGAGGGAC
TTTTGGACATATTC 
ACGTTGGATGTCTTTTC
CACTGTGGCAGTC 
TTCTCCTTGAATTCCTCC 
7 rs23546710 
ACGTTGGATGGCAATG
ATGGCACTGTTCTG 
ACGTTGGATGTTGTGTT
CCATTACAGAGCC 
GGTCAGAGCCATCTCCAC 
7 rs24535614 
ACGTTGGATGTTCATG
AGAGGCAGAGAGAG 
ACGTTGGATGAGGATT
GAGTCCTGCATTGG 
GTGAGGAGCCTGTTTCTC 
7 rs24578426 
ACGTTGGATGAAAGGT
CCCGGGCGCAGGTA 
ACGTTGGATGTGTCTTT
TCCCCACAGGGTC 
CCTTGTCCTCCCGGGCCCA 
7 rs24770735 
ACGTTGGATGCAGCTA
TACAGTCATGTAATG 
ACGTTGGATGGACTGC
TCAAGAAACTACCC 
ACTACCCGTAAGTTGTGAT 
7 rs22917971 
ACGTTGGATGGGGTAA
TTCTTGGCACACTC 
ACGTTGGATGTGAACA
GGTTTAAGCCCCAG 
ATCCCCAGGGTTATATAGTC 
7 rs22289709 
ACGTTGGATGTTTCAG
GTTGAGCCCGAATG 
ACGTTGGATGCCAAGG
ATGCACTATGGATG 
GGATGCTATCAAAGTATACTG 
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VI. Q-PCR data – Shapiro Wilk normality test 
Appendix 5. Normality test results for the Q-PCR datasets as described in Chapters 
7 & 8 
  MMP2 Biglycan Trap Cathepsin K COL 1A1 COL 1A2 IL6 DIRC2 PDIA5 PARP-9 MMP1 
D/N 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
I/C 0.00 0.2 0.00 0.00 0.00 0.00 0.00 0.05 0.00 0.00 0.00 
KEY: D/N disease vs normal tissue,  I/C = TNFα induced vs control data.  
A value less than 0.05 means that the data is non-parametric and does not follow 
a Gaussian distribution 
 
VII. Q-PCR data – primer efficiencies  
Appendix 6. Efficiency data for the Q-PCR primers used in Chapters 7 & 8. 
Gene Threshold Slope R2 Efficiency 
MMP-2 4.57 -2.92 0.99 120% 
Biglycan 0.52 -2.96 0.99 118% 
TRAP 3.98 -3.60 0.99 90% 
Cathepsin K 0.60 -3.10 0.97 110% 
COL1a1 0.40 -3.05 0.97 113% 
COl1a2 0.33 -3.24 0.95 104% 
IL-6 1.51 -2.80 0.97 128% 
DIRC2 1.47 -3.21 0.91 105% 
PDIA5 1.6 -3.18 0.93 106% 
ATIC 1.00 -3.20 0.99 105% 
PARP-9 0.84 -3.54 0.98 92% 
HIRIP 0.52 -3.44 0.99 95% 
MMP-1 0.20 -3.78 0.90 84% 
    Average efficiency: 105% 
 
